TECHNICAL FIELD
[0001] The present invention relates to ionic silicone hydrogels displaying improved biocompatibility.
More specifically, the present invention relates to a polymer formed from reactive
components comprising at least one hydrophilic monomer, at least two hydroxyl substituted
silicone containing components having different silicone contents, and at least one
acyclic polyamide. The silicone hydrogels of the present invention display excellent
physical, mechanical, and biological properties, making them suitable for ophthalmic
applications such as contact lens materials.
BACKGROUND
[0002] It is well known that contact lenses can be used to improve vision. Various contact
lenses have been commercially produced for many years. Hydrogel contact lenses are
formed from hydrophilic polymers and copolymers containing repeating units such as
2-hydroxyethyl methylacrylate (HEMA). Of these, contact lenses formed from copolymers
of HEMA and methacrylic acid, are among the most comfortable, and have the lowest
rate of adverse events. Contact lenses formed from copolymers of HEMA and MAA, such
ACUVUE
®2 brand contact lenses, display substantial amounts of lysozyme uptake (greater than
500 µg) and retain a majority of the uptaken proteins in their native state. However,
hydrogel contact lenses generally have oxygen permeabilities that are less than about
30.
[0003] Contact lenses made from silicone hydrogels have been disclosed. These silicone hydrogel
lenses have oxygen permeabilities greater than about 60, and many provide reduced
levels of hypoxia compared to conventional hydrogel contact lenses. Silicone hydrogel
lenses may be exposed to extended periods of wear such as for several days in a row,
for example, up to about 30 days.
US 2007/222095 discloses aqueous processes for the production of silicone hydrogel contact lenses.
US 2012/245248 discloses silicone hydrogels formed from mixtures comprising one or more hydrophilic
high molecular weight polymers, one or more hydroxyl-functionalized silicone containing
monomers, one or more crosslinkers and a compatabilizing diluent, but without a substantial
amount of a reactive hydrophilic monomer or macromer.
US 2013/184372 discloses a silicone polymer comprising a sulfonic acid component formed from reactive
components comprising (i) at least one silicone component and (ii) at least one sulfonic
acid-containing component, wherein the sulfonic acid-containing component is comprised
of a non-polymerizable, hydrophobic cation and a polymerizable sulfonic acid.
[0004] U.S. Patent No. 8,815,972 (Rathore) is directed to ionic silicone hydrogels having improved hydrolytic stability
and desirable protein uptake.
SUMMARY
[0006] The invention is defined by the claims. Silicone hydrogels disclosed herein exhibit
improved biocompatibility with regards to interactions and absorption of tear film
components as well as interactions and absorption of preservatives used for disinfecting
contact lenses made from such silicone hydrogels. The lack of protein, lipid, or other
biological deposits on the surface of contact lenses may limit, reduce, or eliminate
any immunological responses or microbial fouling.
[0007] For reusable wear modalities, in which contact lenses are disinfected with multipurpose
cleaning solutions between uses, another important characteristic of biocompatibility
is low absorption of preservatives which may be released into the ocular environment
upon subsequent wear.
[0008] The silicone hydrogels of the present invention exhibit many of these biocompatible
properties, while achieving an excellent balance of physical and mechanical properties.
[0009] The present invention provides a silicone hydrogel formed from a reactive monomer
mixture comprising:
- a. between about 1 and about 15 wt% at least one polyamide;
- b. at least one first mono-functional, hydroxyl substituted poly(disubstituted siloxane)
having 4 to 8 siloxane repeating units;
- c. at least one second hydroxyl substituted poly(disubstituted siloxane) selected
from the group consisting of mono-functional hydroxyl substituted poly(disubstituted
siloxane)s having 10 to 200 or 10-100 siloxane repeating units and multifunctional
hydroxyl substituted poly(disubstituted siloxane)s having 10 to 200, or 10 to 100
siloxane repeating units, and mixtures thereof;
- d. about 5 to about 30 wt% at least one additional hydrophilic monomer;
- e. wherein the first hydroxyl substituted, linear poly(disubstituted siloxane) and
the second mono-functional hydroxyl substituted, linear poly(disubstituted siloxane)
are present in concentrations to provide a ratio of wt% of all first hydroxyl substituted,
linear poly(disubstituted siloxane) to wt% of all one second hydroxyl substituted
poly(disubstituted siloxane)s of 0.4-1.3, or 0.4-1.0.
[0010] The present invention provides a silicone hydrogel formed from a reactive monomer
mixture comprising:
- i. between about 1 and about 15 wt% at least one polyamide;
- ii. at least one hydroxyl silicone-containing monomer;
- iii. at least one hydroxyl substituted poly(disubstituted siloxane) selected from
the group consisting of poly(disubstituted siloxane) having 4 to 8 siloxane repeating
units, monofunctional hydroxyl substituted poly(disubstituted siloxane)s having 10
to 200 or 10-100 siloxane repeating units and multifunctional hydroxyl substituted
poly(disubstituted siloxane)s having 10 to 200, or 10 to 100 siloxane repeating units,
and mixtures thereof;
- iv. about 5 to about 20 wt% at least one additional hydrophilic monomer;
- v. wherein the first hydroxyl substituted, linear poly(disubstituted siloxane) and
the second monofunctional hydroxyl substituted, linear poly(disubstituted siloxane)
are present in concentrations to provide a ratio of wt% of all first hydroxyl substituted,
linear poly(disubstituted siloxane) to wt% of all one second hydroxyl substituted
poly(disubstituted siloxane)s of 0.4-1.3, or 0.4-1.0.
[0011] The present invention also provides biomedical devices, ophthalmic devices and contact
lenses comprising the silicone hydrogels described herein.
[0012] These and other embodiments of the invention will become apparent from the following
description, which are illustrative of the invention. The description does not limit
the scope of the invention, which is defined by the claims and equivalents thereof.
Variations and modifications of the invention may be effected without departing from
the scope of the novel contents of the disclosure.
DETAILED DESCRIPTION
[0013] Provided are silicone hydrogels formed from a reactive monomer mixture comprising:
a first hydroxyl substituted, linear poly(disubstituted siloxane) having 4 to 8 siloxane
repeating units; a second hydroxyl substituted, linear poly(disubstituted siloxane)
selected from the group consisting of a monofunctional hydroxyl substituted, linear
poly(disubstituted siloxane) having 10 to 20 siloxane repeating units and a multifunctional
hydroxyl substituted, linear poly(disubstituted siloxane) having 10 to 200, or 10
to 100 siloxane repeating units; and at least one polyamide; wherein the ratio of
the first hydroxyl substituted linear poly(disubstituted siloxane) to the second hydroxyl
substituted, linear poly(disubstituted siloxane) is in a range of 0.4 to 1.2, or 0.4
to 1.0.
[0014] With respect to the terms used in this disclosure, the following definitions are
provided. The polymer definitions are consistent with those disclosed in the Compendium
of Polymer Terminology and Nomenclature, IUPAC Recommendations 2008, edited by: Richard
G. Jones, Jaroslav Kahovec, Robert Stepto, Edward S. Wilks, Michael Hess, Tatsuki
Kitayama, and W. Val Metanomski.
[0015] As used herein, the term "about" refers to a range of +/-5% of the number that is
being modified. For example, the phrase "about 10" would include both 9.5 and 10.5.
[0016] The term "(meth)" designates optional methyl substitution. Thus, a term such as "(meth)acrylate"
denotes both methacrylate and acrylate radicals.
[0017] Wherever chemical structures are given, it should be appreciated that alternatives
disclosed for the substituents on the structure may be combined in any combination.
Thus, if a structure contained substituents R* and R**, each of which contained three
lists of potential groups, 9 combinations are disclosed. The same applies for combinations
of properties.
[0018] When a subscript, such as "n" in the generic formula [***]
n, is used to depict the number of repeating units in a polymer's chemical formula,
the formula should be interpreted to represent the number average molecular weight
of the macromolecule.
[0019] A "macromolecule" is an organic compound having a molecular weight of greater than
1500, and may be reactive or non-reactive.
[0020] A "polymer" is a macromolecule of repeating chemical units linked together into a
chain or network structure and is composed of repeating units derived from the monomers
and macromers included in the reactive mixture.
[0021] A "homopolymer" is a polymer made from one monomer or macromer; a "copolymer" is
a polymer made from two or more monomers, macromers or a combination thereof; a "terpolymer"
is a polymer made from three monomers, macromers or a combination thereof. A "block
copolymer" is composed of compositionally different blocks or segments. Diblock copolymers
have two blocks. Triblock copolymers have three blocks. "Comb or graft copolymers"
are made from at least one macromer.
[0022] A "repeating unit" or "repeating chemical unit" is the smallest repeating group of
atoms in a polymer that result from the polymerization of monomers and macromers.
[0023] "Biomedical device" is any article that is designed to be used while either in or
on mammalian tissues or fluid, and preferably in or on human tissue or fluids. Examples
of these devices include but are not limited to wound dressings, sealants, tissue
fillers, drug delivery systems, coatings, adhesion prevention barriers, catheters,
implants, stents, sutures, and ophthalmic devices such as intraocular lenses and contact
lenses. The biomedical devices may be ophthalmic devices, such as contact lenses,
including contact lenses made from silicone hydrogels.
[0024] "Individual" includes humans and vertebrates.
[0025] "Ocular surface" includes the surface and glandular epithelia of the cornea, conjunctiva,
lacrimal gland, accessory lacrimal glands, nasolacrimal duct and meibomian gland,
and their apical and basal matrices, puncta and adjacent or related structures, including
eyelids linked as a functional system by both continuity of epithelia, by innervation,
and the endocrine and immune systems.
[0026] "Ophthalmic device" refers to any device which resides in or on the eye or any part
of the eye, including the ocular surface. These devices can provide optical correction,
cosmetic enhancement, vision enhancement, therapeutic benefit (for example as bandages)
or delivery of active components such as pharmaceutical and nutraceutical components,
or a combination of any of the foregoing. Examples of ophthalmic devices include,
but are not limited to, lenses and optical and ocular inserts, including, but not
limited to punctal plugs and the like. The "term lens" includes soft contact lenses,
hard contact lenses, hybrid contact lenses, intraocular lenses, and overlay lenses.
The ophthalmic device may comprise a contact lens.
[0027] "Contact lens" refers to an ophthalmic device that can be placed on the cornea of
an individual's eye. The contact lens may provide corrective, cosmetic, therapeutic
benefit, including wound healing, delivery of active components such as drugs or neutraceuticals,
diagnostic evaluation or monitoring, or UV blocking and visible light or glare reduction,
or a combination thereof. A contact lens can be of any appropriate material known
in the art, and can be a soft lens, a hard lens, or a hybrid lens containing at least
two distinct portions with different properties, such as modulus, water content, light
absorbing characteristics or combinations thereof.
[0028] The biomedical devices, ophthalmic devices, and lenses of the present invention may
be comprised of silicone hydrogels. These silicone hydrogels typically contain a silicone
component and/or hydrophobic and hydrophilic monomers that are covalently bound to
one another in the cured device.
[0029] "Silicone hydrogel contact lens" refers to a contact lens comprising at least one
silicone hydrogel material. Silicone hydrogel contact lenses generally have increased
oxygen permeability compared to conventional hydrogels. Silicone hydrogel contact
lenses use both their water and polymer content to transmit oxygen to the eye.
[0030] A "polymeric network" is cross-linked macromolecule that can swell but cannot dissolve
in solvents, because the polymeric network is essentially one macromolecule. "Hydrogel"
or "hydrogel material" refers to a polymeric network that contains water in an equilibrium
state. Hydrogels generally contain at least about 10 wt.% water, or at least about
15 wt.% water
[0031] " Conventional hydrogels" refer to polymeric networks made from monomers without
any siloxy, siloxane or carbosiloxane groups. Conventional hydrogels are prepared
from monomeric mixtures predominantly containing hydrophilic monomers, such as 2-hydroxyethyl
methacrylate ("HEMA"), N-vinyl pyrrolidone ("NVP"), N, N-dimethylacrylamide ("DMA"),
or vinyl acetate.
United States Patent Nos. 4,436,887,
4,495,313,
4,889,664,
5,006,622,
5,039459,
5,236,969,
5,270,418,
5,298,533,
5,824,719,
6,420,453,
6,423,761,
6,767,979,
7,934,830,
8,138,290, and
8,389,597 disclose the formation of conventional hydrogels. Commercially available hydrogel
formulations include, but are not limited to, etafilcon, polymacon, vifilcon, genfilcon,
lenefilcon, hilafilcon, nesofilcon, and omafilcon, including all of their variants.
[0032] "Silicone hydrogel" refers to a hydrogel obtained by copolymerization of at least
one silicone-containing component with at least one hydrophilic component. Hydrophilic
components may also include non-reactive polymers. Each of the silicone-containing
components and the hydrophilic components may be a monomer, macromer or combination
thereof. A silicone-containing component contains at least one siloxane or carbosiloxane
group. Examples of commercially available silicone hydrogels include balafilcon, acquafilcon,
lotrafilcon, comfilcon, delefilcon, enfilcon, fanfilcon, foimofilcon, galyfilcon,
senofilcon, narafilcon, falcon II, asmofilcon A, samfilcon, riofilcon, stenficlon,
somofilcon, as well as silicone hydrogels as prepared in
US Patent Nos. 4,659,782,
4,659,783,
5,244,981,
5,314,960,
5,331,067,
5,371,147,
5,998,498,
6,087,415,
5,760,100,
5,776,999,
5,789,461,
5,849,811,
5,965,631,
6,367,929,
6,822,016,
6,867,245,
6,943,203,
7,247,692,
7,249,848,
7,553,880,
7,666,921,
7,786,185,
7,956,131,
8,022,158,
8,273,802,
8,399,538,
8,470,906,
8,450,387,
8,487,058,
8,507,577,
8,637,621,
8,703,891,
8,937,110,
8,937,111,
8,940,812,
9,056,878,
9,057,821,
9,125,808,
9,140,825,
9156,934,
9,170,349,
9,244,196,
9,244,197,
9,260,544,
9,297,928,
9,297,929 as well as
WO 03/22321,
WO 2008/061992, and
US 2010/048847.
[0033] "Silicone-containing component" refers to a monomer, macromer, prepolymer, cross-linker,
initiator, additive, or polymer that contains at least one silicon-oxygen bond, in
the form of siloxane [-Si-O-Si] group or carbosiloxane group. Examples of silicone-containing
components include, but are not limited to, silicone macromers, prepolymers, and monomers.
Examples of silicone macromers include, but are not limited to, polydimethylsiloxane
methacrylated with pendant hydrophilic groups. Examples of silicone-containing components
which are useful in this invention may be found in
U.S. Patent Nos. 3,808,178,
4,120,570,
4,136,250,
4,153,641,
4,740,533,
5,034,461,
5,962,548,
5,244,981,
5,314,960,
5,331,067,
5,371,147,
5,760,100,
5,849,811,
5,962,548,
5,965,631,
5,998,498,
6,367,929,
6,822,016, and
5,070,215, and
European Patent No. 080539.
[0034] "Reactive mixture" and "reactive monomer mixture" refer to the mixture of components
(both reactive and non-reactive) which are mixed together and when subjected to polymerization
conditions, form the silicone hydrogels and lenses of the present invention. The reactive
mixture comprises reactive components such as monomers, macromers, prepolymers, cross-linkers,
initiators, diluents, and additional components such as wetting agents, release agents,
dyes, light absorbing compounds such as UV absorbers, pigments, dyes and photochromic
compounds, any of which may be reactive or non-reactive but are capable of being retained
within the resulting biomedical device, as well as active components such as pharmaceutical
and nutraceutical compounds, and any diluents. It will be appreciated that a wide
range of additives may be added based upon the biomedical device which is made, and
its intended use. Concentrations of components of the reactive mixture are given in
weight % of all components in the reaction mixture, excluding diluent. When diluents
are used their concentrations are given as weight % based upon the amount of all components
in the reaction mixture and the diluent.
[0035] "Monomer" is a molecule having non-repeating functional groups, which can undergo
chain growth polymerization, and in particular, free radical polymerization. Some
monomers have di-functional impurities that can act as cross-linking agents. "Macromers"
are linear or branched polymers having a repeating structure and at least one reactive
group that can undergo chain growth polymerization. Monomethacryloxypropyl terminated
mono-n-butyl terminated polydimethylsiloxane (molecular weight = 500-1500 g/mol) (mPDMS)
and mono-(2-hydroxy-3-methacryloxypropyl)-propyl ether terminated mono-n-butyl terminated
polydimethylsiloxane (molecular weight = 500-1500 g/mol) (OH-mPDMS) are referred to
as macromers. Typically, the chemical structure of the macromer is different than
the chemical structure of the target macromolecule, that is, the repeating unit of
the macromer's pendent group is different than the repeating unit of the target macromolecule
or its mainchain.
[0036] "Reactive components" are the components in the reactive mixture which become part
of the structure of the polymeric network of the resulting silicone hydrogel, by covalent
bonding, hydrogen bonding or the formation of an interpenetrating network. Diluents
and processing aids which do not become part of the structure of the polymer are not
reactive components.
[0037] "Polymerizable" means that the compound comprises at least one reactive group which
can undergo chain growth polymerization, such as free radical polymerization. Examples
of reactive groups include the monovalent reactive groups listed below. "Non-polymerizable"
means that the compound does not comprises such a polymerizable group.
[0038] "Monovalent reactive groups" are groups that can undergo chain growth polymerization,
such as free radical and/or cationic polymerization. Non-limiting examples of free
radical reactive groups include (meth)acrylates, styrenes, vinyl ethers, (meth)acrylamides,
N-vinyllactams,
N-vinylamides, O-vinylcarbamates, O-vinylcarbonates, and other vinyl groups. In one
embodiment, the free radical reactive groups comprise (meth)acrylate, (meth)acrylamide,
N-vinyl lactam, N-vinylamide, and styryl functional groups, or (meth)acrylates, (meth)acrylamides,
and mixtures of any of the foregoing.
[0039] Examples of the foregoing include substituted or unsubstituted C
1-6alkyl(meth)acrylates, C
1-6alkyl(meth)acrylamides, C
2-12alkenyls, C
2-12alkenylphenyls, C
2-12alkenylnaphthyls, C
2-6alkenylphenylC
1-6alkyls, where suitable substituents on said C
1-6 alkyls include ethers, hydroxyls, carboxyls, halogens and combinations thereof.
[0040] Other polymerization routes such as living free radical and ionic polymerization
can also be employed. The device-forming monomers may form hydrogel copolymers. For
hydrogels, the reactive mixture will typically include at least one hydrophilic monomer.
[0041] Hydrophilic components are those which yield a clear single phase when mixed with
deionized water at 25°C at a concentration of 10 wt.%.
[0042] "Interpenetrating polymer networks" or "IPNs" are polymers comprising two or more
polymeric networks which are at least partially interlaced on a molecular scale, but
not covalently bonded to each other and cannot be separated unless chemical bonds
are broken.
[0043] "Semi-interpenetrating polymer networks" or "semi-IPNs" are polymer comprising one
or more polymer network(s) and one or more linear or branched polymer(s) characterized
by the penetration on a molecular scale of at least one of the networks by at least
some of the linear or branched chains.
[0044] A "cross-linking agent" is a di-functional or multi-functional component which can
undergo free radical polymerization at two or more locations on the molecule, thereby
creating branch points and a polymeric network. Common examples are ethylene glycol
dimethacrylate, tetraethylene glycol dimethacrylate, trimethylolpropane trimethacrylate,
methylene bisacrylamide, triallyl cyanurate, and the like.
[0045] The phrase "without a surface treatment" means that the exterior surfaces of the
devices (e.g. silicone hydrogels, contact lenses) of the present invention are not
separately treated to improve the wettability of the device. Treatments which may
be foregone include, plasma treatments, grafting, coating, and the like. Coatings,
however, which provide properties other than improved wettability, such as, but not
limited to antimicrobial coatings and the application of color or other cosmetic enhancement
may be applied to devices of the present invention.
[0046] Non-SI units disclosed in this description are convertible as following:
- 1 inch = 25.4 mm
- 1 psi = 6894.76 Pa
- 1 lb = 453.592 g.
[0047] A silicone hydrogel may be formed from a reactive monomer mixture comprising at least
one anionic monomer, at least one first mono-functional hydroxyl-substituted poly(disubstituted
siloxane), at least one second mono-functional hydroxyl-substituted poly(disubstituted
siloxane), at least one hydroxyl functional monomer, and at least one acylic polyamide.
Polyamide
[0048] The reactive monomer mixture includes at least one polyamide. As used herein, the
term "polyamide" refers to polymers and copolymers comprising repeating units containing
amide groups. The polyamide may comprise cyclic amide groups, acyclic amide groups
and combinations thereof, and may be any polyamide known to those of skill in the
art.
[0049] Acyclic polyamides comprise pendant acyclic amide groups and are capable of association
with hydroxyl groups. Cyclic polyamides comprise cyclic amide groups and are capable
of association with hydroxyl groups.
[0050] Examples of suitable acyclic polyamides include polymers and copolymers comprising
repeating units of Formula I or Formula II:
wherein X is a direct bond, -(CO)-, or -(CO)-NHRe-, wherein Re is a C1 to C3 alkyl group; Ra is selected from H, straight or branched, substituted or unsubstituted C1 to C4 alkyl groups; Rb is selected from H, straight or branched, substituted or unsubstituted C1 to C4 alkyl groups, amino groups having up to two carbon atoms, amide groups having up
to four carbon atoms, and alkoxy groups having up to two carbon groups; Rc is selected from H, straight or branched, substituted or unsubstituted C1 to C4 alkyl groups, or methyl, ethoxy, hydroxyethyl, and hydroxymethyl; Rd is selected from H, straight or branched, substituted or unsubstituted C1 to C4 alkyl groups; or methyl, ethoxy, hydroxyethyl, and hydroxymethyl wherein the number
of carbon atoms in Ra and Rb taken together is 8 or less, including 7, 6, 5, 4, 3, or less, and wherein the number
of carbon atoms in Rc and Rd taken together is 8 or less, including 7, 6, 5, 4, 3, or less. The number of carbon
atoms in Ra and Rb taken together may be 6 or less or 4 or less. The number of carbon atoms in Rc and Rd taken together may be 6 or less. As used herein substituted alkyl groups include
alkyl groups substituted with an amine, amide, ether, hydroxyl, carbonyl, carboxy
groups or combinations thereof.
Ra and Rb can be independently selected from H, substituted or unsubstituted C1 to C2 alkyl groups. X may be a direct bond, and Ra and Rb may be independently selected from H, substituted or unsubstituted C1 to C2 alkyl groups.
Rc and Rd can be independently selected from H, substituted or unsubstituted C1 to C2 alkyl groups, methyl, ethoxy, hydroxyethyl, and hydroxymethyl.
[0051] The acyclic polyamides of the present invention may comprise a majority of the repeating
unit of Formula I or Formula II, or the acyclic polyamides can comprise at least about
50 mole % of the repeating unit of Formula I or Formula II, including at least about
70 mole %, and at least 80 mole %.
[0052] Specific examples of repeating units of Formula I and Formula II include repeating
units derived from N-vinyl-N-methylacetamide, N-vinylacetamide, N-vinyl-N-methylpropionamide,
N-vinyl-N-methyl-2-methylpropionamide, N-vinyl-2-methyl-propionamide, N-vinyl-N,N'-dimethylurea,
N, N-dimethylacrylamide, methacrylamide, and acyclic amides of Formulae IIIa and IIIb:

[0053] The acyclic polyamides may also be copolymers comprising both acyclic and cyclic
amide repeating units. Examples of suitable cyclic amides that can be used to form
the acyclic polyamides include α-lactam, β-lactam, γ-lactam, δ-lactam, and ε-lactam.
Examples of suitable cyclic amides include repeating units of Formula IV:

wherein R
1 is independently a hydrogen atom or methyl; f is a number from 1 to 10, X is a direct
bond, -(CO)-, or -(CO)-NH-R
e-, wherein R
e is a C
1 to C
3 alkyl group. In Formula IV, f may be 8 or less, including 7, 6, 5, 4, 3, 2, or 1.
In Formula IV, f may be 6 or less, including 5, 4, 3, 2, or 1. In Formula IV, f may
be from 2 to 8, including 2, 3, 4, 5, 6, 7, or 8. In Formula IV, f may be 2 or 3.
[0054] When X is a direct bond, f may be 2. In such instances, the cyclic polyamide may
be poly(vinyl pyrrolidone) (PVP).
[0055] Specific examples of repeating units of Formula IV include repeating units derived
from N-vinylpyrrolidone (NVP).
[0056] Additional repeating units may be formed from monomers selected from N-vinyl amides,
acrylamides, hydroxyalkyl(meth)acrylates, alkyl(meth)acrylates and siloxane substituted
acrylates or methacrylates. Specific examples of monomers which may be used to form
the additional repeating units of the acyclic polyamides include as N-vinylpyrrolidone,
N,N-dimethylacrylamide (DMA), 2-hydroxyethylmethacrylate, vinyl acetate, acrylonitrile,
hydroxypropyl methacrylate, 2-hydroxyethyl acrylate, methyl methacrylate and butyl
methacrylate, hydroxybutyl methacrylate, GMMA, PEGS, , and the like and mixtures thereof.
Ionic monomers may also be included. Examples of ionic monomers include acrylic acid,
methacrylic acid, 2-methacryloyloxyethyl phosphorylcholine, 3-(dimethyl(4-vinylbenzyl)ammonio)propane-1-sulfonate
(DMVBAPS), 3-((3-acrylamidopropyl)dimethylammonio)propane-1-sulfonate (AMPDAPS), 3-((3-methacrylamidopropyl)dimethylammonio)propane-1-sulfonate
(MAMPDAPS), 3-((3-(acryloyloxy)propyl)dimethylammonio)propane-1-sulfonate (APDAPS),
methacryloyloxy)propyl)dimethylammonio)propane-1-sulfonate (MAPDAPS), ), 1-propanaminium,N-(2-carboxyethyl)-N,N-dimethyl-3-[(1-oxo-2-propen-1-yl)amino]-,
inner salt (CBT, carboxybetaine;
CAS 79704-35-1), 1-propanaminium, N,N-dimethyl-N-[3-[(1-oxo-2-propen-1-yl)amino]propyl]-3-sulfo-,
inner salt (SBT, sulfobetaine,
CAS 80293-60-3), 3,5-Dioxa-8-aza-4-phosphaundec-10-en-1-aminium, 4-hydroxy-N,N,N-trimethyl-9-oxo-,
inner salt, 4-oxide (9CI) (PBT, phosphobetaine,
CAS 163674-35-9).
[0057] The at least one acylic polyamide may be selected from the group consisting of polyvinylmethylacrylamide
(PVMA), polyvinylacetamide (PNVA), polydimethylacrylamide (PDMA), polyacrylamide and
poly[N-vinyl N-alkyl acetamide] wherein the N-alkyl group is selected from the group
consisting of linear and branched alkyl groups containing between one (C
1) and five (C
5) carbon atoms.
[0058] The reactive monomer mixture may comprise both an acyclic polyamide and a cyclic
polyamide or copolymers thereof. The acyclic polyamide can be any of those acyclic
polyamides described herein or copolymers thereof, and the cyclic polyamide can be
formed from any combination of the repeating units of Formula IV, either alone or
with other repeating units. Examples of cyclic polyamides include PVP and PVP copolymers.
Other polymeric internal wetting agents, such as poly(hydroxyethyl(meth)acrylamide),
may also be included.
[0059] Without intending to be bound by theory, the polyamide functions as an internal wetting
agent in the resulting silicone hydrogel. The polyamides of the present invention
may be non-polymerizable, and in this case is incorporated into the silicone hydrogels
as a semi-interpenetrating network. The non-polymerizable polyamide is "entrapped",
or physically retained within a hydrogel matrix. Alternatively, the polyamides of
the present invention may be polymerizable, for example as polyamide macromers, which
are covalently incorporated into the silicone hydrogels. Reactive polyamides may be
functionalized to contain at least one monovalent reactive group.
[0060] When the polyamides are incorporated into the reactive monomer mixture they may have
a weight average molecular weight of at least about 100,000 Daltons; greater than
about 150,000; between about 150,000 to about 2,000,000 Daltons, between about 300,000
to about 1,800,000 Daltons.
[0061] The polyamides may also comprise at least one reactive group. For polyamides having
molecular weights of 10,000 Daltons, a single reactive group may be included. For
polyamides having molecular weights greater than about 10,000, greater than about
30,000, or greater than about 100,000 Daltons, more than one reactive group may be
included. Mixtures of reactive and non-reactive polyamides may also be used.
[0062] The polyamides may be incorporated into the hydrogel by a variety of methods. For
example, the polyamide may be added to the reaction mixture such that the hydrogel
polymerizes "around" the polyamide, forming a semi-interpenetrating network.
[0063] The total amount of all polyamides in the reactive mixture may be from about 1 to
about 15 wt%, between about 3 and about 15 wt%, or between about 3 and about 12 wt%,
based upon the total weight of the reactive components of the reactive monomer mixture.
[0064] The reactive monomer mixture also includes a mixture of hydroxyl-containing silicone
components of different molecular weights or different compositions. The first hydroxyl-containing
silicone component may be selected from hydroxyl-containing silicone monomers, and
hydroxyl containing polydisubstituted siloxanes having at least 4 polydisubstituted
siloxane repeating units or 4-8 polydisubstituted siloxane repeating units; and at
least one monovalent reactive group. When the first hydroxyl-containing silicone component
is a hydroxyl-containing silicone monomer, the second hydroxyl-containing silicone
component may be selected from hydroxyl substituted poly(disubstituted siloxane) having
4 to 8 siloxane repeating units, monofunctional hydroxyl substituted poly(disubstituted
siloxane)s having 10 to 200, 10-100 or 10-20 siloxane repeating units and multifunctional
hydroxyl substituted poly(disubstituted siloxane)s having 10 to 200, or 10 to 100
siloxane repeating units, and mixtures thereof. When the first hydroxyl-containing
silicone component is a hydroxyl-substituted poly(disubstituted siloxane) having 4
to 8 siloxane repeating units, the second hydroxyl-containing silicone component may
be selected from monofuntional hydroxyl substituted poly(disubstituted siloxane)s
having 10 to 200, 10-100 or 10-20 siloxane repeating units and multifunctional hydroxyl
substituted poly(disubstituted siloxane)s having 10 to 200, or 10 to 100 siloxane
repeating units, and mixtures thereof.
[0065] Hydroxyl-containing silicone components having 4 polydisubstituted siloxane repeating
units in the siloxane chain are not a distribution and have four repeating units in
each monomer. For all hydroxyl-containing silicone components having more than four
polydisubstituted siloxane repeating units in the siloxane chain the number of repeating
units is a distribution, with the peak of the distribution centered around the listed
number of repeat units.
[0066] The elemental Si content of the hydroxyl containing silicone component is greater
than about 20 weight percent, to about 38 weight percent of the total molecular weight
of the hydroxyl containing silicone component.
Hydroxyl-Containing Silicone Components
[0067] Examples of hydroxyl-containing silicone monomers include propenoic acid-2-methyl-2-hydroxy-3-[3-[1,3,3,3-tetramethyl-1-[(trimethylsilyl)oxy]-1-disiloxanyl]propoxy]propyl
ester ("SiGMA"), and 2-hydroxy-3-methacryloxypropyloxypropyl-tris(trimethylsiloxy)silane,
and compounds of Formula VI:

wherein R
1 is a hydrogen atom or methyl group and R
2 is a linear, branched or cyclic alkyl groups containing 1 to 8 carbon atoms or a
trimethylsiloxy group.
[0068] The hydroxyl-containing silicone components may be selected from monofunctional hydroxyl
substituted, poly(disubstituted siloxane)s of Formula VII-1:
wherein Z is selected from O, N, S or NCH2CH2O, when Z is O or S R2 is not present;
R1 is independently H or methyl;
R2 is H or is a linear, branched, or cyclic alkyl group containing one to eight carbon
atoms, any of which may be further substituted with at least one hydroxy group, amide,
ether, and combinations thereof;
R3 and R4 are independently a linear, branched, or cyclic alkyl group containing one to eight
carbon atoms, any of which may be further substituted with at least one hydroxy group,
and which may be optionally substituted with amide, ether, and combinations thereof;
R3 and R4 may be independently selected from methyl, ethyl or phenyl, or may be methyl;
n is the number of siloxane units and is from 4 to 8 for the first monofunctional
hydroxyl substituted poly(disubstituted siloxane) monomer (or, when the compound is
present as a second hydroxyl substituted poly(disubstituted siloxane), n may be 10
to 200, or 10-100, or 10-50, or 10-20, or 12-18), and
R5 is selected from straight or branched C1 to C8 alkyl groups, which may be optionally substituted with one or more hydroxyl, amide,
ether, and combinations thereof. R5 may be straight or branched C4 alkyl, either of which may optionally be substituted with hydroxyl, or may be methyl.
[0069] The hydroxyl-containing silicone components may be selected from monofunctional hydroxyl
substituted, poly(disubstituted siloxane)s of Formula VII-2:
wherein Z is selected from O, N, S or NCH2CH2O, when Z is O or S R2 is not present;
R1 is independently H or methyl;
R2 is H or is a linear, branched, or cyclic alkyl group containing one to eight carbon
atoms, any of which may be further substituted with at least one hydroxy group, amide,
ether, and combinations thereof;
R3 and R4 are independently a linear, branched, or cyclic alkyl group containing one to eight
carbon atoms, any of which may be further substituted with at least one hydroxy group,
and which may be optionally substituted with amide, ether, and combinations thereof;
R3 and R4 may be independently selected from methyl, ethyl or phenyl, or may be methyl;
n is the number of siloxane units and is from 10 to 200, or 10-100, or 10-50, or 10-20,
or 12-18 for the second monofunctional hydroxyl substituted poly(disubstituted siloxane);
and
R5 is selected from straight or branched C1 to C8 alkyl groups, which may be optionally substituted with one or more hydroxyl, amide,
ether, and combinations thereof. R5 may be straight or branched C4 alkyl, either of which may optionally be substituted with hydroxyl, or may be methyl.
[0070] Examples of monofunctional hydroxyl containing silicone components include mono-(2-hydroxy-3-methacryloxypropyl)-propyl
ether terminated mono-n-butyl terminated polydimethylsiloxanes (OH-mPDMS) as shown
in Formula VIIa wherein n is between 4 and 30, 4-8 or 10-20 or 4 to 15; and polydimethylsiloxanes
having the chemical structures as shown in Formulae VIIb through VIIId, where n is
between 4 and 30, 4 and 8 or 10 and 20; n
1 and n
2 are independently between 4 to 100; 4 to 50; 4 to 25; n
3 is 1-50, 1-20, or 1-10; R
5 is selected from straight or branched C1 to C8 alkyl groups, which may be optionally
substituted with one or more hydroxyl, amide, ether, polyhydroxyl groups selected
from straight or branched C1 to C8 groups having a formula of C
fH
g(OH)
h wherein f=1-8 and g+h=2f+1 and cyclic C1 to C8 groups having a formula of C
fH
g(OH)
h wherein f=1-8 and g+h=2f-1, and combinations thereof; or R
5 may be selected from methyl, butyl or hydroxyl substituted C2-C5 alkyl, including
hydroxyl ethyl, hydroxyl propyl, hydroxyl butyl, hydroxyl pentyl and 2,3-dihydroxypropyl;
and polycarbosiloxanes of Formula IXa and IXb wherein "a" = 4-8 for the first hydroxyl-containing
silicone component and "a" is between 4-100 for the second hydroxyl-containing silicone
component, R
1 and R
5 are as defined above; wherein Z is selected from O, N, S or NCH
2CH
2O, when Z is O or S R
2 is not present; R
2 is independently selected from the group consisting of a linear, branched, or cyclic
alkyl group containing one to eight carbon atoms, any of which may be further substituted
with at least one hydroxy group, and which may be optionally substituted with amide,
ether, and combinations thereof; and R
3 and R
4 are independently a linear, branched, or cyclic alkyl group containing one to eight
carbon atoms, any of which may be further substituted with at least one hydroxy group,
and which may be optionally substituted with amide, ether, and combinations thereof;
R
3 and R
4 may be independently selected from methyl, ethyl or phenyl, or may be methyl.

[0071] The second hydroxyl-containing silicone component may be selected from the group
consisting of a second monofunctional hydroxyl substituted, poly(disubstituted siloxane)
of general Formula VI, or compounds of Formulae VIIa-IX having 10 to 200 siloxane
repeating units and a multifunctional hydroxyl substituted, poly(disubstituted siloxane)
of Formula X having 10 to 500, or 10 to 200, or 10 to 100 siloxane repeating units,
and mixtures thereof:
wherein in Formula X, Z is selected from O, N, S or NCH2CH2O; wherein R1 is independently a hydrogen atom or methyl group; for Z = O and S, R2 is not required;
R2, R3, R4, R5, R6, R7 are independently selected from the group consisting of a hydrogen atom or any of
the substituents defined for R8 through R11;
R8, R9, R10, R11 are independently selected from the group consisting of a linear, branched, or cyclic
alkyl group containing one to eight carbon atoms, any of which may be further substituted
with at least one hydroxy group, amido, ether, amino, carboxyl, carbonyl groups and
combinations; a linear or branched alkyleneoxy group, specifically ethyleneoxy groups,
[CH2CH2O]p wherein p is between 1 and 200, or 1 and 100, or 1 and 50, or 1 and 25, or 1 and
20, optionally substituted with one or more hydroxyl, amino, amido, ether, carbonyl,
carboxyl, and combinations thereof; a C1-C6 linear or branched fluoroalkyl groups optionally substituted with one or more hydroxyl,
amino, amido, ether, carbonyl, carboxyl, and combinations thereof; a substituted or
un-substituted aryl groups, specifically phenyl groups, wherein the substituents are
selected from halogen, hydroxyl, alkoxy, alkylcarbonyl, carboxy, and linear or branched
or cyclic alkyl groups which may be further substituted with halogen, hydroxyl, alkoxy,
alkylcarbonyl, and carboxyl groups, and combinations thereof;
a, b, c, x, y and z are independently between 0 and 100, between 0 and 50, between
0 and 20, between 0 and 10, or between 0 and 5, and may be ordered in any molecular
sequence to make a wide range of substituted hydroxy-oxa-alkylene chains, and n is
the number of siloxane repeating units and is from 10 to 500; 10 to 200; 10 to 100;
10 to 50; 10 to 20.
[0072] The weight ratio of the first mono-functional hydroxyl-substituted poly(disubstituted
siloxane) to the second hydroxyl-substituted poly(disubstituted siloxane) is in a
range of 0.1 to 2, or 0.1 to 1.
[0073] The hydroxyl-containing silicone components may comprise a mixture of a first mono-functional
hydroxyl-substituted poly(disubstituted siloxane) of Formula VI, or VIIa-IX where
n is from 4 to 8 and a second hydroxyl-substituted poly(disubstituted siloxane) selected
from the group consisting of a mono-functional hydroxyl-substituted poly(disubstituted
siloxane) of Formula VI or VIIa to IX, wherein n is from 10-200, 10-100 or 10-20 and
a di-functional hydroxyl-substituted poly(disubstituted siloxane) of Formula XI

wherein R
1 is independently a hydrogen atom or methyl group; R
2 and R
3 are independently a linear, branched, or cyclic alkyl group containing one to eight
carbon atoms, any of which may be further substituted with at least one hydroxy group,
amido, ether, amino, carboxyl, carbonyl groups and combinations thereof; or are independently
selected from unsubstituted C
1-4 alkyl groups and C
1-4 alkyl groups substituted with hydroxyl or ether; or are selected from methyl, ethyl
or -(CH
2CH
2O)
xOCH
3 where x = 1-5-, 1-20, and 1-20; and n = 1-200, 1-100, and 1-50.
[0074] The hydroxyl-containing silicone components may comprise a mixture of a first mono-functional
hydroxyl-substituted poly(disubstituted siloxane) of Formula VI, or VIIa-IX where
n is from 4 to 8, a second hydroxyl-substituted poly(disubstituted siloxane) selected
from the group consisting of a mono-functional hydroxyl-substituted poly(disubstituted
siloxane) of Formula VI or VIIa to IX, wherein n is from 10-200, 10-100 or 10-20,
and a di-functional hydroxyl-substituted poly(disubstituted siloxane) of Formula XI.
[0075] Examples of multifunctional hydroxyl containing silicones include α-(2-hydroxy-1-methacryloxypropyloxypropyl)-ω-butyl-decamethylpentasiloxane
and those of Formula XII:

wherein in Formula XII, Z is selected from O, N, S or NCH
2CH
2O; wherein R
1 is independently a hydrogen atom or methyl group; for Z = O and S, R
2 is not required; R
2 is selected from the group consisting of H or a linear, branched, or cyclic alkyl
group containing one to eight carbon atoms, any of which may be further substituted
with at least one hydroxy group, amido, ether, amino, carboxyl, carbonyl groups and
combinations; a linear or branched alkyleneoxy group, specifically ethyleneoxy groups,
[CH
2CH
2O]
p wherein p is between 1 and 200, or 1 and 100, or 1 and 50, or 1 and 25, or 1 and
20, optionally substituted with one or more hydroxyl, amino, amido, ether, carbonyl,
carboxyl, and combinations thereof; a C
1-C
6 linear or branched fluoroalkyl groups optionally substituted with one or more hydroxyl,
amino, amido, ether, carbonyl, carboxyl, and combinations thereof; a substituted or
un-substituted aryl groups, specifically phenyl groups, wherein the substituents are
selected from halogen, hydroxyl, alkoxy, alkylcarbonyl, carboxy, and linear or branched
or cyclic alkyl groups which may be further substituted with halogen, hydroxyl, alkoxy,
alkylcarbonyl, and carboxyl groups, and combinations thereof; and n
1 and n
2 are independently selected from is 4 to 100; 4 to 50; or 4 to 25, and n
3 is 1-50, 1-20, and 1-10.
[0076] The ratio of the first hydroxyl-containing silicone component to any of the above
described second hydroxyl substituted, poly(disubstituted siloxane) can be in a range
of 0.2-1.3, 0.4-1.3, 0.4-1 and 0.6-1.
[0077] The hydroxyl-containing silicone components may be present in amounts between about
40-about 70wt%, or about 45-about 70wt%.
Silicone-Containing Compounds without Hydroxyl Functionality
[0078] Additional silicone-containing compounds without hydroxyl functionality may also
be included. Suitable examples include those of Formula XIII:

wherein in Formula XIII at least one R
1 is a monovalent reactive group, and the remaining R
1 are independently selected from monovalent reactive groups, monovalent alkyl groups,
or monovalent aryl groups, any of the foregoing which may further comprise functionality
selected from hydroxy, amino, oxa, carboxy, alkyl carboxy, alkoxy, amido, carbamate,
carbonate, halogen or combinations thereof; fluoroalkyl alkyl or aryl groups; partially
fluorinated alkyl or aryl groups; halogens; linear, branched or cyclic alkoxy or aryloxy
groups; linear or branched polyethyleneoxyalkyl groups, polypropyleneoxyalkyl groups,
or poly(ethyleneoxy-co-propyleneoxyalkyl groups; and monovalent siloxane chains comprising
between 1-100 siloxane repeat units which may further comprise functionality selected
from alkyl, alkoxy, hydroxy, amino, oxa, carboxy, alkyl carboxy, alkoxy, amido, carbamate,
halogen or combinations thereof; and wherein n is 0 to 500 or 0 to 200, or 0 to 100,or
0 to 20, where it is understood that when n is other than 0, n is a distribution having
a mode equal to a stated value.
[0079] In Formula XIII, from one to three R
1 may comprise monovalent reactive groups. Suitable monovalent alkyl and aryl groups
include unsubstituted and substituted monovalent linear, branched or cyclic C
1 to C
16 alkyl groups, or unsubstituted monovalent C
1 to C
6 alkyl groups, such as substituted and unsubstituted methyl, ethyl, propyl, butyl,
substituted or unsubstituted C
6-C
14 aryl groups, or a substituted or un-substituted C
6 aryl group, wherein the substituents include amido, ether, amino, halo, hydroxyl,
carboxyl, carbonyl groups; or a phenyl or benzyl group, combinations thereof and the
like.
[0080] When one R
1 is a monovalent reactive group, the additional silicone containing compounds may
be selected from the polydisubstituted siloxane macromer of Formula XIVa or XIVb;
the styryl polydisubstituted siloxane macromer of Formula XVa or XVb; or the carbosilane
of Formula XVc:

wherein R
1 is a hydrogen atom or methyl; Z is selected from O, N, S or NCH
2CH
2O; when Z = O or S, R
2 is not required; wherein R
2 is selected from the group consisting of H or a linear, branched, or cyclic alkyl
group containing one to eight carbon atoms, any of which may be further substituted
with at least one hydroxy group, amido, ether, amino, carboxyl, carbonyl groups and
combinations; a linear or branched alkyleneoxy group, specifically ethyleneoxy groups,
[CH
2CH
2O]
p wherein p is between 1 and 200, or 1 and 100, or 1 and 50, or 1 and 25, or 1 and
20, optionally substituted with one or more hydroxyl, amino, amido, ether, carbonyl,
carboxyl, and combinations thereof; a C
1-C
6 linear or branched fluoroalkyl groups optionally substituted with one or more hydroxyl,
amino, amido, ether, carbonyl, carboxyl, and combinations thereof; a substituted or
un-substituted aryl groups, specifically phenyl groups, wherein the substituents are
selected from halogen, hydroxyl, alkoxy, alkylcarbonyl, carboxy, and linear or branched
or cyclic alkyl groups which may be further substituted with halogen, hydroxyl, alkoxy,
alkylcarbonyl, and carboxyl groups, and combinations thereof; wherein R
3 is a substituted or unsubstituted C
1-6, C
1-4 or C
2-4 alkylene segment (CH
2)
r each methylene group may optionally be independently substituted with ethers, amines,
carbonyls, carboxylates, carbamates and combinations thereof; or an oxyalkylene segment
(OCH
2)
k and k is a whole number from one to three, or wherein R
3 may be a mixture of alkylene and oxyalkylene segments and the sum of r and k is between
1 and 9; wherein each R
4 is independently a linear, branched, or cyclic alkyl group containing between one
and six carbon atoms, a linear, branched, or cyclic alkoxy group containing between
one and six carbon atoms, a linear or branched polyethyleneoxyalkyl group, a phenyl
group, a benzyl group, a substituted or un-substituted aryl group, a fluoroalkyl group,
a partially fluorinated alkyl group, a perfluoroalkyl group, a fluorine atom, or combinations
thereof; wherein R
5 is a substituted or un-substituted linear or branched alkyl group having 1 to eight
carbon atoms, or 1 to 4 carbon atoms, or methyl or butyl; or an aryl group, any of
which may be substituted with one or more fluorine atoms; wherein j is a whole number
between 1 and 20; wherein q is up to 50, 5 to 30 or 10-25; and wherein n
1 and n
2 are independently selected from is 4 to 100; 4 to 50; or 4 to 25, and n
3 is 1-50, 1-20, and 1-10.
[0081] When Z is O, non-limiting examples of polysiloxane macromers include monomethacryloxypropyl
terminated mono-n-butyl terminated polydimethylsiloxanes (mPDMS) as shown in Formula
XVI wherein n is between 3 and 15; monomethacryloxypropyl terminated mono-n-alkyl
terminated polydimethylsiloxanes, mono-n-alkyl terminated, polydimethyl, polyethylene
glycol siloxanes as shown in Formula XVIIa and XVIIb wherein R
1 is a proton or methyl group; wherein R
5 may be C
1-C
4 alkyl or methyl or butyl; wherein n is 3-15; wherein n
1 and n
2 are between 4 to 100, 4 to 50, or 4 to 25, and n
3 is 1-50, 1-20, or 1-10; and macromers having the chemical structures as shown in
formulae XVIIIa through XXIb wherein R
1 is a proton or methyl group; wherein n is between 4-100, 4 and 20, or between 3 and
15; wherein n
1 and n
2 are between 4 to 100, 4 to 50, or 4 to 25, and n
3 is 1-50, 1-20, or 1-10; and R
5 may be C
1-C
4 alkyl or methyl or butyl.

[0082] Examples of suitable mono(meth)acryloxyalkylpolydisubstituted siloxanes include mono(meth)acryloxypropyl
terminated mono-n-butyl terminated polydimethylsiloxane, mono(meth)acryloxypropyl
terminated mono-n-methyl terminated polydimethylsiloxane, mono(meth)acryloxypropyl
terminated mono-n-butyl terminated polydiethylsiloxane, mono(meth)acryloxypropyl terminated
mono-n-methyl terminated polydiethylsiloxane, mono(meth)acrylamidoalkylpolydialkylsiloxanes
mono(meth)acryloxyalkyl terminated mono-alkyl polydiarylsiloxanes, and mixtures thereof.
[0083] In Formula XIII, when n is zero, one R
1 may be a monovalent reactive group, and at least 3 R
1 are selected from monovalent alkyl groups having 1 to 16, 1 to 6 or 1-4 carbon atoms.
Non-limiting examples of silicone components include, 3-methacryloxypropyltris(trimethylsiloxy)silane
(TRIS), 3-methacryloxypropyl-bis(trimethylsiloxy)methylsilane, and 3-methacryloxypropylpentamethyl
disiloxane.
[0084] The number of siloxane repeating units, n, may also be 2 to 50, 3 to 25, or 3 to
15; wherein at least one terminal R
1 comprises a monovalent reactive group and the remaining R
1 are selected from monovalent alkyl groups having 1 to 16 carbon atoms, or from monovalent
alkyl groups having 1 to 6 carbon atoms. Non-hydroxyl containing silicone compounds
may also include those where n is 3 to 15, one terminal R
1 comprises a monovalent reactive group, the other terminal R
1 comprises a monovalent alkyl group having 1 to 6 carbon atoms and the remaining R
1 comprise monovalent alkyl group having 1 to 3 carbon atoms. Non-limiting examples
of silicone components include monomethacryloxypropyl n-butyl terminated polydimethylsiloxanes
(M
n=800-1000), (mPDMS, as shown in XXII).

[0085] Formula XIII may also include compounds where n is 5 to 400 or from 10 to 300, both
terminal R
1 comprise monovalent reactive groups and the remaining R
1 are independently of one another selected from monovalent alkyl groups having 1 to
18 carbon atoms which may have ether linkages between carbon atoms and may further
comprise halogen.
[0086] One to four R
1 in Formula XIII may comprise a vinyl carbonate or vinyl carbamate of Formula XXIIIa:

wherein Y denotes O-, S- or NH-; R
1 denotes a hydrogen atom or methyl.
[0087] The silicone-containing vinyl carbonate or vinyl carbamate monomers specifically
include: 1,3-bis[4-(vinyloxycarbonyloxy)but-1-yl]tetramethyl-disiloxane; 3-(vinyloxycarbonylthio)
propyl-[tris (trimethylsiloxy)silane]; 3-[tris(trimethylsiloxy)silyl] propyl allyl
carbamate; 3-[tris(trimethylsiloxy)silyl] propyl vinyl carbamate; trimethylsilylethyl
vinyl carbonate; trimethylsilylmethyl vinyl carbonate, and the crosslinking agent
of Formula XXIIIb.

[0088] Where biomedical devices with moduli below about 200 psi are desired, only one R
1 comprises a monovalent reactive group and no more than two of the remaining R
1 groups comprise monovalent siloxane groups.
[0089] Another suitable silicone-containing macromer is compound of Formula XXIV in which
the sum of x and y is a number in the range of 10 to 30. The silicone containing macromer
of Formula XXIV is formed by the reaction of fluoroether, hydroxy-terminated polydimethylsiloxane,
isophorone diisocyanate and isocyanatoethylmethacrylate.

[0090] The non-hydroxyl containing silicone-containing component may be selected from non-hydroxyl
containing acrylamide silicones of
U.S. Patent No. 8,415,405. Other silicone components suitable for use in this invention include those described
is
WO 96/31792 such as macromers containing polysiloxane, polyalkylene ether, diisocyanate, polyfluorinated
hydrocarbon, polyfluorinated ether and polysaccharide groups. Another class of suitable
silicone-containing components includes silicone-containing macromers made via GTP,
such as those disclosed in
U.S. Patent Nos. 5,314,960,
5,331,067,
5,244,981,
5,371,147, and
6,367,929.
U.S. Patent Nos. 5,321,108,
5,387,662, and
5,539,016 describe polysiloxanes with a polar fluorinated graft or side group having a hydrogen
atom attached to a terminal difluoro-substituted carbon atom.
US 2002/0016383 describes hydrophilic siloxanyl methacrylates containing ether and siloxanyl linkages
and crosslinkable monomers containing polyether and polysiloxanyl groups. Any of the
foregoing polysiloxanes can also be used as the silicone-containing component in this
invention.
[0091] In one embodiment where a modulus of less than about 120 psi is desired, the majority
of the mass fraction of the silicone-containing components used in the lens formulation
should contain only one polymerizable functional group.
[0092] The non-hydroxyl containing silicone component may be selected from the group consisting
of monomethacryloxypropyl terminated, mono-n-alkyl terminated linear polydisubstituted
siloxane; methacryloxypropyl-terminated linear polydisubstituted siloxane; and mixtures
thereof.
[0093] The non-hydroxyl containing silicone component may also be selected from monomethacrylate
terminated, C
1-C
4 alkyl terminated, linear polydimethylsiloxanes; and mixtures thereof.
[0094] In some instances, the non-hydroxyl functionalized silicone-containing component
may be used in amounts up to about 10 wt%. Examples include those selected from mPDMS
of Formula XXII where R
5 is methyl or butyl, compounds of Formulae XXVIa, XVIIb through XVIIIb, XX, XXIa,
XXIb and the macromers shown in Formula XXV or XXVI where n is n is 1-50 and m is
1-50, 1-20 or 1-10:

[0095] Specific examples of non-hydroxyl functionalized silicone-containing components include
mPDMS of Formula XVIIa, compounds of Formulae XVIII or XIX where R
1 is methyl and R
5 is selected from methyl or butyl and the macromers shown in Formula XXV where n is
1-50 or 4-40, 4-20.
[0096] Specific examples of silicone containing crosslinkers include bismethacryloxypropyl
polydimethyl siloxane, where n may be 4-200, or 4-150, and the following compounds
of Formula XXVIIa-XXVIIIc, where n
1 and n
2 are independently selected from 4 to 100; 4 to 50; or 4 to 25; n
3 is 1-50, 1-20 or 1-10; n is 1-100, 1-50, 1-20 or 1-10; m is 1-100, 1-50, 1-20 or
1-10; s is up to 50, 5-30 or 10-25; and q is up to 50, 5-30 or 10-25.

[0097] The non-hydroxyl containing silicone component may have an average molecular weight
of from about 400 to about 4000 Daltons.
[0098] The silicone-containing component(s) (both hydroxyl and non-hydroxyl containing)
may be present in amounts up to about 85 weight %, or from about 10 and about 80,
or from about 20 and about 75 weight %, based upon all reactive components of the
reactive mixture (e.g., excluding diluents).
Charged Reactive Component
[0099] The reactive monomer mixture may further comprise at least one reactive component
which is charged under physiological conditions. The charged monomer may be selected
from anions, cations, zwitterions, betaines, and mixtures thereof.
[0100] The charged monomers, when incorporated into the silicone hydrogels of the present
invention, provide a net negative charge distribution. Anionic monomers comprise at
least one anionic group and at least one reactive group. Specifically, the anionic
group can include, but is not limited to, carboxylate groups, phosphates, sulfates,
sulfonates, phosphonates, borates, and mixtures thereof. The anionic groups may comprise
from three to ten carbon atoms, or from three to eight carbon atoms. The anionic groups
may comprise carboxylic acid groups. Specifically, the charged monomer may be a carboxylic
acid monomer selected from the group consisting of acrylic acid, methacrylic acid,
furmaric acid, maelic acid, itaconic acid, crotonic acid, cinnamic acid, vinylbenzoic
acid, monoesters of furmaric acid, maelic acid, and itaconic acid, and mixtures thereof.
[0101] The charged monomer may also comprise a mixture of anionic and cationic monomer.
[0102] The charged monomer can be a zwitterionic monomer. Zwitterionic monomers comprise
at least one zwitterionic group and at least one reactive group. As used herein, the
term "zwitterion" refers to a neutral chemical compound with both a positive and negative
electrical charge. Zwitterionic monomers include betaine monomers.
[0103] The charged monomer can be a betaine monomer. Betaine monomers comprise at least
one betaine group and at least one reactive group. As used herein, the term "betaine"
refers to a neutral chemical compound with a positively charged cationic functional
group such as a quaternary ammonium or phosphonium cation which bears no hydrogen
atom and with negatively charged functional group such as a carboxylate group which
may not be adjacent to the cationic site.
[0104] The charged monomer contains at least one polymerizable group, or reactive group.
Reactive groups include groups that can undergo free radical polymerization. Non-limiting
examples of free radical reactive groups include (meth)acrylates, styryls, vinyls,
vinyl ethers, C
1-6 alkyl(meth)acrylates, (meth)acrylamides, C
1-6 alkyl (meth)acrylamides, N-vinyllactams, N-vinylamides, C
2-12 alkenyls, C
2-12 alkenylphenyls, C
2-12 alkenylnaphthyls, C
2-6 alkenylphenyl, C
1-6 alkyls, O-vinylcarbamates, and O-vinylcarbonates.
[0105] Examples of "charged monomers" include (meth)acrylic acid, N-[(ethenyloxy)carbonyl]-β-alanine
(VINAL,
CAS #148969-96-4), 3-acrylamidopropanoic acid (ACA1), 5-acrylamidopropanoic acid (ACA2), 3-acrylamido-3-methylbutanoic
acid (AMBA), 2-(methacryloyloxy)ethyl trimethylammonium chloride (Q Salt or METAC),
2-acrylamido-2-methylpropane sulfonic acid (AMPS), 1-propanaminium, N-(2-carboxyethyl)-N,N-dimethyl-3-[(1-oxo-2-propen-1-yl)amino]-,
inner salt (CBT, carboxybetaine;
CAS 79704-35-1), 1-propanaminium, N,N-dimethyl-N-[3-[(1-oxo-2-propen-1-yl)amino]propyl]-3-sulfo-,
inner salt (SBT, sulfobetaine,
CAS 80293-60-3), 3,5-Dioxa-8-aza-4-phosphaundec-10-en-1-aminium, 4-hydroxy-N,N,N-trimethyl-9-oxo-,
inner salt, 4-oxide (9CI) (PBT, phosphobetaine,
CAS 163674-35-9, 2-methacryloyloxyethyl phosphorylcholine, 3-(dimethyl(4-vinylbenzyl)ammonio)propane-1-sulfonate
(DMVBAPS), 3-((3-acrylamidopropyl)dimethylammonio)propane-1-sulfonate (AMPDAPS), 3-((3-methacrylamidopropyl)dimethylammonio)propane-1-sulfonate
(MAMPDAPS), 3-((3-(acryloyloxy)propyl)dimethylammonio)propane-1-sulfonate (APDAPS),
methacryloyloxy)propyl)dimethylammonio)propane-1-sulfonate (MAPDAPS).
[0106] The charged monomer may be selected from (meth)acrylic acid, 3-acrylamidopropanoic
acid (ACA1), 5-acrylamidopropanoic acid (ACA2), and mixtures thereof..
[0107] The charged monomer can be present in an amount up to about 10 weight percent (wt.
%), based on the total weight of the reaction monomer mixture, including a range of
about 0.5 to about 5 wt.%, about 0.5 to about 3 wt.%, about 0.5 to about 2 wt.%, about
1 to about 10 wt.%, about 1 to about 5 wt.%, about 1 to about 3 wt.%, and about 1
to about 2 wt.%.
Hydrophilic Components
[0108] The reactive monomer mixture also includes at least one hydrophilic component selected
from hydrophilic monomers and macromers. Hydrophilic monomers can be any of the hydrophilic
monomers known to be useful to make hydrogels. Examples of suitable families of hydrophilic
monomers include
N-vinyl amides,
N-vinylimides,
N-vinyl lactams, (meth)acrylates, (meth)acrylamides, styrenes, vinyl ethers,
O-vinyl carbonates,
O-vinyl carbamates,
N-vinyl ureas, other hydrophilic vinyl compounds and mixtures thereof.
[0109] The hydrophilic monomers that may be used to make the polymers of this invention
have at least one polymerizable double bond and at least one hydrophilic functional
group. Such hydrophilic monomers may themselves be used as crosslinking agents, however,
where hydrophilic monomers having more than one polymerizable functional group are
used, their concentration should be limited as discussed above to provide a contact
lens having the desired modulus. The term "vinyl-type" or "vinyl-containing" monomers
refer to monomers containing the vinyl grouping (-CH=CH
2) and are generally highly reactive. Such hydrophilic vinyl-containing monomers are
known to polymerize relatively easily.
[0110] "Acrylic-type" or "acrylic-containing" monomers are those monomers containing an
acrylic group (CH
2=CRCOX) wherein R is H or CH
3, and X is O or N, which are also known to polymerize readily, such as
N,N-dimethyl acrylamide (DMA), 2-hydroxyethyl methacrylamide, polyethyleneglycol monomethacrylate,
methacrylic acid, acrylic acid, mixtures thereof and the like.
[0111] Non-limiting examples of hydrophilic (meth)acrylate and (meth)acrylamide monomers
include: acrylamide, N-isopropyl acrylamide, N,N-dimethylaminopropyl (meth)acrylamide,
N,N-dimethyl acrylamide (DMA), N-2-hydroxyethyl (meth)acrylamide, 2,3-dihydroxypropyl
(meth)acrylamide, N,N-bis(2-hydroxyethyl) (meth)acrylamide, N-(2-hydroxypropyl) (meth)acrylamide,
N,N-bis(2-hydroxypropyl) (meth)acrylamide, N-(3-hydroxypropyl) (meth)acrylamide, vinyl
acetate, acrylonitrile, and mixtures thereof.
[0112] Non-limiting examples of hydrophilic N-vinyl lactam and N-vinyl amide monomers include:
N-vinyl pyrrolidone (NVP), N-vinyl-2-piperidone, N-vinyl-2-caprolactam, N-vinyl-3-methyl-2-caprolactam,
N-vinyl-3-methyl-2-piperidone, N-vinyl-4-methyl-2-piperidone, N-vinyl-4-methyl-2-caprolactam,
N-vinyl-3-ethyl-2- pyrrolidone, N-vinyl-4,5-dimethyl-2-pyrrolidone, N-vinyl acetamide
(NVA), N-vinyl-N-methylacetamide (VMA), N-vinyl-N-ethyl acetamide, N-vinyl-N-ethyl
formamide, N-vinyl formamide, N-vinyl-N-methylpropionamide, N-vinyl-N-methyl-2-methylpropionamide,
N-vinyl-2-methylpropionamide, N-vinyl-N,N'-dimethylurea, 1-methyl-3-methylene-2-pyrrolidone,
1-methyl-5-methylene-2-pyrrolidone, 5-methyl-3-methylene-2-pyrrolidone; 1-ethyl-5-methylene-2-pyrrolidone,
N-methyl-3-methylene-2-pyrrolidone, 5-ethyl-3-methylene-2-pyrrolidone, 1-N-propyl-3-methylene-2-pyrrolidone,
1-N-propyl-5-methylene-2-pyrrolidone, 1-isopropyl-3-methylene-2-pyrrolidone, 1-isopropyl-5-methylene-2-pyrrolidone,
N-vinyl-N-ethyl acetamide, N-vinyl-N-ethyl formamide, N-vinyl formamide, N-vinyl isopropylamide,
N-vinyl caprolactam, N-carboxyvinyl-β-alanine (VINAL), N-carboxyvinyl-α-alanine, N-vinylimidazole,
and mixtures thereof.
[0113] Non-limiting examples of hydrophilic O-vinyl carbamates and O-vinyl carbonates monomers
include: N-2-hydroxyethyl vinyl carbamate and N-carboxy-β-alanine N-vinyl ester. Further
examples of the hydrophilic vinyl carbonate or vinyl carbamate monomers are disclosed
in
U.S. Patent No. 5,070,215, and the hydrophilic oxazolone monomers are disclosed in
U.S. Patent No. 4,910,277.
[0114] Other hydrophilic vinyl compounds include ethylene glycol vinyl ether (EGVE), di(ethylene
glycol) vinyl ether (DEGVE), allyl alcohol, 2-ethyl oxazoline, vinyl acetate, acrylonitrile,
and mixtures thereof.
[0115] Other suitable hydrophilic monomers will be apparent to one skilled in the art.
[0116] The hydrophilic components of the present invention may also be macromers of linear
or branched poly(ethylene glycol), poly(propylene glycol), or statistically random
or block copolymers of ethylene oxide and propylene oxide. The macromers of these
polyethers have one or more reactive group. Non-limiting examples of such reactive
groups are acrylates, methacrylates, styrenes, vinyl ethers, acrylamides, methacrylamides,
and other vinyl compounds. In one embodiment, the macromers of these polyethers comprise
(meth)acrylates, (meth)acrylamides, and mixtures thereof.
[0117] The hydrophilic monomers which may be incorporated into the polymers disclosed herein
may be selected from
N,N-dimethyl acrylamide (DMA), 2-hydroxyethyl acrylamide, 2-hydroxyethyl methacrylamide,
N-hydroxypropyl methacrylamide, bishydroxyethyl acrylamide, 2,3-dihydroxypropyl (meth)acrylamide,
N-vinylpyrrolidone (NVP),
N-vinyl-
N-methyl acetamide,
N-vinyl methacetamide (VMA), and polyethyleneglycol monomethacrylate.
[0118] The hydrophilic monomers may be selected from DMA, NVP, VMA, NVA, and mixtures thereof.
[0119] It is a surprising effect of the present invention that silicone hydrogels with a
desirable balance of wettability, water content and biocompatibility may be formed
from reaction mixtures with 35 wt%, or less or less than about 30 wt%, or less than
about 25 wt%, or less than about 20 wt% hydrophilic amide monomers. The hydrophilic
amide monomers may be included in the reactive mixtures of the present invention in
amounts between about 5 and 28 wt%, or 5 and about 25 wt%, or between about 8 and
about 20 wt%.
[0120] The hydrophilic components (including the charged components and the hydrophilic
hydroxyl components (discussed below), but excluding the polyamide) may be present
in amounts up to about 50 wt%, or in an amount in the range of about 10 to about 50
wt. %, or in the range of about 10 to about 40 wt. %, based on the total weight of
the reactive components in the reactive monomer mixture.
Hydroxyl alkyl methacrylate monomer
[0121] The reactive mixtures of the present invention may further comprise, in addition
to the hydrophilic monomer described above, at least one hydroxyalkyl (meth)acrylate
where the hydroxyl alkyl group may be selected from C
2-C
4 mono or dihydroxy substituted alkyl, and poly(ethylene glycol) having 1-10 repeating
units; or is selected from 2-hydroxyethyl, 2,3-dihydroxypropyl, or 2-hydroxypropyl.
[0122] Examples of suitable hydroxyalkyl (meth)acrylate monomer include 2-hydroxyethyl (meth)acrylate,
3-hydroxypropyl (meth)acrylate, 2-hydroxypropyl (meth)acrylate, 2,3-dihydroxypropyl
(meth)acrylate, 2-hydroxybutyl (meth)acrylate, 3-hydroxybutyl (meth)acrylate, 1-hydroxypropyl-2-(meth)acrylate,
2-hydroxy-2-methylpropyl (meth)acrylate, 3-hydroxy-2,2-dimethyl-propyl (meth)acrylate,
4-hydroxybutyl (meth)acrylate, glycerol (meth)acrylate, polyethyleneglycol monomethacrylate,
and mixtures thereof.
[0123] The hydroxyalkyl monomer may also be selected from the group consisting of 2-hydroxyethyl
methacrylate, glycerol methacrylate, 2-hydroxypropyl methacrylate, hydroxybutyl methacrylate,
3-hydroxy-2,2-dimethyl-propyl methacrylate, and mixtures thereof.
[0124] The hydroxyalkyl monomer may comprise 2-hydroxyethyl methacrylate, 3-hydroxy-2,2-dimethyl-propyl
methacrylate, hydroxybutyl methacrylate or glycerol methacrylate.
[0125] Hydroxyl containing (meth)acrylamides are generally too hydrophilic to be included
as compatibilizing hydroxyalkyl monomers, and when included are hydrophilic monomers.
[0126] When at least one hydroxyalkyl methacrylate is included, the lower amount of hydroxyalkyl
monomers may be selected to provide a haze value to the final lens of less than about
50% or less than about 30%.
[0127] It will be appreciated that the amount of hydroxyl component will vary depending
upon a number of factors, including, the number of hydroxyl groups on the hydroxyalkyl
monomer, the amount, molecular weight and presence of hydrophilic functionality on
the silicone containing components. The hydrophilic hydroxyl component may be present
in the reactive mixture in amounts up to about 15%, up to about 10 wt%, between about
3 and about 15 wt% or about 5 and about 15 wt%.
Cross-linking Agent
[0128] It is generally desirable to add one or more cross-linking agents to the reaction
mixture. The cross-linking agents may be selected from bifunctional cross-linkers,
trifunctional cross-linkers, tetrafunctional cross-linkers, including silicone-containing
and non-silicone containing cross-linking agents, and mixtures thereof. Non-silicone
containing cross-linking agents include ethylene glycol dimethacrylate ("EGDMA"),
diethyleneglycol dimethacrylate; tetraethylene glycol dimethacrylate (TEGDMA), trimethylolpropane
trimethacrylate ("TMPTMA"), glycerol trimethacrylate, 1,3-propanediol dimethacrylate;
2,3-propanediol dimethacrylate; 1,6-hexanediol dimethacrylate; 1,4-butanediol dimethacrylate;
triallyl cyanurate (TAC), methacryloxyethyl vinylcarbonate (HEMAVc), allylmethacrylate,
methylene bisacrylamide (MBA), polyethylene glycol dimethacrylate (wherein the polyethylene
glycol has a molecular weight up to about 5000 Daltons). The cross-linking agents
are used in amounts from about 0.000415 to about 0.0156 moles per 100 grams of reactive
components in the reaction mixture. Alternatively, if the hydrophilic monomers and/or
the silicone-containing components are multifunctional or contain multifunctional
impurities, the addition of a crosslinking agent to the reaction mixture is optional.
Examples of hydrophilic monomers which can act as the crosslinking agent and when
present do not require the addition of an additional crosslinking agent to the reaction
mixture include (meth)acrylate and (meth)acrylamide endcapped polyethers.
Further Constituents
[0129] The reactive monomer mixture may contain additional components such as, but not limited
to, diluents, wetting agents, light absorbing compounds, including UV absorbers and
photochromic compounds, tints, pigment and dyes, any of which may be reactive or non-reactive,
but capable of being retained in the biomedical device, medicinal agents, antimicrobial
compounds, pharmaceutical compounds, nutriceutical compounds, release agents, releasable
wetting agents, and combinations thereof.
[0130] The reactive components may be mixed in a diluent to form a reaction mixture. Suitable
diluents are known in the art. For silicone hydrogels suitable diluents are disclosed
in
WO 03/022321 and
US6020445.
[0131] Classes of suitable diluents for silicone hydrogel reaction mixtures include alcohols
having 2 to 20 carbons, amides having 10 to 20 carbon atoms derived from primary amines,
and carboxylic acids having 8 to 20 carbon atoms. Primary and tertiary alcohols may
be used. Preferred classes include alcohols having 5 to 20 carbons and carboxylic
acids having 10 to 20 carbon atoms.
[0132] Specific diluents which can be used include 1-ethoxy-2-propanol, diisopropylaminoethanol,
isopropanol, 3,7-dimethyl-3-octanol, 1-decanol, 1-dodecanol, 1-octanol, 1-pentanol,
2-pentanol, 1-hexanol, 2-hexanol, 2-octanol, 3-methyl- 3-pentanol, tert-amyl alcohol,
tert-butanol, 2-butanol, 1-butanol, 2-methyl-2-pentanol, 2-propanol, 1-propanol, ethanol,
2-ethyl-1-butanol, (3-acetoxy-2-hydroxypropyloxy) propylbis(trimethylsiloxy)methylsilane,
1-tert-butoxy-2-propanol, 3,3-dimethyl-2-butanol, tert-butoxyethanol, 2-octyl-1-dodecanol,
decanoic acid, octanoic acid, dodecanoic acid, 2-(diisopropylamino)ethanol mixtures
thereof and the like.
[0133] The diluents may include 3,7-dimethyl-3-octanol, 1-dodecanol, 1-decanol, 1-octanol,
1-pentanol, 1-hexanol, 2-hexanol, 2-octanol, 3-methyl-3-pentanol, 2-pentanol, t-amyl
alcohol, tert-butanol, 2-butanol, 1-butanol, 2-methyl-2-pentanol, 2-ethyl-1-butanol,
ethanol, 3,3-dimethyl-2-butanol, 2-octyl-1-dodecanol, decanoic acid, octanoic acid,
dodecanoic acid, mixtures thereof and the like.
[0134] The diluents may include 3,7-dimethyl-3-octanol, 1-dodecanol, 1-decanol, 1-octanol,
1-pentanol, 1-hexanol, 2-hexanol, 2-octanol, 1-dodecanol, 3-methyl-3-pentanol, 1-pentanol,
2-pentanol, t-amyl alcohol, tert-butanol, 2-butanol, 1-butanol, 2-methyl-2-pentanol,
2-ethyl-1-butanol, 3,3-dimethyl-2-butanol, 2-octyl-1-dodecanol, mixtures thereof and
the like.
[0135] Mixtures of diluents may be used. If a diluent is present, generally there are no
particular restrictions with respect to the amount of diluent present. When diluent
is used, the diluent may be present in an amount in the range of about 2 to about
70 wt%, including in the range of about 5 to about 50 wt%, about 5 to about 45wt%,
about 15 to about 40 wt%, based on the total weight of the reactive mixtures (including
reactive and nonreactive components).
[0136] A polymerization catalyst may be used in the reaction mixture. The polymerization
catalyst or initiator can include at least one of lauryl peroxide, benzoyl peroxide,
iso- propyl percarbonate, azobisisobutyronitrile, and the like, that generate free
radicals at moderately elevated temperatures, and photoinitiator systems such as aromatic
alpha-hydroxy ketones, alkoxyoxybenzoins, acetophenones, acylphosphine oxides, bisacylphosphine
oxides, and a tertiary amine plus a diketone, mixtures thereof and the like. Illustrative
examples of photoinitiators are 1-hydroxycyclohexyl phenyl ketone, 2-hydroxy-2-methyl-1-phenyl-propan-1-one,
bis(2,6-dimethoxybenzoyl)-2,4-4-trimethylpentyl phosphine oxide (DMBAPO), bis(2,4,6-trimethylbenzoyl)-phenyl
phosphinthere of eoxide (Irgacure 819), 2,4,6-trimethylbenzyldiphenyl phosphine oxide
and 2,4,6-trimethylbenzoyl diphenylphosphine oxide, benzoin methyl ester and a combination
of cam- phorquinone and ethyl 4-(N,N-dimethylamino)benzoate.
[0137] Commercially available visible light initiator systems include Irgacure
® 819, Irgacure
® 1700, Irgacure
® 1800, Irgacure
® 819, Irgacure
® 1850 (all from Ciba Specialty Chemicals) and Lucrin
® TPO initiator (available from BASF). Commercially available UV photoinitiators include
Darocur
® 1173 and Darocur
® 2959 (Ciba Specialty Chemicals). These and other photoinitiators which may be used
are disclosed in
Volume III, Photoinitiators for Free Radical Cationic & Anionic Photopolymerization,
2nd Edition by J. V. Crivello & K. Dietliker; edited by G. Bradley; John Wiley and
Sons; New York; 1998. The initiator is used in the reaction mixture in effective amounts to initiate photopolymerization
of the reaction mixture, e.g., from about 0.1 to about 2 parts by weight per 100 parts
of reactive monomer. Polymerization of the reaction mixture can be initiated using
the appropriate choice of heat or visible or ultraviolet light or other means depending
on the polymerization initiator used. Alternatively, initiation can be conducted without
a photoinitiator using, for example, e-beam. However, when a photoinitiator is used,
the preferred initiators are bisacylphosphine oxides, such as bis(2,4,6-trimethylbenzoyl)-phenyl
phosphine oxide (Irgacure
® 819) or a combination of 1-hydroxycyclohexyl phenyl ketone and bis(2,6-dimethoxybenzoyl)-2,4-4-trimethylpentyl
phosphine oxide (DMBAPO), and in another embodiment the method of polymerization initiation
is via visible light activation.
[0138] Polymerization of the reaction mixture can be initiated using the appropriate choice
of heat or visible or ultraviolet light or other means depending on the polymerization
initiator used. Alternatively, initiation can be conducted without a photoinitiator
using, for example, e-beam.
Curing of Silicone Polymer/Hydrogel and Manufacture of Lens
[0139] The reactive mixtures of the present invention can be formed by any of the methods
known in the art, such as shaking or stirring, and used to form polymeric articles
or devices by known methods. The reactive components (hydrophilic monomer, hydroxyl-containing
silicone component, cross-linking agent, polyamide, etc.) are mixed together either
with or without a diluent to form the reactive mixture.
[0140] For examples, the silicone hydrogels may be prepared by mixing reactive components,
and, optionally, diluent(s), with a polymerization initiator and curing by appropriate
conditions to form a produce that can be subsequently formed into the appropriate
shape by lathing, cutting, and the like. Alternatively, the reaction mixture may be
placed in a mold and subsequently cure into the appropriate article.
[0141] The reactive mixture of the present invention may be cured via any known process
for molding the reaction mixture in the production of contact lenses, including spincasting
and static casting. Spincasting methods are disclosed in
US3,408,429 and
US3,660,545, and static casting methods are disclosed in
US 4,113,224 and
US4,197,266. The contact lenses of this invention may be formed by the direct molding of the
silicone hydrogels, which is economical, and enables precise control over the final
shape of the hydrated lens. For this method, the reaction mixture is placed in a mold
having the shape of the final desired silicone hydrogel and the reaction mixture is
subjected to conditions whereby the monomers polymerize, to thereby produce a polymer
in the approximate shape of the final desired product.
[0142] After curing, the lens may be subjected to extraction to remove unreacted components
and release the lens from the lens mold. The extraction may be done using conventional
extraction fluids, such organic solvents, such as alcohols or may be extracted using
aqueous solutions.
[0143] Aqueous solutions are solutions which comprise water. The aqueous solutions of the
present invention may comprise at least about 30 weight % water, or at least about
50 weight % water, or at least about 70% water, or at least about 90 weight % water.
Aqueous solutions may also include additional water soluble components such as release
agents, wetting agents, slip agents, pharmaceutical and nutraceutical components,
combinations thereof and the like. Release agents are compounds or mixtures of compounds
which, when combined with water, decrease the time required to release a contact lens
from a mold, as compared to the time required to release such a lens using an aqueous
solution that does not comprise the release agent. The aqueous solutions may comprise
less than about 10 weight %, or less than about 5 weight % organic solvents such as
isopropyl alcohol, or may be free from organic solvents. The aqueous solutions may
not require special handling, such as purification, recycling or special disposal
procedures.
[0144] In various embodiments, extraction can be accomplished, for example, via immersion
of the lens in an aqueous solution or exposing the lens to a flow of an aqueous solution.
In various embodiments, extraction can also include, for example, one or more of:
heating the aqueous solution; stirring the aqueous solution; increasing the level
of release aid in the aqueous solution to a level sufficient to cause release of the
lens; mechanical or ultrasonic agitation of the lens; and incorporating at least one
leach aid in the aqueous solution to a level sufficient to facilitate adequate removal
of unreacted components from the lens. The foregoing may be conducted in batch or
continuous processes, with or without the addition of heat, agitation or both.
[0145] Some embodiments can also include the application of physical agitation to facilitate
leach and release. For example, the lens mold part to which a lens is adhered can
be vibrated or caused to move back and forth within an aqueous solution. Other embodiments
may include ultrasonic waves through the aqueous solution.
[0146] The lenses may be sterilized by known means such as, but not limited to autoclaving.
[0147] The contact lenses of the present invention display desirable combination of both
mechanical and biological properties including water content, haze, contact angle,
modulus, oxygen permeability, lipid uptake, lysozyme uptake and PQ1 uptake, as shown
in the following table. All values are prefaced by "about", and the ophthalmic devices
of the present invention may have any combination of the listed properties.
Table 1
| [H2O] % |
>20 |
>30 |
>40 |
20-60 |
30-60 |
| % haze |
>50 |
>30 |
|
|
|
| DCA (°) |
>90 |
>70 |
≥50 |
≥40 |
≥20 |
| Modulus (psi) |
>120 |
>110 |
50-120 |
50-110 |
|
| Dk (barrers) |
>80 |
80-200 |
90-180 |
100-160 |
|
| Lipid uptake (µg/lens) |
<20 |
<10 |
<5 |
|
|
| Lysozyme uptake (µg/lens) |
>50 |
>100 |
>200 |
>500 |
>700 |
| PQ1 uptake (%) |
<10 |
<5 |
|
|
|
[0148] Lysozyme uptake may also be at least about 800 or between 50 and 1500, 100-1500 or
200-1500 µg/lens.
[0149] In addition to displaying desirable stability, the lenses of the present invention
also display compatibility with the components of human tears.
Test Methods
[0150] It will be appreciated that all of the tests specified herein have a certain amount
of inherent error. Standard deviations are shown in parentheses. Accordingly, the
results reported herein are not to be taken as absolute numbers, but numerical ranges
based upon the precision of the particular test.
[0151] Haze was measured by placing a hydrated test lens in borate buffered saline in a clear
glass cell at ambient temperature above a flat black background, illuminating from
below with a fiber optic lamp (Dolan-Jenner PL-900 fiber optic light with 0.5 inch
diameter light guide) at an angle of 66° normal to the lens cell, and capturing an
image of the test lens from above, normal to the glass cell with a video camera (DVC
1310C RGB camera or equivalent equipped with a suitable zoom camera lens) placed 14
cm above the lens holder. The background scatter is subtracted from the scatter of
the test lens by subtracting an image of a blank cell with borate buffered saline
(baseline) using EPIX XCAP V 3.8 software. The subtracted scattered light image is
quantitatively analyzed by integrating over the central 10 mm of the test lens and
then compared to a frosted glass standard.
[0152] The light intensity/power setting was adjusted to achieve a mean grayscale value
in the range of 900-910 for the frosted glass standard; at this setting, the baseline
mean grayscale value was in the range of 50-70. The mean grayscale values of the baseline
and frosted glass standard are recorded and used to create a scale from zero to 100,
respectively. In the grayscale analysis, the mean and standard deviations of the baseline,
frosted glass, and every test lens was recorded. For each lens, a scaled value was
calculated according to the equation: scaled value equals the mean grayscale value
(lens minus baseline) divided by the mean grayscale value (frosted glass minus baseline)
times by 100. Three to five test lenses are analyzed, and the results are averaged.
[0153] Water content was measured gravimetrically. Lenses were equilibrated in packing solution for 24
hours. Each of three test lens are removed from packing solution using a sponge tipped
swab and placed on blotting wipes which have been dampened with packing solution.
Both sides of the lens are contacted with the wipe. Using tweezers, the test lens
are placed in a tared weighing pan and weighed. The two more sets of samples are prepared
and weighed. All weight measurements were done in triplicate, and the average of those
values used in the calculations. The wet weight is defined as the combined weight
of the pan and wet lenses minus the weight of the weighing pan alone.
[0154] The dry weight was measured by placing the sample pans in a vacuum oven which has
been preheated to 60°C for 30 minutes. Vacuum was applied until the pressure reaches
at least 1 inch of Hg is attained; lower pressures are allowed. The vacuum valve and
pump are turned off and the lenses are dried for at least 12 hours; typically overnight.
The purge valve is opened allowing dry air or dry nitrogen gas to enter. The oven
is allowed reach atmospheric pressure. The pans are removed and weighed. The dry weight
is defined as the combined weight of the pan and dry lenses minus the weight of the
weighing pan alone. The water content of the test lens was calculated as follows:

[0155] The average and standard deviation of the water content were calculated and the average
value reported as the percent water content of the test lens.
[0156] The
refractive index (RI) of a contact lens was measured by a Leica ARIAS 500 Abbe refractometer in manual
mode or by a Reichert ARIAS 500 Abbe refractometer in automatic mode with a prism
gap distance of 100 microns. The instrument was calibrated using deionized water at
20°C (+/- 0.2 °C). The prism assembly was opened and the test lens placed on the lower
prism between the magnetic dots closest to the light source. If the prism is dry,
a few drops of saline were applied to the bottom prism. The front curve of the lens
was against the bottom prism. The prism assembly was then closed. After adjusting
the controls so that the shadow line appeared in the reticle field, the refractive
index was measured. The RI measurement was made on five test lenses. The average RI
calculated from the five measurements was recorded as the refractive index as well
as its standard deviation.
[0157] Oxygen permeability (Dk) was determined by the polarographic method generally described in ISO 9913-1:1996
and ISO 18369-4:2006, but with the following modifications. The measurement was conducted
at an environment containing 2.1% oxygen created by equipping the test chamber with
nitrogen and air inputs set at the appropriate ratio, for example, 1800 mL/min of
nitrogen and 200 mL/min of air. The t/Dk is calculated using the adjusted oxygen concentration.
Borate buffered saline was used. The dark current was measured by using a pure humidified
nitrogen environment instead of applying MMA lenses. The lenses were not blotted before
measuring. Four lenses were stacked instead of using lenses of various thickness (t)
measured in centimeters. A curved sensor was used in place of a flat sensor; radius
was 7.8 mm. The calculations for a 7.8 mm radius sensor and 10% (v/v) air flow are
as follows:

[0158] The edge correction was related to the Dk of the material.
[0159] For all Dk values less than 90 barrers:

[0160] For Dk values between 90 and 300 barrers:

[0161] For Dk values greater than 300 barrers:

[0162] Non-edge corrected Dk was calculated from the reciprocal of the slope obtained from
the linear regression analysis of the data wherein the x variable was the center thickness
in centimeters and the y variable was the t/Dk value. On the other hand, edge corrected
Dk was calculated from the reciprocal of the slope obtained from the linear regression
analysis of the data wherein the x variable was the center thickness in centimeters
and the y variable was the edge corrected t/Dk value. The resulting Dk value was reported
in barrers.
[0163] Wettability of lenses was determined using the methods below. Dynamic contact angle (DCA) was
determined by a Wilhelmy plate method using a Cahn DCA-315 instrument at room temperature
and using deionized water as the probe solution. The experiment was performed by dipping
the lens specimen of known parameter into the packing solution of known surface tension
while measuring the force exerted on the sample due to wetting by a sensitive balance.
The advancing contact angle of the packing solution on the lens is determined from
the force data collected during sample dipping. The receding contact angle is likewise
determined from force data while withdrawing the sample from the liquid. The Wilhelmy
plate method is based on the following formula: Fg = γρcosθ - B, wherein F = the wetting
force between the liquid and the lens (mg), g = gravitational acceleration (980.665
cm/sec
2), γ = surface tension of probe liquid (dyne/cm), ρ = the perimeter of the contact
lens at the liquid/lens meniscus (cm), θ = the dynamic contact angle (degree), and
B = buoyancy (mg). B is zero at the zero depth of immersion. Four test strips were
cut from the central area of the contact lens. Each strip was approximately 5 mm in
width and equilibrated in packing solution. Then, each sample was cycled four times,
and the results were averaged to obtain the advancing and receding contact angles
of the lens.
[0164] Wettability of lenses was also determined using a sessile drop technique measured
using KRUSS DSA-100 TM instrument at room temperature and using DI water as probe
solution. The lenses to be tested (3-5/sample) were rinsed in DI water to remove carry
over from packing solution. Each test lens was placed on blotting lint free wipes
which were dampened with packing solution. Both sides of the lens were contacted with
the wipe to remove surface water without drying the lens. To ensure proper flattening,
lenses were placed "bowl side down" on the convex surface of contact lens plastic
molds. The plastic mold and the lens were placed in the sessile drop instrument holder,
ensuring proper central syringe alignment. A 3 to 4 microliter drop of deionized water
was formed on the syringe tip using DSA 100-Drop Shape Analysis software ensuring
the liquid drop was hanging away from the lens. The drop was released smoothly on
the lens surface by moving the needle down. The needle was withdrawn away immediately
after dispensing the drop. The liquid drop was allowed to equilibrate on the lens
for 5 to 10 seconds, and the contact angle was measured between the drop image and
the lens surface.
[0165] The
mechanical properties of the contact lenses were measured by using a tensile testing machine such as an
Instron model 1122 or 5542 equipped with a load cell and pneumatic grip controls.
Minus one diopter lens is the preferred lens geometry because of its central uniform
thickness profile. A dog-bone shaped sample cut from a -1.00 power lens having a 0.522
inch length, 0.276 inch "ear" width and 0.213 inch "neck" width was loaded into the
grips and elongated at a constant rate of strain of 2 inches per minute until it breaks.
The center thickness of the dog-bone sample was measured using an electronic thickness
gauge prior to testing. The initial gauge length of the sample (Lo) and sample length
at break (Lf) were measured. At least five specimens of each composition were measured,
and the average values were used to calculate the percent elongation to break: percent
elongation = [(Lf - Lo)/Lo] × 100. The tensile modulus was calculated as the slope
of the initial linear portion of the stress-strain curve; the units of modulus are
pounds per square inch or psi. The tensile strength was calculated from the peak load
and the original cross-sectional area: tensile strength = peak load divided by the
original cross-sectional area; the units of tensile strength are psi. Toughness was
calculated from the energy to break and the original volume of the sample: toughness
= energy to break divided by the original sample volume; the units of toughness are
in-lbs/in
3.
[0166] PQ1 uptake was measured chromatographically. The HPLC was calibrated using a series of standard
PQ1 solutions having concentrations 2, 4, 6, 8, 12 and 15 µg/mL. Lenses were placed
into polypropylene contact lens cases with 3 mL of Optifree Replenish or similar lens
solution (PQ1 concentration = 10 micrograms/mL) which is commercially available from
Alcon. A control lens case, containing 3 mL of solution, but no contact lens was also
prepared. The lenses and control solutions were stored at room temperature for 72
hours. 1 mL of solution was removed from each of the samples and controls and mixed
with trifluoroacetic acid (10 µL). The analysis was conducted using HPLC/ELSD and
a Phenomenex Luna C5 (4.6 mm × 5 mm; 5 µm particle size) column with the following
equipment and conditions: Agilent 1200 HPLC or equivalent with an ELSD operating at
T= 100°C, Gain = 12, Pressure = 4.4 bar, Filter = 3s; ELSD parameters may vary from
instrument to instrument; using mobile phase A of water (0.1% TFA) and mobile phase
B of acetonitrile (0.1% TFA), a column temperature of 40°C and an injection volume
of 100 µL. An elution profile was used and listed in Table A. A calibration curve
was created by plotting the peak area value as a function of the concentration of
the PQ1 standard solutions. The concentration of PQ1 in a sample was then calculated
by solving the quadratic equation representing the calibration curve. Three lenses
were run for each analysis, and the results were averaged. PQ1 uptake was reported
as the percentage loss of PQ1 after soak with lens compared to the PQ1 present in
the control without lens.
Table A. HPLC Elution Profile
| Time (minutes) |
% A |
% B |
Flow Rate (mL/min) |
| 0.00 |
100 |
0 |
1.2 |
| 1.00 |
100 |
0 |
1.2 |
| 5.00 |
0 |
100 |
1.2 |
| 8.50 |
0 |
100 |
1.2 |
| 8.60 |
100 |
0 |
1.2 |
| 11.00 |
100 |
0 |
1.2 |
[0167] The amount of cholesterol absorbed by a contact lens was determined by a LC-MS method
(
lipid uptake in the data tables). Lenses were soaked in a cholesterol solution and then extracted
with dichloromethane. The dichloromethane extract was evaporated and reconstituted
with a heptane/isopropanol mixture with subsequent analysis by LC-MS. The results
were reported as micrograms of cholesterol per lens. A deuterated cholesterol internal
standard was used to improve accuracy and precision of the method.
[0168] A cholesterol stock solution was prepared by placing 15.0 ± 0.5 milligrams of cholesterol
into a wide-mouth 10 mL glass volumetric flask followed by dilution with isopropanol.
[0169] A cholesterol soak solution was prepared by placing 0.430 ± 0.010 grams of lysozyme
(purity = 93%), 0.200 ± 0.010 grams of albumin, and 0.100 ± 0.010 grams of β-lactoglobulin
into a 200 mL glass volumetric flask, adding approximately 190 milliliters of PBS
to the flask, and swirling to dissolve the contents. 2 Milliliters of the cholesterol
stock solution was then added and diluted to volume with PBS. The volumetric flask
was capped and shaken well. The concentration of the cholesterol soak solution was
approximately 15 µg/mL. Note: The mass of these components may be adjusted to account
for lot-to-lot purity variability so that the target concentrations can be achieved.
[0170] Six contact lenses were removed from their packages and blotted with lint-free paper
towels to remove excess packing solution. The lenses were placed into six separate
8 mL glass vials (one lens per vial), and 3.0 mL of the cholesterol soak solution
was added to each vial. The vials were capped and placed into a New Brunswick Scientific
incubator-shaker for 72 hours at 37°C and 100 rpm. After incubation, each lens was
rinsed three times with PBS in 100 mL beakers and placed into a 20-mL scintillation
vial.
[0171] To each lens-containing scintillation vial, 5 mL of dichloromethane and 100 µL of
the internal standard solution were added. After a minimum of 16 hours of extraction
time, the supernatant liquid was transferred into a 5 mL disposable glass culture
tube. The tube was placed into the Turbovap and the solvent completely evaporated.
Place 1mL of the diluent into the culture tube and re-dissolve the contents. The aforementioned
diluent was a 70:30 (v/v) mixture of heptane and isopropanol. The diluent was also
the mobile phase. The resulting solution was carefully transferred into an autosampler
vial and ready for LC-MS analysis.
[0172] An internal standard stock solution was prepared by weighing approximately 12.5 +
2 mg of deuterated cholesterol (2,2,3,4,4,6-d6-cholesterol) in a 25 mL volumetric
flask followed by dilution with the diluent. The concentration of the internal standard
stock solution was approximately 500 µg/mL.
[0173] An internal standard solution was prepared by placing 1.0 mL of the internal standard
stock solution in a 50mL volumetric flask followed by dilution to volume with diluent.
The concentration of this intermediate internal standard solution is approximately
10 µg/mL.
[0174] A reference standard stock solution was prepared by weighing approximately 50 + 5
mg of cholesterol in a 100 mL volumetric flask followed by dilution with diluent.
The concentration of the cholesterol in this reference stock solution is approximately
500 µg/mL.
[0175] Working standard solutions were then made according to Table 2 by placing the appropriate
amount of standard solutions into the listed 25-mL, 50-mL or 100-mL volumetric flasks.
After the standard solutions were added to the volumetric flasks, the mixture was
diluted to volume with diluent and swirled well.
Table B. Working Standard Solution Formulations
| Working Standard Name |
Volume of Internal Standard Solution (mL) |
Volume of Reference Standard Stock Solution (µL) |
Final Volume (mL) |
Approximate Cholesterol Concentration (µg/mL) |
| Std 1 |
10 |
20 |
100 |
0.10 |
| Std 2 |
5 |
25 |
50 |
0.25 |
| Std 3 |
5 |
50 |
50 |
0.50 |
| Std 4 |
5 |
100 |
50 |
1.00 |
| Std 5 |
2.5 |
125 |
25 |
2.50 |
| Std 6 |
2.5 |
250 |
25 |
5.00 |
[0176] The following LC-MS analysis was performed:
- (1) Make 6 injections of the "Std4" to evaluate system suitability. The RSD% of the
peak areas for the working standards and the internal standards must be < 5% and RSD(%)
of their peak area ratios must be < 7% to pass system suitability.
- (2) Inject working standards 1-6 to create a calibration curve. The square of the
correlation coefficient (r2) must be > 0.99.
- (3) Inject test samples followed by a bracketing standard (Std4). The peak area ratio
of the bracketing standard must be within ± 10% of the averaged peak area ratio from
the system suitability injections.
[0177] A calibration curve was constructed by plotting the peak area ratio (reference std/internal
std) value that corresponds to the concentration of each working standard solution.
The concentration of cholesterol in sample is calculated by solving a quadratic equation.
Typical equipment and their settings for the LC-MS analysis are listed below and shown
in Tables C and D. The values for the instrument tune parameters may change each time
the mass spectrometer is tuned.
Turbovap Conditions:
[0178]
Temperature: 45°C
Time: 30 minutes or more to dryness
Gas: nitrogen @ 5psi
HPLC Conditions:
[0179]
HPLC: Thermo Accela HPLC Instrument or equivalent
HPLC Column: Agilent Zorbax NH2 (4.6 mm × 150 mm; 5 µm particle size)
Mobile Phase: 70% heptane and 30% isopropanol
Column Temperature: 30 °C
Injection Volume: 25 µL
Flow Rate: 1000 µL/min
Table C. Mass Spectrometry Conditions
| |
Thermo Finnigan TSQ Quantum Ultra |
| |
MS Settings |
|
Value |
| |
Ionization |
|
APCI |
| |
Polarity |
|
Positive |
| |
Scan type |
|
SIM |
| |
APCI probe position |
|
D |
| |
Mass (m/z) of Reference Standards |
|
369.2 |
| |
Mass (m/z) of Internal Standards |
|
375.3 |
| |
Mass width (m/z) |
|
1.0 |
| |
Scan time (s) |
|
0.10 |
| |
Data type |
|
Centroid |
| |
Peak Width Q3 (FWHM) |
|
0.40 |
| |
Skimmer Offset (V) |
|
10 |
Table D. Tune Parameters
| |
Instrument Tune Parameters |
|
Value |
| |
Discharge Current (arbitrary units): |
|
20 |
| |
Capillary temperature (°C): |
|
240 |
| |
Vaporizer Temperature (°C): |
|
500 |
| |
Tube lens offset (V): |
|
68 |
| |
Sheath gas pressure (arbitrary units): |
|
20 |
| |
Auxiliary gas flow (arbitrary units): |
|
15 |
[0180] The amount of
lysozyme uptake by a contact lens was measured by a HPLC-UV method. Lysozyme uptake was determined
as the difference of lysozyme content in phosphate-buffered saline solution (PBS)
before contact lenses are immersed and the concentration in the test solution after
72 hours of lens immersion at 37°C.
[0181] A lysozyme soak solution was prepared by placing 0.215 ± 0.005 grams of lysozyme
(purity = 93%) into a 100 mL volumetric flask followed by adding 50 mL of PBS to dissolve
the lysozyme by swirling followed by dilution to volume with PBS. The resulting lysozyme
soak solution was filtered/sterilized using a Millipore Stericup filtration device.
The concentration of the lysozyme soak solution is approximately 2000 µg/mL. The mass
of lysozyme may be adjusted to account for lot-to-lot purity variability so that a
2000 µg/mL concentration can be achieved.
[0182] Three contact lenses were removed from their packages and blotted with lint-free
paper towel to remove excess packing solution. The lenses were placed into three separate
8 mL glass vials (one lens per vial). 1.5 mL of the lysozyme soak solution was added
to each vial. The vials were capped and inspected to ensure each lens was completely
immersed in the soak solution. As control samples, 1.5 mL of lysozyme soak solution
were added into three separate 8 mL glass vials. The samples were then incubated on
a New Brunswick Scientific incubator-shaker for 72 hours at 37°C and 100 rpm.
[0183] A diluent was prepared by mixing 900 mL water, 100 mL acetonitrile and 1 mL trifluoroacetic
acid into a 1L glass bottle.
[0184] A lysozyme stock solution was prepared by placing 0.240 ± 0.010 grams of lysozyme
(purity = 93%) into a 100 mL volumetric flask followed by dilution to volume with
diluent. The concentration of the lysozyme stock solution is approximately 2200 µg/mL.
[0185] shown in Table E, a series of working standard solutions was prepared by mixing the
appropriate amounts of lysozyme stock solution with diluent using 5 mL volumetric
flasks.
Table E. Working Standards
| |
Working Standard Name |
|
Volume of Stock Solution (mL) |
|
Final Volume (mL) |
|
Approximate Lysozyme Concentration (µg/mL) |
| |
Std 1 |
|
1.135 |
|
5 |
|
500 |
| |
Std 2 |
|
1.815 |
|
5 |
|
800 |
| |
Std 3 |
|
2.725 |
|
5 |
|
1200 |
| |
Std 4 |
|
3.635 |
|
5 |
|
1600 |
| |
Std 5 |
|
4.540 |
|
5 |
|
2000 |
| |
Std 6 (stock) |
|
- |
|
- |
|
2200 |
[0186] A 10% (v/v) solution was prepared by adding 1 mL of trifluoroacetic acid into a 10
mL glass volumetric flask followed by dilution with HPLC water. Samples for HPLC-UV
analysis were prepared as follows: (1) by placing 1000 µL of test sample and 10 µL
of the 10% TFA solution into an autosampler vial or (2) by placing 1000 µL of reference
standard and 10 µL of reference standard diluent into an autosampler vial.
[0187] The analysis involved the following steps:
- (1) Perform 6 injections of the "Std4" to evaluate system suitability. The RSD% of
the peak areas and retention times must be < 0.5% to pass system suitability.
- (2) Inject working standards 1-6 to create a calibration curve. The square of the
correlation coefficient (r2) must be > 0.99.
- (3) Inject test samples followed by a bracketing standard (Std4). The peak area of
the bracketing standard must be ± 1% of the averaged peak areas from the system suitability
injections.
[0188] A calibration curve was constructed by plotting the peak area value that corresponds
to the concentration of each lysozyme working standard solution. The concentration
of lysozyme in the test samples was calculated by solving a linear equation. Typical
equipment and their settings are listed below or shown in Table F.
Instrument: Agilent 1200 HPLC with UV detection (or equivalent HPLC-UV)
Detection: UV @ 280 nm (5 nm bandwidth)
Column: Phenomenex Luna C5 (50 × 4.6 mm) or Agilent PLRP-S (50 × 4.6 mm)
Mobile Phase A: H2O (0.1% TFA)
Mobile Phase B: Acetonitrile (0.1% TFA)
Column Temperature: 40 °C
Injection Volume: 10 µL
Table F. HPLC Run Conditions
| |
Time (minutes) |
|
% A |
|
%B |
|
Flow Rate (mL/min) |
| |
0.0 |
|
5 |
|
5 |
|
1.2 |
| |
4.0 |
|
5 |
|
95 |
|
1.2 |
| |
4.1 |
|
5 |
|
5 |
|
1.2 |
| |
6.5 |
|
5 |
|
5 |
|
1.2 |
[0189] Alternatively, lysozyme uptake was measured as follows. A lysozyme solution was prepared
from chicken egg white (Sigma, L7651) at a concentration of 2 mg/mL in phosphate saline
buffer supplemented by sodium bicarbonate at 1.37g/L and D-glucose at 0.1 g/L.
[0190] Three lenses for each test sample were tested using each protein solution, and three
were tested using PBS as a control solution. The test lenses were blotted on sterile
gauze to remove packing solution and aseptically transferred, using sterile forceps,
into sterile 24 well cell culture plates (one lens per well) each well containing
2 mL of the lysozyme solution. Each lens was fully immersed in the solution. As controls,
2 mL of the lysozyme solution was placed in wells without a contact lens.
[0191] The plates were sealed using parafilm to prevent evaporation and dehydration and
placed onto an orbital shaker and incubated at 35°C with agitation at 100 rpm for
72 hours. After the 72 hour incubation period, the lenses were rinsed 3 to 5 times
by dipping lenses into 200 mL of PBS. The lenses were blotted on a paper towel to
remove excess PBS and transferred into sterile conical tubes (1 lens per tube), each
tube containing a volume of PBS determined based upon an estimate of lysozyme uptake
expected based upon on each lens composition. The lysozyme concentration in each tube
to be tested must be within the albumin standards range as described by the manufacturer
(0.05 micrograms to 30 micrograms). Samples known to uptake a level of lysozyme lower
than 100 µg per lens were diluted 5 times. Samples known to uptake levels of lysozyme
higher than 500 µg per lens were diluted 20 times.
[0192] Lysozyme uptake was determined using on-lens bicinchoninic acid method using QP-BCA
kit ( Sigma, QP-BCA) following the procedure described by the manufacturer and was
calculated by subtracting the optical density measured on PBS soaked lenses from the
optical density determined on lenses soaked in lysozyme solution. The optical density
was measured using a Synergy II Micro-plate reader capable of reading optical density
at 562 nm.
[0193] The invention is now described with reference to the following examples. Before describing
several exemplary embodiments of the invention, it is to be understood that the invention
is not limited to the details of construction or process steps set forth in the following
description. The invention is capable of other embodiments and of being practiced
or being carried out in various ways.
[0194] The following abbreviations will be used throughout the Examples and have the following
meanings:
BC: back curve plastic mold
FC: front curve plastic mold
RMM: reactive monomer mixture
NVP: N-vinylpyrrolidone (Acros or Aldrich)
DMA: N, N-dimethylacrylamide (Jarchem)
HEMA: 2-hydroxyethyl methacrylate (Bimax)
HPMA: 2-hydroxypropyl methacrylate
HEAA: 2-hydroxyethyl acrylate
Bis-HEAA: N,N-bis(2-hydroxyethyl) acrylamide
GMMA: 2,3-dihydroxypropyl methacrylate
HBMA: 2-hydroxybutyl methacrylate
VMA: N-vinyl N-methyl acetamide (Aldrich)
AA: acrylic acid
MAA: methacrylic acid (Acros)
VINAL: N-[(ethenyloxy)carbonyl]-β-alanine; CAS #148969-96-4
ACA1: 3-acrylamidopropanoic acid
ACA2: 5-acrylamidopropanoic acid
Q Salt or METAC: 2-(methacryloyloxy)ethyl trimethylammonium chloride
AMPS: 2-acrylamido-2-methylpropane sulfonic acid
CBT: 1-Propanaminium, N-(2-carboxyethyl)-N,N-dimethyl-3-[(1-oxo-2-propen-1-yl)amino]-, inner salt; carboxybetaine; CAS 79704-35-1
SBT: 1-Propanaminium, N,N-dimethyl-N-[3-[(1-oxo-2-propen-1-yl)amino]propyl]-3-sulfo-, inner salt; sulfobetaine; CAS 80293-60-3
PBT: 3,5-Dioxa-8-aza-4-phosphaundec-10-en-1-aminium, 4-hydroxy-N,N,N-trimethyl-9-oxo-, inner salt, 4-oxide (9CI); phosphobetaine; CAS 163674-35-9
Blue HEMA: 1-amino-4-[3-( 4-(2-methacryloyloxy-ethoxy)-6-chlorotriazin-2-ylamino)-4-sulfophenylamino]anthraquinone-2-sulfonic
acid, as described in US Patent No. 5,944,853
Styryl-TRIS: tris(trimethylsiloxy)silyl styrene (Melrob)
PVMA: poly(N-vinyl N-methyl acetamide)
PVP: poly(N-vinylpyrrolidone) (ISP Ashland)
Poly[DMA-NVP]: random or block copolymer of DMA and NVP
Poly[DMA-CBT]: random or block copolymer of DMA and CBT
EGDMA: ethylene glycol dimethacrylate (Esstech)
TEGDMA: tetraethylene glycol dimethacrylate (Esstech)
TMPTMA: trimethylolpropane trimethacrylate (Esstech)
MBA: methylene bisacrylamide (Aldrich)
TAC: Triallyl Cyanurate (Polysciences)
BMPP: 2,2-bis(4-methacryloxyphenyl)-propane (Polysciences)
BAPP: 2,2-bis[4-(2-acryloxyethoxy)phenyl]propane (Polysciences)
BHMPP: 2,2-bis[4-(2-hydroxy-3-methacryloxypropoxy)phenyl]propane (Polysciences)
Tegomer V-Si 2250: diacryloxypolydimethylsiloxane (Evonik)
Irgacure 819: bis(2,4,6-trimethylbenzoyl)-phenylphosphineoxide (BASF or Ciba Specialty
Chemicals)
Irgacure 1870: blend of bis(2,6-dimethoxybenzoyl)-2,4,4-trimethyl-pentylphosphineoxide
and 1-hydroxy-cyclohexyl-phenyl-ketone (BASF or Ciba Specialty Chemicals)
AIBN: azobisisobutyronitrile
Te-Bu: ethyl 2-methyl-2-(butyltellanyl)propanoate
TEMPO: 2,6-tetramethylpiperidine N-oxide
TERP: organotellurium mediated living radical polymerization
mPDMS: monomethacryloxypropyl terminated mono-n-butyl terminated polydimethylsiloxane
(800-1000 MW) (Gelest)
ac-PDMS: bis-3-acryloxy-2-hydroxypropyloxypropyl polydimethylsiloxane
HO-mPDMS: mono-(2-hydroxy-3-methacryloxypropyl)-propyl ether terminated mono-n-butyl
terminated polydimethylsiloxane (400-1000 MW) (Ortec or DSM-Polymer Technology Group)
TRIS: 3-methacryloxypropyl tris(trimethylsiloxy)silane
ac-TRIS: 3-acryloxypropyl tris(trimethylsiloxy)silane
SiMAA: 2-propenoic acid, 2-methyl-2-hydroxy-3-[3-[1,3,3,3-tetramethyl-1-[(trimethylsilyl)oxy]disiloxanyl]propoxy]propyl
ester (Toray)
SA2: N-(2,3-dihydroxylpropyl)-N-(3-tetra(dimethylsiloxy)-dimethylbutylsilane)propyl)
acrylamide
mPEG 950 : polyethylene glycol mono-methacrylate (Aldrich)
D3O: 3,7-dimethyl-3-octanol (Vigon)
TAM: t-amyl alcohol (BASF)
3E3P: 3-ethyl 3-pentanol
TPME: tripropylene glycol mono-methyl ether
DA: decanoic acid
DI water: deionized water
MeOH: methanol
IPA: isopropyl alcohol
Norbloc: 2-(2'-hydroxy-5-methacrylyloxyethylphenyl)-2H-benzotriazole (Janssen)
P2 Poly[DMA-NVP]: Copolymer of DMA-NVP, MW = 195 kDa by SEC-MALS, made according to Preparation 2
P3 Poly[DMA-NVP]: Copolymer of DMA-NVP, Mw (MALS) = 304 kDa, made according to Preparation 3
PP: polypropylene which is the homopolymer of propylene
TT: Tuftec which is a hydrogenated styrene butadiene block copolymer (Asahi Kasei
Chemicals)
Z: Zeonor which is a polycycloolefin thermoplastic polymer (Nippon Zeon Co Ltd)
EXAMPLES
Preparation 1 - Synthesis of poly(N-vinyl N-methyl acetamide) (PVMA)
[0195] 380 mL (3.48 mol) of distilled
N-vinyl-
N-methyl acetamide and 187 mg (1.14 mmol) of azobisisobutyronitrile were added to a
3-neck round bottom flask fitted with reflux condenser, magnetic stirring bar and
thermocouple and purged of oxygen gas for 2 hours by bubbling nitrogen gas through
the reaction mixture. Then, the reaction mixture was heated at 75°C for 24 hours during
which time the reaction mixture solidified. The reaction product was quenched in air
and isolated by work-up procedure 1 or work-up procedure 2. Work-up Procedure 1: The
reaction product was dissolved in 800 mL of methylene chloride at 40°C and cooled
to room temperature. The solution was poured into 2L of cold diethyl ether with manual
stirring to afford a white solid after decanting off the solvents. The solid product
was air dried followed by vacuum drying overnight at 50°C. The precipitated product
was ground into a fine white powder and vacuum dried overnight at 50°C (85% yield).
Work-up Procedure 2: The reaction product was dissolved in water and dialyzed extensively
in dialysis membrane tubing (Spectra Pore MWCO 3500) and freeze dried (LABCONCO, Freezone
® Triad
™ freeze dry system, Model # 7400030) or spray dried (BUCHI mini spray dryer, Model
# B-290). The molecular weight was determined by Size Exclusion Chromatography with
Multi-Angle Light Scattering (SEC-MALS). The SEC-MALS setup employed methanol (with
10 mM LiBr) as the mobile phase at a flow rate of 0.6 mL/min at 50 °C. Three Tosoh
Biosciences TSK-gel columns in series were used [SuperAW3000 4 um, 6.0 mm ID × 15
cm (PEO/DMF Exclusion Limit = 60,000 g/mole), SuperAW4000 6 um, 6.0 mm ID × 15 cm
(PEO/DMF Exclusion Limit = 400,000 g/mole) and a SuperAW5000 7 um, 6.0 mm ID × 15
cm (PEO/DMF Exclusion Limit = 4,000,000 g/mole)] with an online Agilent 1200 UV/VIS
diode array detector, a Wyatt Optilab rEX interferometric refractometer, and a Wyatt
mini-DAWN Treos multiangle laser scattering (MALS) detector (λ=658nm). A dη/dc value
of 0.1829 mL/g at 30 °C (λ=658 nm) was used for absolute molecular weight determination.
Absolute molecular weights and polydispersity data were calculated using the Wyatt
ASTRA 6.1.1.17 SEC/LS software package. The weight average molecular weight typically
varied from about 500 kDa to about 700 kDa, but can be controlled by the reaction
conditions and isolation procedures. The polydispersity varied from about 1.8 to about
2.8 among the samples.
Preparation 2 - TERP Synthesis of Poly[DMA-NVP], MW = 195 kDa
[0196] 12 milligrams (0.073 mmol) AIBN were dissolved in 200 mL MeOH in a 500 mL three necked
round bottom flask equipped with a reflux condenser and pressure balanced addition
funnel and containing a magnetic stirring bar. 42 grams (424 mmol) DMA and 47.09 grams
(424 mmol) NVP were dissolved in 100 mL MeOH and added into the addition funnel. The
solutions in both the round bottom flask and the addition funnel were purged with
nitrogen gas for 30 minutes. Then, 26 milligrams (0.1 mmol) of Te-Bu were added into
the round bottom flask, and heating of the round bottom flask to reflux (about 65°C)
commenced. Slow dropwise addition of the monomer solution also started when heating
commenced. The monomer addition occurred over 7.5 hours. The reaction mixture was
then allowed to cool down to room temperature. The MeOH was removed by rotary evaporation.
The crude product was re-dissolved in MeOH and precipitated into hexanes three times.
The copolymer was vacuum dried at 50°C.
Preparation 3: Poly[DMA-NVP], Mw (MALS) = 304 kDa
[0197] 12 milligrams (0.073 mmol) AIBN were dissolved in 200 mL MeOH in a 500 mL three necked
round bottom flask equipped with a reflux condenser and pressure balanced addition
funnel and containing a magnetic stirring bar. 42 grams (424 mmol) DMA and 47.09 grams
(424 mmol) NVP were dissolved in 100 mL MeOH and added into the addition funnel. The
solutions in both the round bottom flask and the addition funnel were purged with
nitrogen gas for 60 minutes. Then, 26 milligrams (0.1 mmol) of Te-Bu were added into
the round bottom flask, and heating of the round bottom flask to reflux (about 65°C)
commenced. Slow dropwise addition of the monomer solution also started when heating
commenced. The monomer addition occurred over 4 hours. The reaction mixture was then
refluxed for 20 hours thereafter 45 milligrams (0.29 mmol) TEMPO were added and the
reaction mixture refluxed for another 5 hours. The reaction mixture was then allowed
to cool down to room temperature. The reaction mixture was concentrated by rotary
evaporation, and the crude product isolated by precipitation into diethyl ether. After
decanting off the supernatant liquid, the crude product was re-dissolved in methylene
chloride and precipitated into diethyl ether three times. The copolymer was vacuum
dried at 70°C.
Preparation 4 - TERP Synthesis of Poly[DMA-CBT]
[0198] 26 milligrams (0.16 mmol) AIBN, 20 grams (202 mmol) DMA and 5 grams (22 mmol) CBT
were dissolved in 200 mL 50% (v/v) aqueous MeOH in a 500 mL round bottom flask equipped
with a reflux condenser and containing a magnetic stirring bar. 41 milligrams (0.16
mmol) of Te-Bu were dissolved in 50 mL 50% (v/v) aqueous MeOH. Both solutions were
purged with nitrogen gas for 30 minutes. Then, the Te-Bu solution was added to the
round bottom flask and heated to reflux (about 62°C) for 12 hours. The reaction mixture
was allowed to cool down to room temperature. The aqueous MeOH was removed by rotary
evaporation. The crude product was dissolved in 500 mL acetone and precipitated by
slowing adding 250 mL of hexane with stirring. After decanting off the supernatant
liquid, the copolymer was vacuum dried at 62-68°C. Copolymer designated as Poly[DMA-CBT].
Comparative Examples 1-5
[0199] Each reactive mixture was formed by mixing the reactive components listed in Table
2, filtering through a 3 µm filter using a heated or unheated stainless steel or glass
syringe, and then degassed by applying vacuum at ambient temperature for about 10
minutes. In a glove box with a nitrogen gas atmosphere and less than 0.1 percent oxygen
gas, about 75-100 µL of the reactive mixture were dosed using an Eppendorf pipet at
room temperature into the FC made of Zeonor. The BC made of PP was then placed onto
the FC. The molds were equilibrated for a minimum of twelve hours in the glove box
prior to dosing. The plate was transferred into an adjacent glove box maintained at
55-60°C, and the lenses were cured from the top for 20 minutes using TLO3 lights having
intensity of 4-5 mW/cm
2. The light source was about six inches above the trays. The weight ratio of OH-mPDMS,
n=4 to mPDMS 1000, n=10 was 1.7. The molar ratio of OH-mPDMS, n=4 to mPDMS 1000, n=10
was 2.8.
[0200] The lenses were manually de-molded with most lenses adhering to the FC and released
by suspending the 64 lenses in about one liter of 50% IPA for about one or two hours,
followed by washing with 25% IPA, two times with DI, and finally two times with borate
buffered packaging solution. Each washing step lasted about 30 minutes. A person of
ordinary skill recognizes that the exact lens release process can be varied depending
on the lens formulation and mold materials, regarding the concentrations of the aqueous
isopropanol solutions, the number of washings with each solvent, and the duration
of each step. The purpose of the lens release process is to release all of the lenses
without defects and transition from diluent swollen networks to the packaging solution
swollen hydrogels. The lenses were transferred into vials and subsequently sterilized
by autoclaving at 122°C for 30 minutes. The physical and mechanical properties of
the sterile lenses were measured and listed in Table 3.
TABLE 2
| Component |
CEx 1 |
CEx 2 |
CEx 3 |
CEx 4 |
CEx 5 |
CEx 6 |
CEx 7 |
CEx 8 |
| mPDMS 1000, n=10 |
16.5 |
16.5 |
16.5 |
16.5 |
16.5 |
16.5 |
16.5 |
16.5 |
| OH-mPDMS, n=4 |
27.5 |
27.5 |
27.5 |
27.5 |
27.5 |
27.5 |
27.5 |
27.5 |
| NVP |
46.65 |
44.15 |
41.65 |
39.15 |
35.15 |
23.35 |
11.5 |
0 |
| HEMA |
6.75 |
6.75 |
6.75 |
6.75 |
6.75 |
6.75 |
6.75 |
6.75 |
| DMA |
0 |
2.5 |
5 |
7.5 |
11.5 |
23.3 |
35.15 |
46.65 |
| EGDMA |
0.35 |
0.35 |
0.35 |
0.35 |
0.35 |
0.35 |
0.35 |
0.35 |
| Norbloc |
1.75 |
1.75 |
1.75 |
1.75 |
1.75 |
1.75 |
1.75 |
1.75 |
| CGI 819 |
0.5 |
0.5 |
0.5 |
0.5 |
0.5 |
0.5 |
0.5 |
0.5 |
| Diluent |
10 |
10 |
10 |
10 |
10 |
10 |
10 |
10 |
| TAM |
100 |
100 |
100 |
100 |
100 |
100 |
100 |
100 |
TABLE 3
| Lens |
Weight %Water |
%Haze |
DCA (advancing) |
Mechanicals |
Dk |
| M (psi) |
%ETB |
| CEx 1 |
61 (0) |
6 (1) |
48 (6) |
75 (10) |
145 (57) |
92 |
| CEx 2 |
63 (0) |
7 (1) |
79 (9) |
57 (6) |
171 (36) |
89 |
| CEx 3 |
63 (0) |
9 (1) |
107 (3) |
52 (4) |
164 (53) |
89 |
| CEx 4 |
63 (0) |
9 (1) |
110 (4) |
46 (6) |
162 (45) |
89 |
| CEx 5 |
60 (0) |
6 (1) |
119 (15) |
53 (6) |
184 (56) |
85 |
| CEx 6 |
56 (0) |
4 (0) |
114 (13) |
66 (6) |
195 (44) |
72 |
| CEx 7 |
54 (0) |
4 (1) |
107 (5) |
87 (10) |
211 (56) |
56 |
| CEx 8 |
56 (0) |
4 (1) |
114 (19) |
85 (10) |
258 (58) |
54 |
[0201] The wettability of NVP based silicone hydrogels without a polymeric wetting agent
was reduced by small amounts of DMA in the reactive mixture. At 2.5 wt% DMA and above,
the advancing contact angle increased to 107° (59° increase) compared to formulations
without DMA (Comparative Example 6, with a DCA of 48°).
Comparative Examples 9-12
[0202] Each reactive mixture was formed by mixing the reactive components listed in Table
4, filtering through a 3 µm filter using a heated or unheated stainless steel or glass
syringe, and then degassed by applying vacuum at ambient temperature for about 10
minutes. In a glove box with a nitrogen gas atmosphere and less than 0.1 percent oxygen
gas, about 75-100 µL of the reactive mixture were dosed using an Eppendorf pipet at
room temperature into the FC made of Zeonor. The BC made of PP was then placed onto
the FC. The molds were equilibrated for a minimum of twelve hours in the glove box
prior to dosing. The plate was transferred into an adjacent glove box maintained at
55-60°C, and the lenses were cured from the top for 20 minutes using TLO3 lights having
intensity of 4-5 mW/cm
2. The light source was about six inches above the trays.
[0203] The lenses were manually de-molded with most lenses adhering to the FC and released
by suspending the 64 lenses in about one liter of 50% IPA for about one or two hours,
followed by washing with 25% IPA, two times with DI, and finally two times with borate
buffered packaging solution. Each washing step lasted about 30 minutes. A person of
ordinary skill recognizes that the exact lens release process can be varied depending
on the lens formulation and mold materials, regarding the concentrations of the aqueous
isopropanol solutions, the number of washings with each solvent, and the duration
of each step. The purpose of the lens release process is to release all of the lenses
without defects and transition from diluent swollen networks to the packaging solution
swollen hydrogels. The lenses were transferred into vials and subsequently sterilized
by autoclaving at 122°C for 30 minutes. The physical and mechanical properties of
the sterile lenses were measured and listed in Table 5.
TABLE 4
| Component |
CEx 9 |
CEx 10 |
CEx 11 |
CEx 12 |
| mPDMS 1000 |
16.5 |
16.5 |
16.5 |
16.5 |
| OH-mPDMS, n=4 |
27.5 |
27.5 |
27.5 |
27.5 |
| NVP |
46.55 |
46.05 |
45.55 |
44.05 |
| HEMA |
6.75 |
6.75 |
6.75 |
6.75 |
| DMA |
0 |
0.5 |
1 |
2.5 |
| EGDMA |
0.45 |
0.45 |
0.35 |
0.35 |
| Norbloc |
1.75 |
1.75 |
1.75 |
1.75 |
| CGI 819 |
0.5 |
0.5 |
0.5 |
0.5 |
| Diluent |
0 |
0 |
0 |
0 |
TABLE 5
| Lens |
Weight % Water |
%Haze |
DCA (Advancing) |
Mechanicals |
Dk |
| M (psi) |
%ETB |
| CEx 9 |
54 (0) |
9 (0) |
50 (4) |
111 (12) |
148 (39) |
98 |
| CEx 10 |
54(0) |
11 (1) |
58 (9) |
117 (8) |
167 (36) |
97 |
| CEx 11 |
55 (0) |
10 (1) |
64 (4) |
122 (9) |
170 (27) |
97 |
| CEx 12 |
54 (0) |
10 (0) |
93 (11) |
100 (7) |
146 (31) |
100 |
[0204] These comparative Examples confirm that as little as about 2 wt% DMA in silicone
hydrogel formulations containing greater than about 40 wt% NVP degrade wettability.
Examples 1-3
[0205] Each reactive mixture was formed by mixing the reactive components listed in Table
6, filtering through a 3 µm filter using a heated or unheated stainless steel or glass
syringe, and then degassed by applying vacuum at ambient temperature for about 10
minutes. In a glove box with a nitrogen gas atmosphere and less than 0.1 percent oxygen
gas, about 75-100 µL of the reactive mixture were dosed using an Eppendorf pipet at
room temperature into the FC made of Zeonor. The BC made of PP was then placed onto
the FC. The molds were equilibrated for a minimum of twelve hours in the glove box
prior to dosing. The plate was transferred into an adjacent glove box maintained at
62-65°C, and the lenses were cured from the top for 20 minutes using TLO3 lights having
intensity of 4-5 mW/cm
2. The light source was about six inches above the trays.
[0206] The lenses were manually de-molded with most lenses adhering to the FC and released
by suspending the 64 lenses in about one liter of 70% IPA for about one or two hours,
followed by washing two times with 70% IPA, two times with 25% IPA, two times with
DI, and finally two times with borate buffered packaging solution. Each washing step
lasted about 30 minutes. A person of ordinary skill recognizes that the exact lens
release process can be varied depending on the lens formulation and mold materials,
regarding the concentrations of the aqueous isopropanol solutions, the number of washings
with each solvent, and the duration of each step. The purpose of the lens release
process is to release all of the lenses without defects and transition from diluent
swollen networks to the packaging solution swollen hydrogels. The lenses were transferred
into vials and subsequently sterilized by autoclaving at 122°C for 30 minutes. The
physical and mechanical properties of the sterile lenses were measured and listed
in Table 7. The homogeneity of the reactive mixtures improved as the amount of OH-mPDMS
n=4 increased. Only lenses from Example 3 were suitable for testing, and their wettability
was limited (91°) despite the presence poly[DMA-NVP] in the formulation at 2wt%.
TABLE 6
| Component |
Ex 1 |
Ex 2 |
Ex 3 |
| OH-mPDMS (n=15) |
44.25 |
40.66 |
35 |
| OH-mPDMS (n=4) |
0 |
8.11 |
12.85 |
| Weight ratio of OH-mPDMS (n=4) to OH-mPDMS (n=15) |
0 |
0.20 |
0.37 |
| Molar ratio of OH-mPDMS (n=4) to OH-mPDMS (n=15) |
0 |
0.47 |
0.86 |
| NVP |
40.6 |
37.31 |
37 |
| HEMA |
10 |
9.19 |
10 |
| P2:P[DMA-NVP] |
2 |
1.84 |
2 |
| MAA |
0.75 |
0.69 |
0.75 |
| TEGDMA |
0.2 |
0.18 |
0.2 |
| TAC |
0.2 |
0.18 |
0.2 |
| Norbloc |
1.75 |
1.61 |
1.75 |
| CGI 819 |
0.25 |
0.23 |
0.25 |
| Diluent |
15 |
13.95 |
15 |
| TAM |
100 |
100 |
100 |
TABLE 7
| Lens |
Weight % Water |
% Haze |
DCA (°) (adv, rec) |
Mechanicals |
Dk |
| M (psi) |
%ETB |
| Ex 3 |
53 (0) |
5(1) |
91 (5), 27 (11) |
101 (7) |
159 (44) |
89 |
Examples 4-8
[0207] Each reactive mixture was formed by mixing the reactive components listed in Table
8, filtering through a 3 µm filter using a heated or unheated stainless steel or glass
syringe, and then degassed by applying vacuum at ambient temperature for about 10
minutes. In a glove box with a nitrogen gas atmosphere and less than 0.1 percent oxygen
gas, about 75-100 µL of the reactive mixture were dosed using an Eppendorf pipet at
room temperature into the FC made of Zeonor. The BC made of a 90:10 (w/w) Z:PP was
then placed onto the FC. The molds were equilibrated for a minimum of twelve hours
in the glove box prior to dosing. The plate was transferred into an adjacent glove
box maintained at 62-65°C, and the lenses were cured from the top for 20 minutes using
TLO3 lights having intensity of 4-5 mW/cm
2. The light source was about six inches above the trays.
[0208] The lenses were manually de-molded with most lenses adhering to the FC and released
by suspending the 64 lenses in about one liter of 70% IPA for about one or two hours,
followed by washing two times with 70% IPA, two times with 25% IPA, two times with
DI, and finally two times with borate buffered packaging solution. Each washing step
lasted about 30 minutes. A person of ordinary skill recognizes that the exact lens
release process can be varied depending on the lens formulation and mold materials,
regarding the concentrations of the aqueous isopropanol solutions, the number of washings
with each solvent, and the duration of each step. The purpose of the lens release
process is to release all of the lenses without defects and transition from diluent
swollen networks to the packaging solution swollen hydrogels. The lenses were transferred
into vials and subsequently sterilized by autoclaving at 122°C for 30 minutes. The
lenses of Examples 4 and 5 were hazy (subjectively observed), and were not further
analyzed. The physical and mechanical properties of the sterile lenses were measured
and listed in Table 9.
TABLE 8
| Component |
Ex 4 |
Ex 5 |
Ex 6 |
Ex 7 |
Ex 8 |
| OH-mPDMS (n=15) |
25 |
0 |
25 |
25 |
30 |
| OH-mPDMS (n=4) |
30 |
55 |
30 |
30 |
25 |
| Weight ratio of OH-mPDMS (n=4) to OH-mPDMS (n=15) |
1.2 |
- |
1.2 |
1.2 |
0.83 |
| Molar ratio of OH-mPDMS (n=4) to OH-mPDMS (n=15) |
2.8 |
- |
2.8 |
2.8 |
1.94 |
| NVP |
10.35 |
10.35 |
13.35 |
16.35 |
16.35 |
| HEMA |
9.5 |
9.5 |
10.5 |
10.5 |
10.5 |
| P2:[DMA-NVP] |
17 |
17 |
15 |
12 |
12 |
| mPEG 950 |
5 |
5 |
3 |
3 |
3 |
| MAA |
0.75 |
0.75 |
0.75 |
0.75 |
0.75 |
| TEGDMA |
0.2 |
0.2 |
0.2 |
0.2 |
0.2 |
| TAC |
0.2 |
0.2 |
0.2 |
0.2 |
0.2 |
| Norbloc |
1.75 |
1.75 |
1.75 |
1.75 |
1.75 |
| CGI 819 |
0.25 |
0.25 |
0.25 |
0.25 |
0.25 |
| Diluent |
23 |
23 |
20 |
20 |
20 |
| TAM |
100 |
100 |
100 |
100 |
100 |
TABLE 9
| Lens |
Weight % Water |
% Haze |
DCA (°) (adv, rec) |
Mechanicals |
Dk |
| M (psi) |
%ETB |
| Ex 6 |
51 (0) |
38 (2) |
99 (7), 15 (8) |
84 (5) |
158 (34) |
148 |
| Ex 7 |
50 (1) |
19 (1) |
83 (13), 2 (5) |
116 (7) |
178 (37) |
135 |
| Ex 8 |
48 (0) |
12 (2) |
53 (6), 47 (2) |
118 (9) |
163 (43) |
140 |
[0209] Example 8 had 12 wt% DMA/NVP copolymer and displayed a very desirable contact angle
(53° advancing DCA) and haze (12%). Examples 6-8 had good haze values. Comparing Example
6 to Example 7 shows that decreasing the concentration of acyclic polyamide improves
both haze and contact angle, suggesting that a desirable balance of properties could
be achieved by maintaining a ratio of first to second silicone-containing component
of 1.2, and decreasing the concentration of acyclic polyamide. Example 8 had a ratio
of first to second silicone-containing component of 0.87, and showed improved haze
and contact angle compared to Example 7. Thus, properties may also be balanced by
maintaining the concentration of the acyclic polyamide, and decreasing the ratio first
to second silicone-containing component to within the recited ranges.
Examples 9-11
[0210] Each reactive mixture was formed by mixing the reactive components listed in Table
10, filtering through a 3 µm filter using a heated or unheated stainless steel or
glass syringe, and then degassed by applying vacuum at ambient temperature for about
10 minutes. In a glove box with a nitrogen gas atmosphere and less than 0.1 percent
oxygen gas, about 75-100 µL of the reactive mixture were dosed using an Eppendorf
pipet at room temperature into the FC made of Zeonor. The BC made of PP or a blend
of 90:10 (w/w) Z:PP was then placed onto the FC. The molds were equilibrated for a
minimum of twelve hours in the glove box prior to dosing. The plate was transferred
into an adjacent glove box maintained at 62-65°C, and the lenses were cured from the
top for 20 minutes using TLO3 lights having intensity of 4-5 mW/cm
2. The light source was about six inches above the trays.
[0211] The lenses were manually de-molded with most lenses adhering to the FC and released
by suspending the 64 lenses in about one liter of 70% IPA for about one or two hours,
followed by washing two times with 70% IPA, two times with 25% IPA, two times with
DI, and finally two times with borate buffered packaging solution. Each washing step
lasted about 30 minutes. A person of ordinary skill recognizes that the exact lens
release process can be varied depending on the lens formulation and mold materials,
regarding the concentrations of the aqueous isopropanol solutions, the number of washings
with each solvent, and the duration of each step. The purpose of the lens release
process is to release all of the lenses without defects and transition from diluent
swollen networks to the packaging solution swollen hydrogels. The lenses were transferred
into vials and subsequently sterilized by autoclaving at 122°C for 30 minutes. The
physical and mechanical properties of the sterile lenses were measured and listed
in Table 11.
TABLE 10
| Component |
Ex 9 |
Ex 10 |
Ex 11 |
| OH-mPDMS (n=15) |
30 |
30 |
30 |
| OH-mPDMS (n=4) |
25 |
25 |
25 |
| Weight ratio of OH-mPDMS (n=4) to OH-mPDMS (n=15) |
0.83 |
0.83 |
0.83 |
| Molar ratio of OH-mPDMS (n=4) to OH-mPDMS (n=15) |
1.94 |
1.94 |
1.94 |
| NVP |
16.35 |
16.35 |
16.35 |
| HEMA |
10.5 |
10.5 |
10.5 |
| P2:P[DMA-NVP] |
12 |
0 |
0 |
| P3:P[DMA-NVP] |
0 |
12 |
12 |
| mPEG 950 |
3 |
3 |
3 |
| MAA |
0.75 |
0.75 |
0.75 |
| TEGDMA |
0.2 |
0.2 |
0.2 |
| TAC |
0.2 |
0.2 |
0.2 |
| Norbloc |
1.75 |
1.75 |
1.75 |
| CGI 819 |
0.25 |
0.25 |
0.25 |
| Diluent |
20 |
20 |
20 |
| TAM |
100 |
100 |
100 |
TABLE 11
| Lens |
Weight % Water |
% Haze |
DCA (°) (adv, rec) |
Mechanicals |
Dk |
| M (psi) |
%ETB |
| Ex 9 |
48 (0) |
12 (2) |
53 (6), 47 (2) |
118 (9) |
163 (43) |
140 |
| Ex 10 |
52 (0) |
16 (1) |
67 (8), 28 (4) |
97 (8) |
194 (23) |
122 |
| Ex 11 |
51 (1) |
24 (2) |
64 (6), 27(10) |
121 (9) |
186 (35) |
135 |
[0212] Copolymer P2 had a molecular weight (Mw) of 195kD and copolymer P3 had a Mw of 305
KDa. Examples 9-11 all displayed good haze and contact angle, confirming that copolymeric
wetting agents having molecular weights above about 190 kDa can provide desirable
wettability and haze.
Examples 12-15
[0213] Each reactive mixture was formed by mixing the reactive components listed in Table
12, filtering through a 3 µm filter using a heated or unheated stainless steel or
glass syringe, and then degassed by applying vacuum at ambient temperature for about
10 minutes. In a glove box with a nitrogen gas atmosphere and less than 0.1 percent
oxygen gas, about 75-100 µL of the reactive mixture were dosed using an Eppendorf
pipet at room temperature into the FC made of Zeonor. The BC made of a blend of 90:10
(w/w) Z:PP was then placed onto the FC. The molds were equilibrated for a minimum
of twelve hours in the glove box prior to dosing. The plate was transferred into an
adjacent glove box maintained at 62-65°C, and the lenses were cured from the top for
15 minutes using TLO3 lights having intensity of 4-5 mW/cm
2. The light source was about six inches above the trays.
[0214] The lenses were manually de-molded with most lenses adhering to the FC and released
by heating about 64 lenses in about one liter of DI water at 75°C for about 30-60
minutes, followed by washing two times with DI, and finally two times with borate
buffered packaging solution. Each washing step lasted about 30 minutes. A person of
ordinary skill recognizes that the exact lens release process can be varied depending
on the lens formulation and mold materials, regarding the concentrations of the aqueous
isopropanol solutions, the number of washings with each solvent, and the duration
of each step. The purpose of the lens release process is to release all of the lenses
without defects and transition from diluent swollen networks to the packaging solution
swollen hydrogels. The lenses were transferred into vials and subsequently sterilized
by autoclaving at 122°C for 30 minutes. The physical and mechanical properties of
the sterile lenses were measured and listed in Table 13.
TABLE 12
| Component |
Ex 12 |
Ex 13 |
Ex 14 |
Ex 15 |
| OH-mPDMS (n=15) |
30 |
30 |
30 |
30 |
| OH-mPDMS (n=4) |
25 |
25 |
25 |
25 |
| Weight ratio of OH-mPDMS (n=4) to OH-mPDMS (n=15) |
0.83 |
0.83 |
0.83 |
0.83 |
| Molar ratio of OH-mPDMS (n=4) to OH-mPDMS (n=15) |
1.94 |
1.94 |
1.94 |
1.94 |
| NVP |
16.35 |
16.35 |
16.35 |
16.35 |
| HEMA |
10.5 |
10.5 |
10.5 |
10.5 |
| P3:Poly [DMA-NVP] |
12 |
0 |
0 |
0 |
| PVMA 380 kDa |
0 |
12 |
0 |
0 |
| PVMA 628 kDa |
0 |
0 |
12 |
0 |
| PVMA 1600 kDA |
0 |
0 |
0 |
12 |
| mPEG 950 |
3 |
3 |
3 |
3 |
| MAA |
0.75 |
0.75 |
0.75 |
0.75 |
| TEGDMA |
0.2 |
0.2 |
0.2 |
0.2 |
| TAC |
0.2 |
0.2 |
0.2 |
0.2 |
| Norbloc |
1.75 |
1.75 |
1.75 |
1.75 |
| CGI 819 |
0.25 |
0.25 |
0.25 |
0.25 |
| Diluent |
20 |
20 |
20 |
20 |
| TAM |
100 |
100 |
100 |
100 |
TABLE 13
| Lens |
Weight % Water |
% Haze |
DCA (°) (adv, rec) |
Mechanicals |
Dk |
RI |
| M (psi) |
%ETB |
| Ex 12 |
51 (1) |
24 (2) |
64 (6), 27(10) |
121 (9) |
186 (35) |
135 |
1.4002 |
| Ex 13 |
52 (0) |
28 (2) |
64 (16), 28 (7) |
95 (6) |
194 (41) |
147 |
1.3990 |
| Ex 14 |
53 (0) |
36 (4) |
44 (11), 36 (4) |
105 (4) |
195 (47) |
135 |
1.3954 |
| Ex 15 |
54 (0) |
24 (2) |
34 (11), 27 (4) |
103 (11) |
189 (56) |
122 |
1.3949 7 |
[0215] Examples 12-15 all displayed desirable haze and contact angles. As the molecular
weight (Mw) of the PVMA increased, the contact angle decreased, with Examples 14 (Mw
of 628 kD) and 15 (Mw of 1600 kD) displaying improved wettability and decreased hysteresis
compared to Example 13.
Examples 16-20
[0216] Each reactive mixture was formed by mixing the reactive components listed in Table
14, filtering through a 3 µm filter using a heated or unheated stainless steel or
glass syringe, and then degassed by applying vacuum at ambient temperature for about
10 minutes. In a glove box with a nitrogen gas atmosphere and less than 0.1 percent
oxygen gas, about 75-100 µL of the reactive mixture were dosed using an Eppendorf
pipet at room temperature into the FC made of Zeonor. The BC made of PP was then placed
onto the FC. The molds were equilibrated for a minimum of twelve hours in the glove
box prior to dosing. The plate was transferred into an adjacent glove box maintained
at 62-65°C, and the lenses were cured from the top for 25 minutes using TLO3 lights
having intensity of 4-5 mW/cm
2. The light source was about six inches above the trays.
[0217] The lenses were manually de-molded with most lenses adhering to the FC and released
by suspending the 64 lenses in about one liter of 70% IPA for about one or two hours,
followed by washing two times with 70% IPA, two times with 25% IPA, two times with
DI, and finally two times with borate buffered packaging solution. Each washing step
lasted about 30 minutes. A person of ordinary skill recognizes that the exact lens
release process can be varied depending on the lens formulation and mold materials,
regarding the concentrations of the aqueous isopropanol solutions, the number of washings
with each solvent, and the duration of each step. The purpose of the lens release
process is to release all of the lenses without defects and transition from diluent
swollen networks to the packaging solution swollen hydrogels. The lenses were transferred
into vials and subsequently sterilized by autoclaving at 122°C for 30 minutes. The
physical and mechanical properties of the sterile lenses were measured and listed
in Table 15.
TABLE 14
| Component |
Ex 16 |
Ex 17 |
Ex 18 |
Ex 19 |
Ex 20 |
| OH-mPDMS (n=15) |
30 |
30 |
30 |
30 |
30 |
| OH-mPDMS (n=4) |
25 |
25 |
25 |
25 |
25 |
| Weight ratio of OH-mPDMS (n=4) to OH-mPDMS (n=15) |
0.83 |
0.83 |
0.83 |
0.83 |
0.83 |
| Molar ratio of OH-mPDMS (n=4) to OH-mPDMS (n=15) |
1.94 |
1.94 |
1.94 |
1.94 |
1.94 |
| NVP |
16.23 |
16.10 |
16.35 |
16.23 |
16.10 |
| HEMA |
10.5 |
10.5 |
10.5 |
10.5 |
10.5 |
| PVMA 628 kDa |
6 |
6 |
12 |
12 |
12 |
| PVMA 1600 kDa |
6 |
6 |
0 |
0 |
0 |
| mPEG 950 |
3 |
3 |
3 |
3 |
3 |
| MAA |
0.75 |
0.75 |
0.75 |
0.75 |
0.75 |
| TEGDMA |
0.2 |
0.2 |
0.2 |
0.2 |
0.2 |
| TAC |
0.2 |
0.2 |
0.2 |
0.2 |
0.2 |
| Norbloc |
1.75 |
1.75 |
1.75 |
1.75 |
1.75 |
| CGI 819 |
0.37 |
0.5 |
0.25 |
0.37 |
0.5 |
| Diluent |
20 |
20 |
20 |
20 |
20 |
| TAM |
100 |
100 |
100 |
100 |
100 |
TABLE 15
| Lens |
Weight % Water |
% Haze |
DCA (adv, rec) |
Mechanicals |
Dk |
RI |
| M (psi) |
%ETB |
| Ex 16 |
55 (0) |
38 (5) |
50 (7), 27 (9) |
81 (8) |
202 (55) |
120 |
1.3946 |
| Ex 17 |
56 (1) |
38 (3) |
46 (5), 23 (5) |
81 (5) |
157 (60) |
130 |
1.3947 |
| Ex 18 |
51 (0) |
38 (4) |
48 (11), 6 (6) |
85 (8) |
218 (23) |
144 |
1.4015 |
| Ex 19 |
53 (0) |
32 (2) |
71 (12), 20 (15) |
84 (6) |
181 (50) |
129 |
1.3969 |
| Ex 20 |
55 (1) |
41 (4) |
76 (7), 7 (8) |
63 (5) |
150 (57) |
124 |
1.3996 |
[0218] Examples 16 and 17 contain a mixture of PVMA (6% 628kD and 6% 1600 kD Mw). Examples
19 and 20 were made from similar formulations, but with 12% of PVMA having a Mw of
628 kD. Examples 16 and 17, with the mixture including higher molecular weight PVMA
displayed lower contact angles.
Example 21-24
[0219] Each reactive mixture was formed by mixing the reactive components listed in Table
16, filtering through a 3 µm filter using a heated or unheated stainless steel or
glass syringe, and then degassed by applying vacuum at ambient temperature for about
10 minutes. In a glove box with a nitrogen gas atmosphere and less than 0.1 percent
oxygen gas, about 75-100 µL of the reactive mixture were dosed using an Eppendorf
pipet at room temperature into the FC made of Zeonor. The BC made of PP was then placed
onto the FC. The molds were equilibrated for a minimum of twelve hours in the glove
box prior to dosing. The plate was transferred into an adjacent glove box maintained
at 62-65°C, and the lenses were cured from the top for 15-25 minutes using TLO3 lights
having intensity of 4-5 mW/cm
2. The light source was about six inches above the trays.
[0220] The lenses were manually de-molded with most lenses adhering to the FC and released
by suspending the 64 lenses in about one liter of 70% IPA for about one or two hours,
followed by washing two times with 70% IPA, two times with 25% IPA, two times with
DI, and finally two times with borate buffered packaging solution. Each washing step
lasted about 30 minutes. A person of ordinary skill recognizes that the exact lens
release process can be varied depending on the lens formulation and mold materials,
regarding the concentrations of the aqueous isopropanol solutions, the number of washings
with each solvent, and the duration of each step. The purpose of the lens release
process is to release all of the lenses without defects and transition from diluent
swollen networks to the packaging solution swollen hydrogels. The lenses were transferred
into vials and subsequently sterilized by autoclaving at 122°C for 30 minutes. The
physical and mechanical properties of the sterile lenses were measured and listed
in Table 17.
TABLE 16
| Component |
Ex 21 |
Ex 22 |
Ex 23 |
Ex 24 |
| OH-mPDMS (n=15) |
30 |
30 |
30 |
30 |
| OH-mPDMS (n=4) |
25 |
25 |
25 |
25 |
| Weight ratio of OH-mPDMS (n=4) to OH-mPDMS (n=15) |
0.83 |
0.83 |
0.83 |
0.83 |
| Molar ratio of OH-mPDMS (n=4) to OH-mPDMS (n=15) |
1.94 |
1.94 |
1.94 |
1.94 |
| NVP |
16.1 |
15 |
15 |
12 |
| DMA |
0 |
1.1 |
1.1 |
4.1 |
| HEMA |
10.5 |
11 |
11 |
11 |
| PVMA 628 kDa |
12 |
12 |
6 |
6 |
| PVMA 1600 kDa |
3 |
0 |
6 |
6 |
| mPEG 950 |
3 |
3 |
3 |
3 |
| MAA |
0.75 |
0.75 |
0.75 |
0.75 |
| TEGDMA |
0.2 |
1 |
1 |
1 |
| TAC |
0.2 |
0 |
0 |
0 |
| Norbloc |
1.75 |
2 |
2 |
2 |
| CGI 819 |
0.5 |
0.25 |
0.25 |
0.25 |
| Cure Time (min) |
25 |
15 |
28 |
28 |
| Diluent |
20 |
20 |
28 |
28 |
| D3O |
100 |
100 |
100 |
100 |
TABLE 17
| Lens |
Weight % Water |
% Haze |
DCA (adv, rec) |
Mechanicals |
Dk |
RI |
Lipids (µg/lens) |
| M (psi) |
%ETB |
| Ex 21 |
56 (0) |
32 (2) |
56 (17), 19 (12) |
69 (7) |
156 (60) |
126 |
1.3967 (006) |
6.23 (0.21) |
| Ex 22 |
55 (0) |
17 (1) |
34 (3), 22 (9) |
67 (7) |
166 (58) |
131 |
1.3979 (005) |
6.2 (0.27) |
| Ex 23 |
56 (0) |
16 (1) |
54 (27), 21 (3) |
52 (7) |
195 (53) |
121 |
1.3966 (009) |
6.97 (0.70) |
| Ex 24 |
54 (0) |
25 (1) |
31 (28), 11 (14) |
64 (5) |
178 (56) |
123 |
1.3963 (011) |
6.28 (0.39) |
[0221] The concentration of DMA in the reactive mixture was increased from 0 wt% (Example
21) to 4.1 wt% (Example 24), and the advancing contact angle remained below about
50°. This is in contrast to Comparative Examples 6-17, which showed that in NVP formulations
without a combination of hydroxyl-substituted polydialkylsiloxanes, the inclusion
of as little as about 2 wt% DMA increased contact angle above about 80°. Examples
21 -24 also show lipid uptake of about 6 µg/lens, which is desirably low. Commercially
available lenses containing PVP display lipid uptake values of about 10 µg/lens.
Example 25-29
[0222] Each reactive mixture was formed by mixing the reactive components listed in Table
18, filtering through a 3 µm filter using a heated or unheated stainless steel or
glass syringe, and then degassed by applying vacuum at ambient temperature for about
10 minutes. In a glove box with a nitrogen gas atmosphere and less than 0.1 percent
oxygen gas, about 75-100 µL of the reactive mixture were dosed using an Eppendorf
pipet at room temperature into the FC made of Zeonor. The BC made of PP was then placed
onto the FC. The molds were equilibrated for a minimum of twelve hours in the glove
box prior to dosing. The plate was transferred into an adjacent glove box maintained
at 62-65°C, and the lenses were cured from the top for 25 minutes using TLO3 lights
having intensity of 4-5 mW/cm
2. The light source was about six inches above the trays.
[0223] The lenses were manually de-molded with most lenses adhering to the FC and released
by suspending the 64 lenses in about one liter of 70% IPA for about one or two hours,
followed by washing two times with 70% IPA, two times with 25% IPA, two times with
DI, and finally two times with borate buffered packaging solution. Each washing step
lasted about 30 minutes. A person of ordinary skill recognizes that the exact lens
release process can be varied depending on the lens formulation and mold materials,
regarding the concentrations of the aqueous isopropanol solutions, the number of washings
with each solvent, and the duration of each step. The purpose of the lens release
process is to release all of the lenses without defects and transition from diluent
swollen networks to the packaging solution swollen hydrogels. The lenses were transferred
into vials and subsequently sterilized by autoclaving at 122°C for 30 minutes. The
physical and mechanical properties of the sterile lenses were measured and listed
in Table 19.
TABLE 18
| Component |
Ex 25 |
Ex 26 |
Ex 27 |
Ex 28 |
Ex 29 |
| OH-mPDMS (n=15) |
30 |
33 |
33 |
33 |
33 |
| OH-mPDMS (n=4) |
25 |
25 |
25 |
25 |
25 |
| Weight ratio of OH-mPDMS (n=4) to OH-mPDMS (n=15) |
0.83 |
0.76 |
0.76 |
0.76 |
0.76 |
| Molar ratio of OH-mPDMS (n=4) to OH-mPDMS (n=15) |
1.94 |
1.77 |
1.77 |
1.77 |
1.77 |
| NVP |
7.84 |
6.33 |
6.11 |
5.36 |
4.61 |
| DMA |
7.84 |
6.35 |
6.12 |
5.37 |
4.62 |
| HEMA |
10.5 |
10.5 |
10.5 |
10.5 |
10.5 |
| PVMA 628 kDa |
9 |
9 |
12 |
13.5 |
15 |
| PVMA 1600 kDa |
3 |
3 |
0 |
0 |
0 |
| mPEG 950 |
3 |
3 |
3 |
3 |
3 |
| MAA |
0.75 |
0.75 |
0.75 |
0.75 |
0.75 |
| TEGDMA |
0.75 |
0.75 |
1.2 |
1.2 |
1.2 |
| TAC |
0.2 |
0.2 |
0.2 |
0.2 |
0.2 |
| Norbloc |
1.75 |
1.75 |
1.75 |
1.75 |
1.75 |
| CGI 819 |
0.37 |
0.37 |
0.37 |
0.37 |
0.37 |
| Diluent |
20 |
23 |
23 |
23 |
23 |
| D3O |
100 |
100 |
100 |
100 |
100 |
TABLE 19
| Lens |
Weight % Water |
% Haze |
DCA (adv/rec) |
Mechanicals |
Dk |
Lysozyme (µg/Lens) |
PQ1 Uptake (%) |
Lipid Uptake (µg/lens) |
| M (psi) |
%ETB |
| Ex 25 |
55 (0) |
19 (1) |
6 (12), 6 (12) |
79 (5) |
171 (44) |
129 |
NT |
NT |
6.33 (0.40) |
| Ex 26 |
53 (0) |
29 (1) |
56 (35), 16 (17) |
83 (7) |
194 (65) |
135 |
NT |
NT |
6.25 (0.47) |
| Ex 27 |
49(0) |
20 (1) |
0 (0), 2 (4) |
86 (10) |
177 (70) |
132 |
81(2) |
3.47 (1.42) |
5.46 (0.49) |
| Ex 28 |
50 (0) |
26 (1) |
9 (11), 7 (12) |
90(6) |
179 (59) |
144 |
49(3) |
1.77 (0.88) |
5.72 (0.2) |
| Ex 29 |
48(0) |
33 (2) |
9 (15), 8 (12) |
96 (9) |
165 (46) |
162 |
19(4) |
0.64 (0.55) |
5.360.15) |
[0224] Lenses made from PVMA 628 kDa and mixtures DMA and NVP exhibited very low lipid (less
than 7 µg/lens) and PQ1 uptake (less than 5%) as well as an excellent balance of physical
and mechanical properties. The concentration of DMA in the reactive mixture was varied
from about 5 wt% (Example 29) to about 8% (Example 25), and the advancing contact
angle remained below about 60°, and in Examples 25, 27-29, below about 10°.
Example 30-34
[0225] Each reactive mixture was formed by mixing the reactive components listed in Table
20, filtering through a 3 µm filter using a heated or unheated stainless steel or
glass syringe, and then degassed by applying vacuum at ambient temperature for about
10 minutes. In a glove box with a nitrogen gas atmosphere and less than 0.1 percent
oxygen gas, about 75-100 µL of the reactive mixture were dosed using an Eppendorf
pipet at room temperature into the FC. The BC was then placed onto the FC. The molds
were equilibrated for a minimum of twelve hours in the glove box prior to dosing.
Examples 30-32 used FC made of a 90:10 (w/w) blend of Z:TT and BC made of PP; examples
33-38 used FC made of Z and BC made of a 55:45 (w/w) blend of Z:PP. The plate was
transferred into an adjacent glove box maintained at 62-65°C, and the lenses were
cured from the top for 25 minutes using TLO3 lights having intensity of 4-5 mW/cm
2 for Examples 30-32 and 3-4 mW/cm
2 for Examples 33-38. The light source was about six inches above the trays.
[0226] The lenses were manually de-molded with most lenses adhering to the FC and released
by suspending the 64 lenses in about one liter of 70% IPA for about one or two hours,
followed by washing two times with 70% IPA, two times with 25% IPA, two times with
DI, and finally two times with borate buffered packaging solution. Each washing step
lasted about 30 minutes. A person of ordinary skill recognizes that the exact lens
release process can be varied depending on the lens formulation and mold materials,
regarding the concentrations of the aqueous isopropanol solutions, the number of washings
with each solvent, and the duration of each step. The purpose of the lens release
process is to release all of the lenses without defects and transition from diluent
swollen networks to the packaging solution swollen hydrogels. The lenses were transferred
into vials and subsequently sterilized by autoclaving at 122°C for 30 minutes. The
physical and mechanical properties of the sterile lenses were measured and listed
in Table 21.
TABLE 20
| Component |
Ex 30 |
Ex 31 |
Ex 32 |
Ex 33 |
Ex 34 |
Ex 35 |
Ex 36 |
Ex 37 |
Ex 38 |
| OH-mPDMS (n=15) |
33 |
33 |
33 |
32 |
32 |
32 |
32 |
31 |
30 |
| OH-mPDMS (n=4) |
25 |
25 |
25 |
25 |
25 |
25 |
25 |
25 |
25 |
| Weight ratio of OH-mPDMS (n=4) to OH-mPDMS (n=15) |
0.76 |
0.76 |
0.76 |
0.78 |
0.78 |
0.78 |
0.78 |
0.81 |
0.83 |
| Molar ratio of OH-mPDMS (n=4) to OH-mPDMS (n=15) |
1.77 |
1.77 |
1.77 |
1.82 |
1.82 |
1.82 |
1.82 |
1.87 |
1.94 |
| NVP |
5.36 |
5.26 |
5.16 |
5.41 |
5.41 |
5.66 |
5.54 |
5.54 |
5.54 |
| DMA |
5.37 |
5.27 |
5.17 |
5.42 |
5.42 |
5.67 |
5.54 |
6.54 |
7.54 |
| HEMA |
10.5 |
10.5 |
10.5 |
10.73 |
11.33 |
11.33 |
11.33 |
11.33 |
11.33 |
| Blue HEMA |
0 |
0 |
0 |
0.02 |
0.02 |
0.02 |
0.02 |
0.02 |
0.02 |
| PVMA 628 kDa |
13.5 |
13.5 |
13.5 |
13.5 |
13.5 |
13.5 |
13.5 |
13.5 |
13.5 |
| mPEG 950 |
3 |
3 |
3 |
3 |
3 |
3 |
3 |
3 |
3 |
| MAA |
0.75 |
0.75 |
0.75 |
1 |
1 |
1 |
1 |
1 |
1 |
| TEGDMA |
1.2 |
1.40 |
1.60 |
1.60 |
0 |
0 |
0 |
0 |
0 |
| TAC |
0.2 |
0.2 |
0.2 |
0.2 |
0.2 |
0.2 |
0.2 |
0.2 |
0.2 |
| EGDMA |
0 |
0 |
0 |
0 |
1 |
0.5 |
0.75 |
0.75 |
0.75 |
| Norbloc |
1.75 |
1.75 |
1.75 |
1.75 |
1.75 |
1.75 |
1.75 |
1.75 |
1.75 |
| CGI 819 |
0.37 |
0.37 |
0.37 |
0.37 |
0.37 |
0.37 |
0.37 |
0.37 |
0.37 |
| Diluent |
23 |
23 |
23 |
23 |
23 |
23 |
23 |
23 |
23 |
| D3O |
100 |
100 |
100 |
100 |
100 |
100 |
100 |
100 |
100 |
TABLE 21
| Lens |
Weight % Water |
% Haze |
DCA (adv, rec) |
Mechanicals |
Dk |
Lysozyme (µg/Lens) |
PQ1 Uptake (%) |
Lipid Uptake (µg/lens) |
| M (psi) |
%ETB |
| Ex 30 |
50 (0) |
24 (2) |
16 (14), 16 (13) |
94(7) |
168 (37) |
148 |
57 (8) |
3.02 (3.39) |
6.58 (0.29) |
| Ex 31 |
50 (0) |
20 (1) |
75 (42), 3 (5) |
100 (7) |
155 (43) |
147 |
52 (8) |
4.21 (1.02) |
7.10 (0.53) |
| Ex 32 |
49 (1) |
17 (1) |
24 (26), 3 (6) |
92 (8) |
128 (30) |
151 |
35 (7) |
1 (1.64) |
6.70 (0.53) |
| Ex 33 |
49 (0) |
18 (1) |
12 (13), 4 (7) |
107 (14) |
115 (32) |
145 |
134 (11) |
6.06 (0.29) |
6.73 (0.74) |
| Ex 34 |
44 (0) |
10 (1) |
24 (12), 0 (0) |
193 (15) |
92 (26) |
151 |
51 (6) |
5.74 (0.18) |
2.58 (6.36) |
| Ex 35 |
50 (0) |
18 (1) |
65 (11), 13 (16) |
103 (8) |
164 (46) |
142 |
186 (14) |
6.65 (0.27) |
10.64 (1.64) |
| Ex 36 |
48 (0) |
13 (1) |
30 (14), 21 (17) |
151 (11) |
110 (31) |
147 |
119 (8) |
6.02 (0.13) |
2.68 (0.33) |
| Ex 37 |
48 (0) |
13 (1) |
41 (9), 27 (16) |
135 (11) |
123 (32) |
140 |
217 (15) |
6.05 (0.12) |
2.52 (7.47) |
| Ex 38 |
49 (0) |
11 (1) |
42 (5), 37 (5) |
127 (11) |
129 (27) |
125 |
301 (14) |
6.46 (0.14) |
2.772.24) |
[0227] Lenses made from PVMA 628 kDa and mixtures DMA and NVP exhibited surprisingly excellent
biometrics, including lipid uptake of about 10 µg/lens or less and PQ1 uptake less
than about 10%, and moderate lysozyme uptake, as well as an excellent balance of physical
and mechanical properties.
Examples 39-43
[0228] Each reactive mixture was formed by mixing the reactive components listed in Table
22, filtering through a 3 µm filter using a heated or unheated stainless steel or
glass syringe, and then degassed by applying vacuum at ambient temperature for about
10 minutes. In a glove box with a nitrogen gas atmosphere and less than 0.1 percent
oxygen gas, about 75-100 µL of the reactive mixture were dosed using an Eppendorf
pipet at room temperature into the FC made of 90:10 (w/w) Z:TT. The BC made of PP
was then placed onto the FC. The molds were equilibrated for a minimum of twelve hours
in the glove box prior to dosing. The plate was transferred into an adjacent glove
box maintained at 62-65°C, and the lenses were cured from the top for 12 minutes using
TLO3 lights having intensity of 4-5 mW/cm
2. The light source was about six inches above the trays.
[0229] The lenses were manually de-molded with most lenses adhering to the FC and released
by suspending the 64 lenses in about one liter of 70% IPA for about one or two hours,
followed by washing two times with 70% IPA, two times with 25% IPA, two times with
DI, and finally two times with borate buffered packaging solution. Each washing step
lasted about 30 minutes. A person of ordinary skill recognizes that the exact lens
release process can be varied depending on the lens formulation and mold materials,
regarding the concentrations of the aqueous isopropanol solutions, the number of washings
with each solvent, and the duration of each step. The purpose of the lens release
process is to release all of the lenses without defects and transition from diluent
swollen networks to the packaging solution swollen hydrogels. The lenses were transferred
into vials and subsequently sterilized by autoclaving at 122°C for 30 minutes. The
physical and mechanical properties of the sterile lenses were measured and listed
in Table 23.
TABLE 22
| Component |
Ex 39 |
Ex 40 |
Ex 41 |
Ex 42 |
Ex 43 |
| OH-mPDMS (n=15) |
33 |
33 |
33 |
33 |
33 |
| OH-mPDMS (n=4) |
25 |
25 |
25 |
25 |
25 |
| Weight ratio of OH-mPDMS (n=4) to OH-mPDMS (n=15) |
0.76 |
0.76 |
0.76 |
0.76 |
0.76 |
| Molar ratio of OH-mPDMS (n=4) to OH-mPDMS (n=15) |
1.77 |
1.77 |
1.77 |
1.77 |
1.77 |
| NVP |
5.16 |
5.04 |
4.91 |
4.79 |
4.66 |
| DMA |
5.17 |
5.04 |
4.92 |
4.79 |
4.67 |
| HEMA |
10.5 |
10.5 |
10.5 |
10.5 |
10.5 |
| PVMA 628 kDa |
13.5 |
13.5 |
13.5 |
13.5 |
13.5 |
| mPEG 950 |
3 |
3 |
3 |
3 |
3 |
| MAA |
0.75 |
1 |
1.25 |
1.5 |
1.75 |
| TEGDMA |
1.60 |
1.60 |
1.60 |
1.60 |
1.60 |
| TAC |
0.2 |
0.2 |
0.2 |
0.2 |
0.2 |
| Norbloc |
1.75 |
1.75 |
1.75 |
1.75 |
1.75 |
| CGI 819 |
0.37 |
0.37 |
0.37 |
0.37 |
0.37 |
| Diluent |
23 |
23 |
23 |
23 |
23 |
| D3O |
100 |
100 |
100 |
100 |
100 |
TABLE 23
| Lens |
Weight % Water |
% Haze |
DCA (adv, rec) |
Mechanicals |
Dk |
Lysozyme (µg/Lens) |
PQ1 Uptake (%) |
Lipid Uptake (µg/lens) |
| M (psi) |
%ETB |
| Ex 39 |
49 (1) |
17 (1) |
24 (26), 3 (6) |
92 (8) |
128 (30) |
151 |
35 (7) |
1 (1.64) |
7.10 (0.53) |
| Ex 40 |
49 (0) |
22 (1) |
52 (34), 10 (14) |
100 (13) |
136 (31) |
146 |
113 (9) |
4.21 (0.59) |
6.98 (0.35) |
| Ex 41 |
49 (0) |
16 (1) |
61 (27), 16 (7) |
89 (12) |
108 (63) |
156 |
253 (7) |
14.99 (3.58) |
7.89 (0.41) |
| Ex 42 |
51 (0) |
18 (1) |
14 (19), 8 (10) |
93 (14) |
123 (47) |
142 |
506 (29) |
39.70 (2.45) |
7.34 (0.37) |
| Ex 43 |
52 (0) |
14 (1) |
48 (36), 7 (8) |
95 (10) |
131 (38) |
134 |
868 (28) |
59.49 (6.05) |
8.650.81) |
[0230] Lysozyme uptake and PQ1 uptake increased with MAA content.
Examples 44-45
[0231] Example 41 was repeated, except that the ratio of the hydroxyl-containing silicone
components was varied, as shown in Table 24. Example 44 is the same lens as Example
41, with only the lysozyme uptake test repeated. Each reactive mixture was formed
by mixing the reactive components listed in Table 24, filtering through a 3 µm filter
using a heated or unheated stainless steel or glass syringe, and then degassed by
applying vacuum at ambient temperature for about 10 minutes. In a glove box with a
nitrogen gas atmosphere and less than 0.1 percent oxygen gas, about 75-100 µL of the
reactive mixture were dosed using an Eppendorf pipet at room temperature into the
FC made of Zeonor. The BC made of PP was then placed onto the FC. The molds were equilibrated
for a minimum of twelve hours in the glove box prior to dosing. The plate was transferred
into an adjacent glove box maintained at 62-65°C, and the lenses were cured from the
top for 20 minutes using TLO3 lights having intensity of 3-4 mW/cm
2. The light source was about six inches above the trays.
[0232] The lenses were manually de-molded with most lenses adhering to the FC and released
by suspending the 64 lenses in about one liter of 70% IPA for about one or two hours,
followed by washing two times with 70% IPA, two times with 25% IPA, two times with
DI, and finally two times with borate buffered packaging solution. Each washing step
lasted about 30 minutes. A person of ordinary skill recognizes that the exact lens
release process can be varied depending on the lens formulation and mold materials,
regarding the concentrations of the aqueous isopropanol solutions, the number of washings
with each solvent, and the duration of each step. The purpose of the lens release
process is to release all of the lenses without defects and transition from diluent
swollen networks to the packaging solution swollen hydrogels. The lenses were transferred
into vials and subsequently sterilized by autoclaving at 122°C for 30 minutes. The
physical and mechanical properties of the sterile lenses were measured and listed
in Table 25.
TABLE 24
| Component |
Ex 44 |
Ex 45 |
Ex 46 |
Ex 47 |
Ex 48 |
Ex 49 |
Ex 50 |
| OH-mPDMS (n=15) |
33 |
32.5 |
32 |
31.5 |
31 |
30.5 |
30 |
| OH-mPDMS (n=4) |
25 |
25 |
25 |
25 |
25 |
25 |
25 |
| Weight ratio of OH-mPDMS (n=4) to OH-mPDMS (n=15) |
0.76 |
0.77 |
0.78 |
0.79 |
0.81 |
0.82 |
0.83 |
| Molar ratio of OH-mPDMS (n=4) to OH-mPDMS (n=15) |
1.77 |
1.79 |
1.82 |
1.84 |
1.87 |
1.91 |
1.94 |
| NVP |
4.91 |
5.16 |
5.41 |
5.66 |
5.91 |
6.16 |
6.41 |
| DMA |
4.92 |
5.17 |
5.42 |
5.67 |
5.92 |
6.17 |
6.42 |
| HEMA |
10.5 |
10.5 |
10.5 |
10.5 |
10.5 |
10.5 |
10.5 |
| PVMA 628 kDa |
13.5 |
13.5 |
13.5 |
13.5 |
13.5 |
13.5 |
13.5 |
| mPEG 950 |
3 |
3 |
3 |
3 |
3 |
3 |
3 |
| MAA |
1.25 |
1.25 |
1.25 |
1.25 |
1.25 |
1.25 |
1.25 |
| TEGDMA |
1.60 |
1.60 |
1.60 |
1.60 |
1.60 |
1.60 |
1.60 |
| TAC |
0.2 |
0.2 |
0.2 |
0.2 |
0.2 |
0.2 |
0.2 |
| Norbloc |
1.75 |
1.75 |
1.75 |
1.75 |
1.75 |
1.75 |
1.75 |
| CGI 819 |
0.37 |
0.37 |
0.37 |
0.37 |
0.37 |
0.37 |
0.37 |
| Diluent |
23 |
23 |
23 |
23 |
23 |
23 |
23 |
| D3O |
100 |
100 |
100 |
100 |
100 |
100 |
100 |
TABLE 25
| Lens |
Weight % Water |
% Haze |
DCA |
Mechanicals |
Dk |
Lysozyme (µg/Lens) |
PQ1 Uptake (%) |
Lipid Uptake (µg/lens) |
| M (psi) |
%ETB |
| Ex 44 |
49 (0) |
16 (1) |
61 (27), 16 (7) |
89 (12) |
108 (63) |
156 |
230 (16) |
14.99 (3.58) |
7.89 (0.41) |
| Ex 45 |
50 (1) |
16 (0) |
21 (16), 14 (13) |
100(11) |
123 (36) |
145 |
250 (17) |
11.87 (3.26) |
6.90 (0.29) |
| Ex 46 |
50 (0) |
16 (0) |
20 (14), 3 (6) |
101 (7) |
129 (30) |
145 |
288 (36) |
12.23 (2.82) |
7.17 (0.26) |
| Ex 47 |
50 (0) |
14 (1) |
65 (21), 16 (11) |
97 (12) |
133 (26) |
158 |
290 (7) |
11.97 (3.07) |
7.49 (0.49) |
| Ex 48 |
52 (0) |
14 (1) |
23 (16), 21 (18) |
100 (7) |
107 (38) |
132 |
451 (39) |
14.73 (3.09) |
7.02 (0.12) |
| Ex 49 |
52 (0) |
14 (1) |
40 (32), 15 (10) |
96(9) |
109 (44) |
131 |
471 (12) |
14.97 (2.86) |
7.74 (0.47) |
| Ex 50 |
52 (0) |
11 (1) |
25 (18), 17 (17) |
98(8) |
144 (36) |
133 |
517(23) |
15.2 (1.08) |
6.520.16) |
[0233] All lenses showed a desirable balance of mechanical and biometric properties.
Examples 51-52
[0234] Each reactive mixture was formed by mixing the reactive components listed in Table
26, filtering through a 3 µm filter using a heated or unheated stainless steel or
glass syringe, and then degassed by applying vacuum at ambient temperature for about
10 minutes. In a glove box with a nitrogen gas atmosphere and less than 0.1 percent
oxygen gas, about 75-100 µL of the reactive mixture were dosed using an Eppendorf
pipet at room temperature into the FC made of Zeonor. The BC made of PP was then placed
onto the FC. The molds were equilibrated for a minimum of twelve hours in the glove
box prior to dosing. The plate was transferred into an adjacent glove box maintained
at 62-65°C, and the lenses were cured from the top for 25 minutes using TLO3 lights
having intensity of 4-5 mW/cm
2. The light source was about six inches above the trays.
[0235] The lenses were manually de-molded with most lenses adhering to the FC and released
by suspending the 64 lenses in about one liter of 70% IPA for about one or two hours,
followed by washing two times with 70% IPA, two times with 25% IPA, two times with
DI, and finally two times with borate buffered packaging solution. Each washing step
lasted about 30 minutes. A person of ordinary skill recognizes that the exact lens
release process can be varied depending on the lens formulation and mold materials,
regarding the concentrations of the aqueous isopropanol solutions, the number of washings
with each solvent, and the duration of each step. The purpose of the lens release
process is to release all of the lenses without defects and transition from diluent
swollen networks to the packaging solution swollen hydrogels. The lenses were transferred
into vials and subsequently sterilized by autoclaving at 122°C for 30 minutes. The
physical and mechanical properties of the sterile lenses were measured and listed
in Table 27.
TABLE 26
| Component |
Ex 51 |
Ex 52 |
| OH-mPDMS (n=15) |
30 |
30 |
| OH-mPDMS (n=4) |
25 |
25 |
| Weight ratio of OH-mPDMS (n=4) to OH-mPDMS (n=15) |
0.83 |
0.83 |
| Molar ratio of OH-mPDMS (n=4) to OH-mPDMS (n=15) |
1.94 |
1.94 |
| NVP |
7.22 |
6.12 |
| DMA |
7.22 |
6.12 |
| HEMA |
10.5 |
10.5 |
| PVMA 628 kDa |
9 |
15 |
| PVMA 1600 kDa |
3 |
0 |
| mPEG 950 |
3 |
3 |
| MAA |
0.75 |
0.75 |
| Q-Salt |
1.25 |
0 |
| TEGDMA |
0.75 |
1.2 |
| TAC |
0.2 |
0.2 |
| Norbloc |
1.75 |
1.75 |
| CGI 819 |
0.36 |
0.36 |
| Diluent |
20 |
23 |
| D3O |
100 |
100 |
TABLE 27
| Ex # |
% Water |
% Haze |
DCA (adv, rec) |
Mechanicals |
Dk |
Lysozyme (µg/Lens) |
PQ1 Uptake (%) |
Lipid Uptake (µg/lens) |
| M (psi) |
%ETB |
| 51 |
52 (0) |
18 (1) |
19 (19), 21 (19) |
70 (6) |
204 (49) |
132 |
47 (5) |
5.93 (0.49) |
2.77 (1.39) |
| 52 |
56 (0) |
14 (1) |
28 (6), 9 (10) |
76(13) |
146 (55) |
121 |
258 (19) |
5.80 (0.16) |
4.05 (3.09) |
[0236] Lenses containing an ammonium chloride salt (Q-Salt) displayed greatly reduced lysozyme
uptake, but a good balance of mechanical properties and low PQ-1 and lipid uptake.
This example shows that cationic components can be added, without negatively impacting
compatibility (as shown by the 18% haze) and while maintaining a desirable balance
of properties.
Examples 53-55
[0237] Each reactive mixture was formed by mixing the reactive components listed in Table
28, filtering through a 3 µm filter using a heated or unheated stainless steel or
glass syringe, and then degassed by applying vacuum at ambient temperature for about
10 minutes. In a glove box with a nitrogen gas atmosphere and less than 0.1 percent
oxygen gas, about 75-100 µL of the reactive mixture were dosed using an Eppendorf
pipet at room temperature into the FC made of Zeonor. The BC made of PP was then placed
onto the FC. The molds were equilibrated for a minimum of twelve hours in the glove
box prior to dosing. The plate was transferred into an adjacent glove box maintained
at 62-65°C, and the lenses were cured from the top for 25 minutes using TLO3 lights
having intensity of 4-5 mW/cm
2. The light source was about six inches above the trays.
[0238] The lenses were manually de-molded with most lenses adhering to the FC and released
by suspending the 64 lenses in about one liter of 70% IPA for about one or two hours,
followed by washing two times with 70% IPA, two times with 25% IPA, two times with
DI, and finally two times with borate buffered packaging solution. Each washing step
lasted about 30 minutes. A person of ordinary skill recognizes that the exact lens
release process can be varied depending on the lens formulation and mold materials,
regarding the concentrations of the aqueous isopropanol solutions, the number of washings
with each solvent, and the duration of each step. The purpose of the lens release
process is to release all of the lenses without defects and transition from diluent
swollen networks to the packaging solution swollen hydrogels. The lenses were transferred
into vials and subsequently sterilized by autoclaving at 122°C for 30 minutes. The
physical and mechanical properties of the sterile lenses were measured and listed
in Table 29.
TABLE 28
| Component |
Ex 53 |
Ex 54 |
Ex 55 |
| OH-mPDMS (n=15) |
32 |
32 |
32 |
| OH-mPDMS (n=4) |
25 |
25 |
25 |
| Weight ratio of OH-mPDMS (n=4) to OH-mPDMS (n=15) |
0.78 |
0.78 |
0.78 |
| Molar ratio of OH-mPDMS (n=4) to OH-mPDMS (n=15) |
1.82 |
1.82 |
1.82 |
| NVP |
5.41 |
6.91 |
5.45 |
| DMA |
5.42 |
6.92 |
5.46 |
| HEMA |
11.33 |
11.33 |
12.75 |
| Blue HEMA |
0.02 |
0.02 |
0.02 |
| PVMA 628 kDa |
13.5 |
13.5 |
10 |
| Poly [DMA-co-CBT] |
0 |
0 |
5 |
| mPEG 950 |
3 |
0 |
0 |
| MAA |
1 |
1 |
1 |
| EGDMA |
1 |
1 |
1 |
| TAC |
0.2 |
0.2 |
0.2 |
| Norbloc |
1.75 |
1.75 |
1.75 |
| CGI 819 |
0.37 |
0.37 |
0.37 |
| Diluent |
23 |
23 |
23 |
| D3O |
100 |
100 |
100 |
TABLE 29
| Ex. |
% Water |
% Haze |
DCA (adv, rec) |
Mechanicals |
Dk |
Lysozyme (µg/Lens) |
PQ1 Uptake (%) |
Lipid Uptake (µg/lens) |
| M (psi) |
%ETB |
| 53 |
44 (0) |
10 (1) |
24 (12), 0 (0) |
193 (15) |
92 (26) |
151 |
51 (6) |
2.58 (6.36) |
5.74 (0.18) |
| 54 |
44 (0) |
14 (1) |
29 (10), 6 (11) |
182 (20) |
93 (34) |
151 |
57 (5) |
8.46 (2.44) |
5.71 (0.36) |
| 55 |
44 (0) |
30 (2) |
18 (13), 3 (7) |
164 (14) |
121 (31) |
132 |
106 (8) |
21.80 (1.03) |
6.020.2) |
[0239] The Poly[DMA-co-CBT], is a random copolymer of DMA and 20 wt% (10 mol%) zwitterionic
monomer carboxybetaine. Carboxybetaine is highly hydrophilic internal salt which is
generally poorly compatible with silicone hydrogel reactive mixtures. It was surprising
that 5wt% of this copolymer could be incorporated into silicone hydrogels formulations
displaying only 30% haze. Lenses containing zwitterionic internal wetting agent showed
increased lysozyme and PQ1 uptake.
Examples 56-63
[0240] A series of lenses were made from reactive mixtures with varying formulation components,
including hydrophilic monomer, hydroxyl-containing silicone component, types and amount
of crosslinker and amounts of ionic monomer. Each reactive mixture was formed by mixing
the reactive components listed in Table 30, filtering through a 3 µm filter using
a heated or unheated stainless steel or glass syringe, and then degassed by applying
vacuum at ambient temperature for about 10 minutes. In a glove box with a nitrogen
gas atmosphere and less than 0.1 percent oxygen gas, about 75-100 µL of the reactive
mixture were dosed using an Eppendorf pipet at room temperature into the FC made of
Zeonor. The BC made of PP was then placed onto the FC. The molds were equilibrated
for a minimum of twelve hours in the glove box prior to dosing. The plate was transferred
into an adjacent glove box maintained at 62-65°C, and the lenses were cured from the
top for 12 minutes using TLO3 lights having intensity of 4-5 mW/cm
2. The light source was about six inches above the trays.
[0241] The lenses were manually de-molded with most lenses adhering to the FC and released
by suspending the 64 lenses in about one liter of 70% IPA for about one or two hours,
followed by washing two times with 70% IPA, two times with 25% IPA, two times with
DI, and finally two times with borate buffered packaging solution. Each washing step
lasted about 30 minutes. A person of ordinary skill recognizes that the exact lens
release process can be varied depending on the lens formulation and mold materials,
regarding the concentrations of the aqueous isopropanol solutions, the number of washings
with each solvent, and the duration of each step. The purpose of the lens release
process is to release all of the lenses without defects and transition from diluent
swollen networks to the packaging solution swollen hydrogels. The lenses were transferred
into vials and subsequently sterilized by autoclaving at 122°C for 30 minutes. The
physical and mechanical properties of the sterile lenses were measured and listed
in Table 31.
TABLE 30
| Component |
Ex 56 |
Ex57 |
Ex 58 |
Ex 59 |
Ex 60 |
Ex 61 |
Ex 62 |
Ex 63 |
| OH-mPDMS (n=15) |
31 |
31 |
31 |
31 |
30 |
31 |
32 |
33 |
| OH-mPDMS (n=4) |
25 |
25 |
25 |
25 |
25 |
25 |
25 |
25 |
| Weight ratio of OH-mPDMS (n=4) to OH-mPDMS (n=15) |
0.81 |
0.81 |
0.81 |
0.81 |
0.83 |
0.81 |
0.78 |
0.76 |
| Molar ratio of OH-mPDMS (n=4) to OH-mPDMS (n=15) |
1.87 |
1.87 |
1.87 |
1.87 |
1.94 |
1.87 |
1.82 |
1.77 |
| NVP |
5.54 |
5.54 |
5.54 |
4.54 |
0 |
0 |
0 |
0 |
| DMA |
6.54 |
6.54 |
6.54 |
6.04 |
16.03 |
15.03 |
14.03 |
13.03 |
| HEMA |
11.33 |
11.33 |
11.33 |
11.33 |
10.5 |
10.5 |
10.5 |
10.5 |
| Blue HEMA |
0.02 |
0.02 |
0.02 |
0.02 |
0.02 |
0.02 |
0.02 |
0.02 |
| PVMA 628 kDa |
13.5 |
13.5 |
13.5 |
15 |
13.5 |
13.5 |
13.5 |
13.5 |
| mPEG 950 |
3 |
3 |
3 |
3 |
0 |
0 |
0 |
0 |
| MAA |
1 |
1 |
1 |
1 |
1.25 |
1.25 |
1.25 |
1.25 |
| TEGDMA |
0 |
0 |
0 |
0 |
1.6 |
1.6 |
1.6 |
1.6 |
| EGDMA |
0.75 |
0.75 |
0.75 |
0.75 |
0 |
0 |
0 |
0 |
| TAC |
0.2 |
0.2 |
0.2 |
0.2 |
0 |
0 |
0 |
0 |
| Norbloc |
1.75 |
1.75 |
1.75 |
1.75 |
1.75 |
1.75 |
1.75 |
1.75 |
| CGI 819 |
0.37 |
0.37 |
0.37 |
0.37 |
0.35 |
0.35 |
0.35 |
0.35 |
| Diluent |
25 |
27.5 |
30 |
30 |
23 |
23 |
23 |
23 |
| D3O |
100 |
100 |
100 |
100 |
100 |
100 |
100 |
100 |
TABLE 31
| Ex |
% Water |
% Haze |
DCA (adv, rec) |
Mechanicals |
Dk |
Lysozyme (µg/Lens) |
PQ1 Uptake (%) |
Lipid Uptake (µg/lens) |
| M (psi) |
%ETB |
| 56 |
49(0) |
15 (1) |
36 (22), 27 (17) |
111(11) |
160(49) |
125 |
294 ± 25 |
3.81 (0.44) |
NT |
| 57 |
49 (0) |
14 (1) |
46 (15), 27 (9) |
99 (11) |
168 (36) |
130 |
317 ± 27 |
5.61 (0.27) |
NT |
| 58 |
50 (0) |
13 (1) |
29 (9), 17 (9) |
96 (6) |
158 (37) |
138 |
341 ± 12 |
1.98 (0.90) |
NT |
| 59 |
51 (0) |
13 (1) |
26 (5), 10 (9) |
115 (11) |
136 (53) |
135 |
191 ± 25 |
1.10 (1.36) |
NT |
| 60 |
53 (0) |
12 (2) |
67 (30), 6 (8) |
84 (8) |
149 (59) |
125 |
819 (66) |
49.47 (5.05) |
6.95 (1.26) |
| 61 |
51 (0) |
12 (1) |
79 (18), 17 (14) |
87 (13) |
125 (52) |
128 |
596 (47) |
48.5 (2.44) |
9.2 (0.78) |
| 62 |
50 (0) |
11 (1) |
39 (2), 11 (7) |
97 (13) |
128 (40) |
139 |
428 (7) |
48.83 (2.54) |
6.66 (0.09) |
| 63 |
51 (0) |
15 (1) |
40 (14), 0 (0) |
98 (8) |
140 (44) |
140 |
355 (17) |
52.57 (1.18) |
7.360.37) |
[0242] All lenses showed a desirable combination of properties. Also, comparing Examples
61-63 to the lenses made in
US822016, using a combination of hydroxyl-containing silicone components instead of one non-hydroxyl
silicone component (mPDMS) and a hydroxyl-functional silicone-containing monomer (SiMAA),
allowed for the incorporation of an anionic component (MAA), without adding thermal
instability, water contents above about 50%, advancing contact angles less than 80
and Dk values of about 130 barrers or more.
Examples 64-68
[0243] Each reactive mixture was formed by mixing the reactive components listed in Table
32, filtering through a 3 µm filter using a heated or unheated stainless steel or
glass syringe, and then degassed by applying vacuum at ambient temperature for about
10 minutes. In a glove box with a nitrogen gas atmosphere and less than 0.1 percent
oxygen gas, about 75-100 µL of the reactive mixture were dosed using an Eppendorf
pipet at room temperature into the FC made of Zeonor. The BC made of a 55:45 (w/w)
blend of Z and PP was then placed onto the FC. The molds were equilibrated for a minimum
of twelve hours in the glove box prior to dosing. The plate was transferred into an
adjacent glove box maintained at 62-65°C. The lenses of Examples 64 and 66-68 were
cured from the top for 20 minutes using 420 nm and 435 nm LED lights, respectively,
having intensity of 4 mW/cm
2. Example 65 was cured using TLO3 bulbs at 5 mW/cm
2, for 15 minutes. The light source was about six inches above the trays.
[0244] The lenses were manually de-molded with most lenses adhering to the FC and released
by suspending the 64 lenses in about one liter of 70% IPA for about one or two hours,
followed by washing two times with 70% IPA, two times with 25% IPA, two times with
DI, and finally two times with borate buffered packaging solution. Each washing step
lasted about 30 minutes. The lenses were transferred into vials and subsequently sterilized
by autoclaving at 122°C for 30 minutes. The physical and mechanical properties of
the sterile lenses were measured and listed in Table 33.
TABLE 32
| Component |
Ex 64 |
Ex 65 |
Ex 66 |
Ex 67 |
Ex 68 |
| OH-mPDMS (n=15) |
31 |
31 |
31 |
31 |
31 |
| OH-mPDMS (n=4) |
25 |
25 |
25 |
25 |
25 |
| Weight ratio of OH-mPDMS (n=4) to OH-mPDMS (n=15) |
0.81 |
0.81 |
0.81 |
0.81 |
0.81 |
| Molar ratio of OH-mPDMS (n=4) to OH-mPDMS (n=15) |
1.87 |
1.87 |
1.87 |
1.87 |
1.87 |
| NVP |
5.66 |
5.35 |
6.1 |
6.1 |
6.1 |
| DMA |
6.54 |
5.35 |
6.1 |
6.1 |
6.1 |
| HEMA |
11.33 |
11.33 |
11.33 |
11.33 |
11.33 |
| Blue HEMA |
0.02 |
0.02 |
0.02 |
0.02 |
0.02 |
| PVMA 628 kDa |
13.5 |
15 |
12 |
10.5 |
8.5 |
| PVP K90 |
0 |
0 |
1.5 |
3 |
5 |
| mPEG 950 |
3 |
3 |
3 |
3 |
3 |
| MAA |
1 |
1 |
1 |
1 |
1 |
| TEGDMA |
0.75 |
0.75 |
0.75 |
0.75 |
0.75 |
| TAC |
0.2 |
0.2 |
0.2 |
0.2 |
0.2 |
| Norbloc |
1.75 |
1.75 |
1.75 |
1.75 |
1.75 |
| CGI 819 |
0.25 |
0.25 |
0.25 |
0.25 |
0.25 |
| Diluent |
30 |
30 |
30 |
30 |
30 |
| D3O |
100 |
100 |
100 |
100 |
100 |
TABLE 33
| Ex |
% Water |
% Haze |
DCA (adv, rec) |
Mechanicals |
Dk |
Lysozyme (µg/Lens) |
PQ1 Uptake (%) |
Lipid Uptake (µg/lens) |
| M (psi) |
%ETB |
| 64 |
49 (0) |
17 (0) |
33 (6), 11 (11) |
99 (12) |
187 (53) |
133 |
245 ± 12 |
-3.04 (1.30) |
NT |
| 65 |
49(0) |
14 (0) |
33 (12,), 12 (16) |
111 (7) |
167 (46) |
142 |
167 ± 8 |
-0.44 (2.40) |
NT |
| 66 |
49(0) |
12 (1) |
24 (9), 16 (5) |
88 (13) |
206 (52) |
117 |
224 ± 14 |
6.13 (0.54) |
2.61 (1.80) |
| 67 |
49(0) |
13 (1) |
52 (7), 22 (8) |
109 (8) |
179 (29) |
125 |
291 ± 4 |
6.96 (0.28) |
-0.09 (3.39) |
| 68 |
47(0) |
15 (1) |
13 (19), 10 (11) |
115 (10) |
165 (60) |
135 |
200 ± 12 |
6.92 (0.23) |
1.940.46) |
[0245] Lenses prepared using mixtures of NVP and DMA together with mixtures of OH-mPDMS
and mixtures of PVMA and PVP as the internal wetting agents showed an excellent balance
of biometric properties including moderate lysozyme, PQ1, and lipid uptake.
Examples 69-72
[0246] Each reactive mixture was formed by mixing the reactive components listed in Table
34, filtering through a 3 µm filter using a heated or unheated stainless steel or
glass syringe, and then degassed by applying vacuum at ambient temperature for about
10 minutes. In a glove box with a nitrogen gas atmosphere and less than 0.1 percent
oxygen gas, about 75-100 µL of the reactive mixture were dosed using an Eppendorf
pipet at room temperature into the FC made of Zeonor. The BC made of a 55:45 (w/w)
blend of Z and PP was then placed onto the FC. The molds were equilibrated for a minimum
of twelve hours in the glove box prior to dosing. The plate was transferred into an
adjacent glove box maintained at 62-65°C, and the lenses were cured from the top for
20 minutes using 435 nm LED lights having intensity of 4 mW/cm
2. The light source was about six inches above the trays.
[0247] The lenses were manually de-molded with most lenses adhering to the FC and released
by suspending the 64 lenses in about one liter of 70% IPA for about one or two hours,
followed by washing two times with 70% IPA, two times with 25% IPA, two times with
DI, and finally two times with borate buffered packaging solution. Each washing step
lasted about 30 minutes. A person of ordinary skill recognizes that the exact lens
release process can be varied depending on the lens formulation and mold materials,
regarding the concentrations of the aqueous isopropanol solutions, the number of washings
with each solvent, and the duration of each step. The purpose of the lens release
process is to release all of the lenses without defects and transition from diluent
swollen networks to the packaging solution swollen hydrogels. The lenses were transferred
into vials and subsequently sterilized by autoclaving at 122°C for 30 minutes. The
physical and mechanical properties of the sterile lenses were measured and listed
in Table 35.
TABLE 34
| Component |
Ex 69 |
Ex 70 |
Ex 71 |
Ex 72 |
Ex 73 |
| OH-mPDMS (n=15) |
31 |
31 |
31 |
31 |
31 |
| OH-mPDMS (n=4) |
25 |
25 |
25 |
25 |
25 |
| Weight ratio of OH-mPDMS (n=4) to OH-mPDMS (n=15) |
0.80 |
0.80 |
0.80 |
0.80 |
0.80 |
| Molar ratio of OH-mPDMS (n=4) to OH-mPDMS (n=15) |
1.87 |
1.87 |
1.87 |
1.87 |
1.87 |
| NVP |
5.35 |
5.32 |
5.35 |
5.35 |
5.35 |
| DMA |
5.35 |
5.32 |
5.35 |
5.35 |
5.35 |
| HEMA |
11.33 |
11.30 |
11.33 |
11.33 |
11.33 |
| Blue HEMA |
0.02 |
0.02 |
0.02 |
0.02 |
0.02 |
| PVMA 628 kDa |
10 |
10 |
7.5 |
5 |
2.5 |
| PVP K90 |
5 |
5 |
7.5 |
10 |
12.5 |
| mPEG 950 |
3 |
3 |
3 |
3 |
3 |
| MAA |
1 |
1 |
1 |
1 |
1 |
| EGDMA |
0.75 |
0.75 |
0.75 |
0.75 |
0.75 |
| TAC |
0.2 |
0.2 |
0.2 |
0.2 |
0.2 |
| Norbloc |
1.75 |
1.75 |
1.75 |
1.75 |
1.75 |
| CGI 819 |
0.25 |
0 |
0.25 |
0.25 |
0.25 |
| CGI 1870 |
0 |
0.34 |
0 |
0 |
0 |
| Diluent |
30 |
30 |
30 |
30 |
30 |
| D3O |
100 |
100 |
100 |
100 |
100 |
TABLE 35
| Ex |
% Water |
% Haze |
DCA (adv, rec) |
Mechanicals |
Dk |
Lysozyme (µg/Lens) |
PQ1 Uptake (%) |
Lipid Uptake (µg/lens) |
| M (psi) |
%ETB |
| 69 |
49 (0) |
15 (1) |
37 (9), 23 (12) |
115 (8) |
180 (40) |
124 |
166 ± 9 |
6.96 (0.14) |
2.58 (1.84) |
| 70 |
47 (0) |
16 (2) |
43 (7), 18 (15) |
118 (11) |
198 (40) |
134 |
133 ± 5 |
7.02 (0.42) |
2.89 (2.45) |
| 71 |
49(0) |
13 (1) |
16 (21), 16 (18) |
102 (11) |
192 (33) |
130 |
185 ± 15 |
8.22 (0.5) |
6.08 (1.37) |
| 72 |
47 (0) |
16 (2) |
18 (11), 4 (6) |
127 (14) |
213 (38) |
139 |
134 ± 19 |
8.29 (0.68) |
2.53 (1.69) |
| 73 |
46.4 (0.3) |
15 (2) |
15 (18), 10 (15) |
134 (18) |
44 (20) |
136 |
97 ± 9 |
NT |
2.49 (1.91) |
[0248] This series of Examples shows that lenses having very low lipid uptake values (less
than about 5 ug/lens, and less than 3 ug/lens) may be prepared using a combination
of acyclic polyamide and PVP. All lenses had a desirable balance of both biometric,
physical and mechanical properties.
Examples 74-77
[0249] Each reactive mixture was formed by mixing the reactive components listed in Table
36, filtering through a 3 µm filter using a heated or unheated stainless steel or
glass syringe, and then degassed by applying vacuum at ambient temperature for about
10 minutes. In a glove box with a nitrogen gas atmosphere and less than 0.1 percent
oxygen gas, about 75-100 µL of the reactive mixture were dosed using an Eppendorf
pipet at room temperature into the FC made of Zeonor. The BC made of a 55:45 (w/w)
blend of Z and PP was then placed onto the FC. The molds were equilibrated for a minimum
of twelve hours in the glove box prior to dosing. The plate was transferred into an
adjacent glove box maintained at 62-65°C, and the lenses were cured from the top for
20 minutes using 435 nm LED lights having intensity of 4 mW/cm
2. The light source was about six inches above the trays.
[0250] The lenses were manually de-molded with most lenses adhering to the FC and released
by suspending the 64 lenses in about one liter of 70% IPA for about one or two hours,
followed by washing two times with 70% IPA, two times with 25% IPA, two times with
DI, and finally two times with borate buffered packaging solution. Each washing step
lasted about 30 minutes. A person of ordinary skill recognizes that the exact lens
release process can be varied depending on the lens formulation and mold materials,
regarding the concentrations of the aqueous isopropanol solutions, the number of washings
with each solvent, and the duration of each step. The purpose of the lens release
process is to release all of the lenses without defects and transition from diluent
swollen networks to the packaging solution swollen hydrogels. The lenses were transferred
into vials and subsequently sterilized by autoclaving at 122°C for 30 minutes. The
physical and mechanical properties of the sterile lenses were measured and listed
in Table 37.
TABLE 36
| Component |
Ex 74 |
Ex 75 |
Ex 76 |
Ex 77 |
| OH-mPDMS (n=15) |
31 |
31 |
26 |
21 |
| mPDMS 1000 (n=10) |
0 |
0 |
10 |
10 |
| OH-mPDMS (n=4) |
25 |
25 |
20 |
25 |
| Weight ratio OH-mPDMS (n=4) to OH-mPDMS (n=15) |
0.81 |
0.81 |
0.77 |
1.19 |
| Molar ratio of OH-mPDMS (n=4) to OH-mPDMS (n=15) |
2.37 |
3.33 |
|
|
| NVP |
5.35 |
5.32 |
5.35 |
5.35 |
| DMA |
5.35 |
5.32 |
5.35 |
5.35 |
| HEMA |
11.33 |
11.30 |
11.33 |
11.33 |
| Blue HEMA |
0.02 |
0.02 |
0.02 |
0.02 |
| PVMA 628 kDa |
5 |
5 |
5 |
5 |
| PVP K90 |
10 |
10 |
10 |
10 |
| mPEG 950 |
3 |
3 |
3 |
3 |
| MAA |
1 |
1 |
1 |
1 |
| EGDMA |
0.75 |
0.75 |
0.75 |
0.75 |
| TAC |
0.2 |
0.2 |
0.2 |
0.2 |
| Norbloc |
1.75 |
1.75 |
1.75 |
1.75 |
| CGI 819 |
0.25 |
0 |
0.25 |
0.25 |
| CGI 1870 |
0 |
0.34 |
0 |
0 |
| Diluent |
30 |
30 |
30 |
30 |
| D3O |
100 |
100 |
100 |
100 |
TABLE 37
| Ex |
% Water |
% Haze |
DCA (adv, rec) |
Mechanicals |
Dk |
Lysozyme (µg/Lens) |
| M (psi) |
%ETB |
| 74 |
45.7 (0.5) |
17 (1) |
13 (16), 4 (9) |
126 (10) |
82 (18) |
129 |
115 ± 12 |
| 75 |
44.8 (0.4) |
19 (1) |
24 (10), 8 (9) |
126 (15) |
73 (12) |
136 |
101 ± 21 |
| 76 |
45.6 (0.5) |
18 (1) |
96 (6), 17 (10) |
133 (12) |
65 (16) |
138 |
174 ± 54 |
| 77 |
46.8 (0.4) |
17 (1) |
91 (16), 18 (16) |
136 (8) |
62 (20) |
135 |
56 ± 2 |
[0251] Lenses prepared using mixtures of NVP and DMA together with mixtures of OH-mPDMS
and mixtures of PVMA and PVP as the internal wetting agents showed an excellent balance
of biometric properties including moderate lysozyme, PQ1, and lipid uptake, except
when mPDMS was also included in the reactive mixture.
Examples 78-82
[0252] Lenses were made from the formulation listed in Example 82 of Table 38, below, using
the procedures described in Examples 74-77. The lenses were transferred into vials
and subsequently sterilized by autoclaving at 122°C for 30 minutes. The physical and
mechanical properties of the sterile lenses of Example 82 were measured and listed
in Table 39.
TABLE 38
| Component |
Ex 78 |
Ex 79 |
Ex 80 |
Ex 81 |
Ex 82 |
| OH-mPDMS (n=4) |
42 |
42 |
42 |
42 |
42 |
| SiMAA |
21 |
21 |
21 |
21 |
21 |
| Weight ratio SiMMA to OH-mPDMS (n=4) |
0.5 |
0.5 |
0.5 |
0.5 |
0.5 |
| DMA |
26.14 |
25.14 |
24.14 |
23.14 |
23.39 |
| PVP K90 |
7 |
8 |
9 |
10 |
10 |
| TEGDMA |
1.5 |
1.5 |
1.5 |
1.5 |
1.5 |
| Blue HEMA |
0.02 |
0.02 |
0.02 |
0.02 |
0.02 |
| Norbloc |
2 |
2 |
2 |
2 |
1.75 |
| CGI 1870 |
0.34 |
0.34 |
0.34 |
0.34 |
0.34 |
| Diluent |
23 |
23 |
23 |
23 |
23 |
| D3O |
100 |
100 |
100 |
100 |
100 |
TABLE 39
| Ex |
Wt % Water |
% Haze |
DCA (adv, rec) |
Mechanicals |
Dk |
Lipid (µg/Lens) |
| M (psi) |
%ETB |
| 82 |
39(0) |
9(1) |
21(11), 21(12) |
119(9) |
277(49) |
98 |
20.49 (3) |
Examples 83-93
[0253] Each reactive mixture was formed by mixing the reactive components listed in Table
40, filtering through a 3 µm filter using a heated or unheated stainless steel or
glass syringe, and then degassed by applying vacuum at ambient temperature for about
10 minutes. In a glove box with a nitrogen gas atmosphere and less than 0.1 percent
oxygen gas, about 75-100 µL of the reactive mixture were dosed using an Eppendorf
pipet at room temperature into the FC made of Zeonor. The BC made of a 55:45 (w/w)
blend of Z and PP was then placed onto the FC. The molds were equilibrated for a minimum
of twelve hours in the glove box prior to dosing. The plate was transferred into an
adjacent glove box maintained at 60-65°C, and the lenses were cured from the top.
Examples 83 and 84 were cured for 20 minutes using 435 nm LED lights having intensity
of 4 mW/cm
2. Examples 85-90 were cured for 15 minutes using TLO3 lights having intensity of 5
mW/cm
2. The light source was about six inches above the trays.
[0254] On the other hand, examples 91-93 were cured using 435 nm LED lights from the top
and bottom first using an intensity of 1 mW/cm
2 for 2 minutes and second using an intensity of 2.5 mW/cm
2 for 6 minutes. Examples 91-93 also used a 90:10 (w/w) Z:TT blend FC and a 90: 10
(w/w) Z:PP blend BC. The reaction temperature was 65°C, and the oxygen gas concentration
was 0.1 percent in the glove box.
[0255] For Examples 83-90, the lenses were manually de-molded with most lenses adhering
to the FC and released by suspending the 64 lenses in about one liter of 40% IPA for
about one or two hours, followed by washing two times with 40% IPA, two times with
DI, and finally two times with borate buffered packaging solution. Each washing step
lasted at least 30 minutes. For Examples 91-93, the lenses were manually de-molded
with most lenses adhering to the FC and released by suspending the 64 lenses in about
one liter of 70% IPA for about one or two hours, followed by washing two times with
70% IPA, two times with DI, and finally two times with borate buffered packaging solution.
Each washing step lasted at least 30 minutes. A person of ordinary skill recognizes
that the exact lens release process can be varied depending on the lens formulation
and mold materials, regarding the concentrations of the aqueous isopropanol solutions,
the number of washings with each solvent, and the duration of each step. The purpose
of the lens release process is to release all of the lenses without defects and transition
from diluent swollen networks to the packaging solution swollen hydrogels. The lenses
were transferred into vials and subsequently sterilized by autoclaving at 122°C for
30 minutes. The physical and mechanical properties of the sterile lenses were measured
and listed in Table 41.
Table 40
| Component |
Ex 83 |
Ex 84 |
Ex 85 |
Ex 86 |
Ex 87 |
Ex 88 |
Ex 89 |
Ex 90 |
Ex 91 |
Ex 92 |
Ex 93 |
| OH-mPDMS n=4 |
30 |
30 |
25 |
20 |
15 |
10 |
10 |
10 |
25 |
25 |
25 |
| OH-mPDMS n=15 |
30 |
30 |
35 |
40 |
45 |
50 |
50 |
50 |
28 |
28 |
28 |
| Tegomer 2250 |
10 |
10 |
10 |
10 |
10 |
10 |
5 |
7.5 |
5 |
5 |
5 |
| EGDMA |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0.25 |
0.25 |
0.25 |
| DMA |
7 |
10 |
10 |
10 |
10 |
10 |
12.5 |
11.25 |
24 |
20 |
20 |
| HEMA |
11 |
11 |
10.98 |
10.98 |
10.98 |
10.98 |
13.48 |
12.23 |
7.89 |
7.89 |
7.89 |
| pVMA (Mw=507KDa) |
10 |
7 |
7 |
7 |
7 |
7 |
7 |
7 |
0 |
0 |
0 |
| PVP K90 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
9 |
7 |
| pVMA (Mw=570KDa) |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
2 |
| PDMA (Mw=740KDa) |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
5 |
0 |
0 |
| UV Absorbers |
1.75 |
1.75 |
1.75 |
1.75 |
1.75 |
1.75 |
1.75 |
1.75 |
4.5 |
4.5 |
4.5 |
| CG1 819 |
0.25 |
0.25 |
0.25 |
0.25 |
0.25 |
0.25 |
0.25 |
0.25 |
0 |
0 |
0 |
| Ingacure 1870 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0.34 |
0.34 |
0.34 |
| Blue HEMA |
0 |
0 |
0.02 |
0.02 |
0.02 |
0.02 |
0.02 |
0.02 |
0.02 |
0.02 |
0.02 |
| Diluent |
23 |
23 |
23 |
23 |
23 |
23 |
23 |
23 |
23 |
23 |
23 |
| D3O |
100 |
100 |
100 |
100 |
100 |
100 |
100 |
100 |
100 |
100 |
100 |
Table 41
| Ex # |
% Water |
% Haze |
Sessile Drop (°) |
DCA Kruss (Adv °) |
Dk |
Lipids (µg/lens) |
Mechanicals |
| Modulus (psi) |
Elong. (%) |
| Ex 83 |
25.5 |
10 (1) |
NT |
55 (17) |
110 |
NT |
220 (24) |
158 (39) |
| Ex 84 |
25.2 |
6 (0) |
NT |
94 (10) |
78 |
NT |
180 (10) |
166 (43) |
| Ex 85 |
24.5 |
5 |
NT |
69 |
96 |
NT |
218 |
124 |
| Ex 86 |
23.8 |
4 |
NT |
92 |
145 |
NT |
182 |
150 |
| Ex 87 |
23.1 |
3 |
NT |
61 |
125 |
NT |
219 |
135 |
| Ex 88 |
24.2 |
5 |
NT |
70 |
135 |
NT |
178 |
158 |
| Ex 89 |
32 |
18 |
NT |
46 |
225 |
NT |
118 |
247 |
| Ex 90 |
27.7 |
12 |
NT |
53 |
170 |
NT |
145 |
126 |
| Ex 91 |
38 |
6 (1) |
39 (3) |
38 (5) |
128 |
1.74 (0.30) |
109 (4) |
163 (83) |
| Ex 92 |
37 |
4 (0) |
44 (2) |
40 (10) |
134 |
2.62 (0.41) |
118 (8) |
252 (48) |
| Ex 93 |
37 |
5 (0) |
43 (3) |
19 (21) |
124 |
2.17 (0.25) |
143 (10) |
216 (75) |
1. A silicone hydrogel formed from a reactive monomer mixture comprising:
a. between 1 and 15 wt% at least one polyamide, wherein "polyamide" refers to polymers
and copolymers comprising repeating units containing amide groups;
b. at least one first mono-functional, hydroxyl substituted, linear poly(disubstituted
siloxane) having 4 to 8 siloxane repeating units;
c. at least one second hydroxyl substituted, linear poly(disubstituted siloxane) selected
from the group consisting of mono-functional hydroxyl substituted poly(disubstituted
siloxane)s having 10 to 200 or 10-100 siloxane repeating units and multifunctional
hydroxyl substituted poly(disubstituted siloxane)s having 10 to 200, or 10 to 100
siloxane repeating units, and mixtures thereof;
d. 5 to 35 wt% of at least one hydrophilic monomer;
wherein the first hydroxyl substituted, linear poly(disubstituted siloxane) and the
second mono-functional hydroxyl substituted, linear poly(disubstituted siloxane) are
present in concentrations to provide a ratio of wt% of all first hydroxyl substituted,
linear poly(disubstituted siloxane) to wt% of all second hydroxyl substituted, linear
poly(disubstituted siloxane)s of 0.4-1.3, or 0.4-1.0;
wherein "functional" means a group which can undergo free radical polymerization;
wherein concentrations of components are given in weight % of all components in the
reaction mixture, excluding diluent.
2. The silicone hydrogel of claim 1, wherein the second hydroxyl substituted linear poly(disubstituted
siloxane) is selected from mono-functional hydroxyl substituted linear poly(disubstituted
siloxane)s having 10 to 200 or 10-100 siloxane repeating units.
3. The silicone hydrogel of claim 1 or 2, wherein:
(a) the first monofunctional hydroxyl substituted, poly(disubstituted siloxane) comprises
compounds of Formula VII-1

wherein
Z is selected from O, N, S or NCH2CH2O, wherein when Z is O or S then R2 is not present;
R1 is independently H or methyl;
R2 is H or is a linear, branched, or cyclic alkyl group containing one to eight carbon
atoms, any of which may be further substituted with at least one hydroxy group, amide,
ether, and combinations thereof;
R3 and R4 are independently a linear, branched, or cyclic alkyl group containing one to eight
carbon atoms, any of which may be further substituted with at least one hydroxy group,
amide, ether, and combinations thereof; R3 and R4 may be independently selected from methyl, ethyl or phenyl, or may be methyl;
n is 4-8; and
R5 is selected from straight or branched C1 to C8 alkyl groups, which may be optionally substituted with one or more hydroxyl, amide,
ether, and combinations thereof; and/or
(b) the second hydroxyl substituted, poly(disubstituted siloxane) comprises a compound
of Formula VII-2:

wherein Z is selected from O, N, S or NCH2CH2O, when Z is O or S R2 is not present;
R1 is independently H or methyl;
R2 is H or is a linear, branched, or cyclic alkyl group containing one to eight carbon
atoms, any of which may be further substituted with at least one hydroxy group, amide,
ether, and combinations thereof;
R3 and R4 are independently a linear, branched, or cyclic alkyl group containing one to eight
carbon atoms, any of which may be further substituted with at least one hydroxy group,
and which may be optionally substituted with amide, ether, and combinations thereof;
R3 and R4 may be independently selected from methyl, ethyl or phenyl, or may be methyl;
n is the number of siloxane units and is from 10 to 200, or 10-100, or 10-50, or 10-20,
or 12-18; and
R5 is selected from straight or branched C1 to C8 alkyl groups, which may be optionally substituted with one or more hydroxyl, amide,
ether, and combinations thereof; and/or
(c) the second hydroxyl-substituted poly(disubstituted siloxane) further comprises
a di-functional hydroxyl-substituted poly(disubstituted siloxane) of Formula XI

wherein
wherein R1 is independently a hydrogen atom or methyl group;
R2 and R3 are independently a linear, branched, or cyclic alkyl group containing one to eight
carbon atoms, any of which may be further substituted with at least one hydroxy group,
amido, ether, amino, carboxyl, carbonyl groups and combinations thereof; or are selected
from methyl, ethyl and -(CH2CH2O)xOCH3 where x is from 1 to 20; and
n is from 1 to 200.
4. The silicone hydrogel of any of the foregoing claims, wherein the first mono-functional
hydroxyl-substituted poly(disubstituted siloxane) and the second hydroxyl-substituted
poly(disubstituted siloxane) are present in the reactive monomer mixture in a total
concentration between 40 and 70 wt%, or 45 to 70 wt% based on all components in the
reaction mixture, excluding diluent.
5. The silicone hydrogel of any of the foregoing claims, wherein:
(a) the polyamide comprises a cyclic polyamide, an acyclic polyamide, or a mixture
of a cyclic polyamide and an acyclic polyamide; or
(b) the polyamide is an acyclic polyamide.
6. The silicone hydrogel of any of the foregoing claims, wherein the first or second
monofunctional hydroxyl substituted, poly(disubstituted siloxane) comprises a monofunctional
hydroxyl substituted, poly(dimethylsiloxane) of any of Formulae VIIa-IXb:
wherein R1 is methyl or H; n is between 4 and 30, 4-8 or 10-20; wherein Z is selected from O,
N, S or NCH2CH2O, when Z is O or S R2 is not present;
R2 is independently selected from the group consisting of a linear, branched, or cyclic
alkyl group containing one to eight carbon atoms, any of which may be further substituted
with at least one hydroxy group, and which may be optionally substituted with amide,
ether, and combinations thereof;
n1 and n2 are independently between 4 to 100; 4 to 50; or 4 to 25;
n3 is 1-50, 1-20, or 1-10;
R5 is selected from straight or branched C1 to C8 alkyl groups, which may be optionally substituted with one or more hydroxyl, amide,
ether, polyhydroxyl groups selected from straight or branched C1 to C8 groups having a formula of CfHg(OH)h wherein f=1-8 and g+h=2f+1 and cyclic C1 to C8 groups having a formula of CfHg(OH)h wherein f=1-8 and g+h=2f-1, and combinations thereof; or R5 may be selected from methyl, butyl or hydroxyl substituted C2-C5 alkyl, including hydroxyl ethyl, hydroxyl propyl, hydroxyl butyl, hydroxyl pentyl
and 2,3-dihydroxypropyl;
a is 4-8 for the first hydroxyl-containing silicone component and between 4-100 for
the second hydroxyl-containing silicone component.
7. The silicone hydrogel of any of the foregoing claims wherein the second hydroxyl substituted,
poly(disubstituted siloxane)s comprises mono-(2-hydroxy-3-methacryloxypropyl)-propyl
ether terminated mono-n-butyl terminated polydimethylsiloxane (OH-mPDMS) having fifteen
siloxane repeating units.
8. The silicone hydrogel of claim 1 or 2, wherein:
(a) the hydrophilic monomer comprises a reactive group selected from the group consisting
of (meth)acrylates, (meth)acrylamides, styrenes, N-vinyllactams, N-vinylamides, O-vinylcarbamates,
O-vinylcarbonates, vinyl ethers, vinyl esters, vinyls, allyls and combinations thereof;
and/or
(b) the hydrophilic monomer is present in the reactive monomer mixture in an amount
between 15 to 35 wt%.
9. The silicone hydrogel of any of the foregoing claims further comprising at least one
charged component.
10. The silicone hydrogel of claim 1 or 2, wherein the second hydroxyl substituted, poly(disubstituted
siloxane)s comprises at least one compound of Formula XII:
wherein R1 is independently a hydrogen atom or methyl group; Z is selected from O, N, S or NCH2CH2O, wherein for Z = O and S, R2 is not required;
R2 is selected from the group consisting of H or a linear, branched, or cyclic alkyl
group containing one to eight carbon atoms, any of which may be further substituted
with at least one hydroxy group, amido, ether, amino, carboxyl, carbonyl groups and
combinations; a linear or branched alkyleneoxy group, specifically ethyleneoxy groups,
[CH2CH2O]p wherein p is between 1 and 200, or 1 and 100, or 1 and 50, or 1 and 25, or 1 and
20, optionally substituted with one or more hydroxyl, amino, amido, ether, carbonyl,
carboxyl, and combinations thereof; a C1-C6 linear or branched fluoroalkyl groups optionally substituted with one or more hydroxyl,
amino, amido, ether, carbonyl, carboxyl, and combinations thereof; a substituted or
un-substituted aryl groups, specifically phenyl groups, wherein the substituents are
selected from halogen, hydroxyl, alkoxy, alkylcarbonyl, carboxy, and linear or branched
or cyclic alkyl groups which may be further substituted with halogen, hydroxyl, alkoxy,
alkylcarbonyl, and carboxyl groups, and combinations thereof;
n1 and n2 are independently selected from 4 to 100; 4 to 50; or 4 to 25; and
n3 is 1-50, 1-20, and 1-10.
11. The silicone hydrogel of claim 1 or 2, wherein the hydrophilic monomer is selected
from hydrophilic amide monomers; optionally
(a) wherein the reactive monomer mixture comprises less than 30 wt%, or less than
25 wt% or less than 20 wt% hydrophilic amide monomers based on all components in the
reaction mixture, excluding diluent; and/or
(b) wherein the hydrophilic amide monomers are included in the reactive mixture in
amounts between 5 and 28 wt%, or 5 and 25 wt%, or between 8 and 20 wt% based on all
components in the reaction mixture, excluding diluent.
12. The silicone hydrogel of claim 1 or 2, wherein:
(a) the hydrophilic monomer is selected from the group consisting of N,N-dimethylacrylamide,
acrylamide, ethylene glycol vinyl ether (EGVE), di(ethylene glycol) vinyl ether (DEGVE),
N-vinyl pyrrolidone (NVP), 1-methyl-3-methylene-2-pyrrolidone, 1-methyl-5-methylene-2-pyrrolidone,
5-methyl-3-methylene-2-pyrrolidone; 1-ethyl-5-methylene-2-pyrrolidone, N-methyl-3-methylene-2-pyrrolidone,
5-ethyl-3-methylene-2-pyrrolidone, 1-n-propyl-3-methylene-2-pyrrolidone, 1-n-propyl-5-methylene-2-pyrrolidone,
1-isopropyl-3-methylene-2-pyrrolidone, 1-isopropyl-5-methylene-2-pyrrolidone, N-vinyl-N-methyl
acetamide (VMA), N-vinyl-N-ethyl acetamide, N-vinyl-N-ethyl formamide, N-vinyl formamide,
N-vinyl acetamide, N-vinyl isopropylamide, allyl alcohol, N-vinyl caprolactam, N-2-hydroxyethyl
vinyl carbamate, N-carboxy-β-alanine N-vinyl ester; N-carboxyvinyl-β-alanine (VINAL),
N-carboxyvinyl-α-alanine and mixtures thereof; or
(b) the hydrophilic monomer is selected from N,N-dimethylacrylamide, N-vinylpyrrolidone,
N-vinyl-N-methyl acetamide, N-vinyl acetamide, and 1-methyl-5-methylene-2-pyrrolidone;
or
(c) the hydrophilic monomer comprises N-vinylpyrrolidone, N,N-dimethylacrylamide,
or mixtures thereof.
13. The silicone hydrogel of any of the foregoing claims, wherein the silicone hydrogel
has an oxygen permeability (Dk) of at least 80 barrers, or 80 to 200 barrers, 90 to
180 barrers, 100 to 160 barrers when oxygen permeability is measured using the "Oxygen
permeability" testing method given in the description.
14. The silicone hydrogel of claim 9, wherein the charged monomer comprises at least one
ionic moiety selected from the group consisting of anions, cations, zwitterions, betaines,
and mixtures thereof.
15. The silicone hydrogel of claim 14, wherein the charged monomer comprises at least
one carboxylic acid group; optionally
(a) wherein the charged monomer comprises at least one carboxylic acid monomer selected
from the group consisting of (meth)acrylic acid, furmaric acid, maelic acid, itaconic
acid, crotonic acid, cinnamic acid, vinylbenzoic acid, monoesters of furmaric acid,
maelic acid, and itaconic acid, and mixtures thereof; or
(b) wherein the charged monomer comprises mixture of anionic and cationic monomer;
or
(c) wherein the charged monomer is selected from the group consisting of (meth)acrylic
acid, N-[(ethenyloxy)carbonyl]-β-alanine (VINAL), 3-acrylamidopropanoic acid (ACA1),
5-acrylamidopropanoic acid (ACA2), 3-acrylamido-3-methylbutanoic acid (AMBA), 2-(methacryloyloxy)ethyl
trimethylammonium chloride (Q Salt), 2-acrylamido-2-methylpropane sulfonic acid (AMPS),
1-propanaminium, N-(2-carboxyethyl)-N,N-dimethyl-3-[(1-oxo-2-propen-1-yl)amino]-,
inner salt (CBT, carboxybetaine), 1-propanaminium, N,N-dimethyl-N-[3-[(1-oxo-2-propen-1-yl)amino]propyl]-3-sulfo-,
inner salt (SBT, sulfobetaine,), 3,5-Dioxa-8-aza-4-phosphaundec-10-en-1-aminium, 4-hydroxy-N,N,N-trimethyl-9-oxo-,
inner salt, 4-oxide (9CI) phosphobetaine(PBT), 2-methacryloyloxyethyl phosphorylcholine,
3-(dimethyl(4-vinylbenzyl)ammonio)propane-1-sulfonate (DMVBAPS), 3-((3-acrylamidopropyl)dimethylammonio)propane-1-sulfonate
(AMPDAPS), 3-((3-methacrylamidopropyl)dimethylammonio)propane-1-sulfonate (MAMPDAPS),
3-((3-(acryloyloxy)propyl)dimethylammonio)propane-1-sulfonate (APDAPS), methacryloyloxy)propyl)dimethylammonio)propane-1-sulfonate
(MAPDAPS), and mixtures thereof; or
(d) wherein the charged monomer is selected from the group consisting of (meth)acrylic
acid, N-[(ethenyloxy)carbonyl]-β-alanine (VINAL), 3-acrylamidopropanoic acid (ACA1),
5-acrylamidopropanoic acid (ACA2), and mixtures thereof.
16. The silicone hydrogel of any of claims 9 or 15, wherein the at least one charged monomer
comprises up to 5 wt%, or between 0.5 to 5 wt.%, or between 0.5 to 3 wt.%, or between
0.5 to 2 wt.%, or between 1 to 5 wt.%, or between 1 to 3 wt, based on the total weight
of the reactive monomer mixture.
17. The silicone hydrogel of any of the foregoing claims, comprising a charged monomer
selected from acrylic acid, methacrylic acid, and mixtures thereof.
18. The silicone hydrogel of claim 1 or 2 wherein:
(a) the polyamide comprises an acyclic polyamide selected from the group consisting
of PVMA, PNVA, and poly[N-vinyl N-alkyl acetamide]s wherein the N-alkyl group is selected
from the group consisting of linear and branched alkyl groups containing between one
and five carbon atoms, and copolymers and mixtures thereof; and/or
(b) wherein the polyamide comprises poly(N-vinyl-N-methyl acetamide), poly(N-vinyl
acetamide), polydimethylacrylamide, or a mixture of two or more thereof; and/or
(c) wherein the polyamide comprises a copolymer; optionally
wherein the copolymer comprises repeating units selected from the group consisting
of N-vinyl amides, acrylamides, hydroxyalkyl(meth)acrylates, alkyl(meth)acrylates,
N-vinylpyrrolidone, N,N-dimethylacrylamide, 2-hydroxyethylmethacrylate, vinyl acetate,
acrylonitrile, hydroxypropyl methacrylate, 2-hydroxyethyl acrylate, methyl methacrylate,
butyl methacrylate, methacryloxypropoyl tristrimethylsiloxysilane, siloxane substituted
acrylates or methacrylates, and mixtures thereof.
19. The silicone hydrogel of claim 1 or 2, wherein the polyamide comprises repeating units
of Formula I or Formula II

wherein X is a direct bond, -(CO)-, or -(CO)-NHR
e-, wherein R
e is a C
1 to C
3 alkyl group;
Ra is selected from H, straight or branched, substituted or unsubstituted C1 to C4 alkyl groups;
Rb is selected from H, straight or branched, substituted or unsubstituted C1 to C4 alkyl groups, amino groups having up to two carbon atoms, amide groups having up
to four carbon atoms, and alkoxy groups having up to two carbon atoms;
Rc is selected from H, straight or branched, substituted or unsubstituted C1 to C4 alkyl groups, or methyl, ethoxy, hydroxyethyl, and hydroxymethyl;
Rd is selected from H, straight or branched, substituted or unsubstituted C1 to C4 alkyl groups, or methyl, ethoxy, hydroxyethyl, and hydroxymethyl;
wherein the number of carbon atoms in Ra and Rb taken together is 8 or less, and wherein the number of carbon atoms in Rc and Rd taken together is 8 or less; optionally
(a) wherein the polyamide is a copolymer comprising at least 80 mole % of the repeating
units from Formula I or Formula II; and/or
(b) wherein Rb is selected from straight or branch unsubstituted C1 to C4 alkyl groups.
20. The silicone hydrogel of claim 1 or 2, wherein the polyamide comprises between 3 and
15 wt% of the reactive monomer mixture, based upon all reactive components; or
wherein the polyamide comprises between 3 and 12 wt% of the reactive mixture based
upon all reactive components.
21. The silicone hydrogel of any of the foregoing claims, wherein the polyamide comprises
a cyclic polyamide; optionally
wherein the cyclic polyamide comprises polyvinylypyrrolidone (PVP) in an amount up
to 15 wt.%, or an amount in the range of 2 to 15 wt. %, or an amount in the range
of 5 to 15 wt.%.
22. The silicone hydrogel of claim 1 or 2, wherein the reactive monomer mixture further
comprises at least one additional constituent selected from the group consisting of
a diluent, a UV absorbing compound, a medicinal agent, an antimicrobial compound,
a pharmaceutical compound, a nutraceutical compound, a photochromic compound, a reactive
tint, a pigment, a copolymerizable dye, a nonpolymerizable dye, a release agent, a
copolymer, and combinations thereof.
23. The silicone hydrogel of any of the foregoing claims further comprising at least one
hydroxylalkyl (meth)acrylate monomer; optionally:
(a) wherein said hydroxyalkyl (meth)acrylate monomer is selected from the group consisting
of 2-hydroxyethyl (meth)acrylate, 3-hydroxypropyl (meth)acrylate, 2-hydroxypropyl
(meth)acrylate, 2,3-dihydroxypropyl (meth)acrylate, 2-hydroxybutyl (meth)acrylate,
3-hydroxybutyl (meth)acrylate, 1-hydroxypropyl-2-(meth)acrylate, 2-hydroxy-2-methyl-propyl
(meth)acrylate, 3-hydroxy-2,2-dimethyl-propyl (meth)acrylate, 4-hydroxybutyl (meth)acrylate,
glycerol (meth)acrylate, polyethylene glycol monomethacrylate, and mixtures thereof;
or
(b) wherein said hydroxyalkyl (meth)acrylate monomer is selected from the group consisting
of 2-hydroxyethyl methacrylate, glycerol methacrylate, 2-hydroxypropyl methacrylate,
hydroxybutyl methacrylate, 3-hydroxy-2,2-dimethyl-propyl methacrylate, and mixtures
thereof; or
(c) wherein said hydroxyalkyl (meth)acrylate monomer is selected from the group consisting
of 2-hydroxyethyl methacrylate, 3-hydroxy-2,2-dimethyl-propyl methacrylate, hydroxybutyl
methacrylate or glycerol methacrylate.
24. The silicone hydrogel of any of the foregoing claims, wherein the reactive monomer
mixture further comprises at least one additional silicone-containing compounds without
a hydroxyl group.
25. The silicone hydrogel of claim 1, wherein the second hydroxyl substituted poly(disubstituted
siloxane) is selected from the group consisting of a monofunctional hydroxyl substituted,
linear poly(disubstituted siloxane) having 10 to 20 siloxane repeating units and a
multifunctional hydroxyl substituted, linear poly(disubstituted siloxane) having 10
to 200, or 10 to 100 siloxane repeating units; and
wherein the ratio of the first hydroxyl substituted linear poly(disubstituted siloxane)
to the second hydroxyl substituted, linear poly(disubstituted siloxane) is in a range
of 0.4 to 1.2, or 0.4 to 1.0.
26. The silicone hydrogel of any of the foregoing claims, wherein the polyamide has a
weight average molecular weight of at least 100,000 Daltons; or greater than 150,000
Daltons; or between 150,000 to 2,000,000 Daltons, or between 300,000 to 1,800,000
Daltons when the molecular weight is determined by Size Exclusion Chromatography with
Multi-Angle Light Scattering.
27. The silicone hydrogel of any of the foregoing claims, wherein the polyamide is added
to the reaction mixture such that the hydrogel polymerizes around the polyamide, forming
a semi-interpenetrating network.
28. A contact lens comprising the silicone hydrogel of any of the foregoing claims.
29. The contact lens of claim 28, wherein the Dk is greater than 80 barrers, wherein the
lysozyme uptake is greater than 50 µg/lens, wherein the lipid uptake is less than
10 µg/lens; wherein the PQ1 uptake is less than 15%; and wherein the contact angle
is less than 50° when measured using the "oxygen permeability", "lipid uptake", "PQ1
uptake", "Dynamic contact angle", and either of the "lysozyme uptake" testing methods
given in the description.
1. Silicon-Hydrogel, gebildet aus einem reaktiven Monomergemisch umfassend:
a. zwischen 1 und 15 Gew.-% an wenigstens einem Polyamid, wobei "Polyamid" Polymere
und Copolymere bezeichnet, die Wiederholungseinheiten, die Amidgruppen enthalten,
umfassen;
b. wenigstens ein erstes monofunktionelles hydroxysubstituiertes lineares Poly(disubstituiertes
Siloxan) mit 4 bis 8 Siloxan-Wiederholungseinheiten;
c. wenigstens ein zweites hydroxysubstituiertes lineares Poly(disubstituiertes Siloxan)
ausgewählt aus der Gruppe bestehend aus monofunktionellen hydroxysubstituierten Poly(disubstituiertes
Siloxan)en mit 10 bis 200 oder 10-100 Siloxan-Wiederholungseinheiten und multifunktionellen
hydroxysubstituierten Poly(disubstituiertes Siloxan)en mit 10 bis 200 oder 10 bis
100 Siloxan-Wiederholungseinheiten und Gemischen davon;
d. 5 bis 35 Gew.-% an wenigstens einem hydrophilen Monomer;
wobei das erste hydroxysubstituierte lineare Poly(disubstituiertes Siloxan) und das
zweite monofunktionelle hydroxysubstituierte lineare Poly(disubstituiertes Siloxan)
in Konzentrationen vorhanden sind, die ein Verhältnis der Gew.-% aller ersten hydroxysubstituierten
linearen Poly(disubstituiertes Siloxan)e zu den Gew.-% aller zweiten hydroxysubstituierten
linearen Poly(disubstituiertes Siloxan)e von 0,4-1,3 oder 0,4-1,0 bereitstellen;
wobei "funktionell" eine Gruppe bedeutet, die radikalische Polymerisation erfahren
kann;
wobei Konzentrationen von Komponenten in Gew.-% bezogen auf alle Komponenten in dem
Reaktionsgemisch mit Ausnahme von Verdünnungsmittel angegeben werden.
2. Silicon-Hydrogel gemäß Anspruch 1, wobei das zweite hydroxysubstituierte lineare Poly(disubstituiertes
Siloxan) ausgewählt ist aus monofunktionellen hydroxysubstituierten linearen Poly(disubstituiertes
Siloxan)en mit 10 bis 200 oder 10-100 Siloxan-Wiederholungseinheiten.
3. Silicon-Hydrogel gemäß Anspruch 1 oder 2, wobei:
(a) das erste monofunktionelle hydroxysubstituierte Poly(disubstituiertes Siloxan)
Verbindungen der Formel VII-1 umfasst,

wobei
Z ausgewählt ist aus O, N, S und NCH2CH2O, wobei, wenn Z O oder S ist, R2 nicht vorhanden ist;
R1 unabhängig H oder Methyl ist;
R2 H ist oder eine lineare, verzweigte oder cyclische Alkylgruppe ist, die ein bis acht
Kohlenstoffatome enthält, von denen jedes ferner mit wenigstens einer/einem Hydroxygruppe,
Amid, Ether und Kombinationen davon substituiert sein kann;
R3 und R4 unabhängig eine lineare, verzweigte oder cyclische Alkylgruppe sind, die ein bis
acht Kohlenstoffatome enthält, von denen jedes ferner mit wenigstens einer/einem Hydroxygruppe,
Amid, Ether und Kombinationen davon substituiert sein kann; wobei R3 und R4 unabhängig ausgewählt sein können aus Methyl, Ethyl und Phenyl oder Methyl sein können;
n 4-8 ist; und
R5 ausgewählt ist aus geraden oder verzweigten C1- bis C8-Alkylgruppen, die gegebenenfalls mit einem oder mehreren Hydroxy, Amid, Ether und
Kombinationen davon substituiert sein können; und/oder
(b) das zweite hydroxysubstituierte Poly(disubstituiertes Siloxan) eine Verbindung
der Formel VII-2 umfasst:

wobei Z ausgewählt ist aus O, N, S und NCH2CH2O, wobei, wenn Z O oder S ist, R2 nicht vorhanden ist;
R1 unabhängig H oder Methyl ist;
R2 H ist oder eine lineare, verzweigte oder cyclische Alkylgruppe ist, die ein bis acht
Kohlenstoffatome enthält, von denen jedes ferner mit wenigstens einer/einem Hydroxygruppe,
Amid, Ether und Kombinationen davon substituiert sein kann;
R3 und R4 unabhängig eine lineare, verzweigte oder cyclische Alkylgruppe sind, die ein bis
acht Kohlenstoffatome enthält, von denen jedes ferner mit wenigstens einer Hydroxygruppe
substituiert sein kann und das gegebenenfalls mit Amid, Ether und Kombinationen davon
substituiert sein kann; wobei R3 und R4 unabhängig ausgewählt sein können aus Methyl, Ethyl und Phenyl oder Methyl sein können;
n die Anzahl von Siloxaneinheiten ist und von 10 bis 200 oder 10-100 oder 10-50 oder
10-20 oder 12-18 beträgt; und R5 ausgewählt ist aus geraden oder verzweigten C1- bis C8-Alkylgruppen, die gegebenenfalls mit einem oder mehreren Hydroxy, Amid, Ether und
Kombinationen davon substituiert sein können; und/oder
(c) das zweite hydroxysubstituierte Poly(disubstituiertes Siloxan) ferner ein difunktionelles
hydroxysubstituiertes Poly(disubstituiertes Siloxan) der Formel XI umfasst,

wobei
wobei R1 unabhängig ein Wasserstoffatom oder eine Methylgruppe ist;
R2 und R3 unabhängig eine lineare, verzweigte oder cyclische Alkylgruppe sind, die ein bis
acht Kohlenstoffatome enthält, von denen jedes ferner mit wenigstens einer/einem Hydroxygruppe,
Amido, Ether, Amino, Carboxy, Carbonylgruppen und Kombinationen davon substituiert
sein kann; oder ausgewählt sind aus Methyl, Ethyl und -(CH2CH2O)XOCH3, wobei x von 1 bis 20 beträgt; und
n von 1 bis 200 beträgt.
4. Silicon-Hydrogel gemäß einem der vorstehenden Ansprüche, wobei das erste monofunktionelle
hydroxysubstituierte Poly(disubstituiertes Siloxan) und das zweite hydroxysubstituierte
Poly(disubstituiertes Siloxan) in dem reaktiven Monomergemisch in einer Gesamtkonzentration
zwischen 40 und 70 Gew.-% oder 45 bis 70 Gew.-% bezogen auf alle Komponenten in dem
Reaktionsgemisch mit Ausnahme von Verdünnungsmittel vorhanden sind.
5. Silicon-Hydrogel gemäß einem der vorstehenden Ansprüche, wobei:
(a) das Polyamid ein cyclisches Polyamid, ein acyclisches Polyamid oder ein Gemisch
von einem cyclischen Polyamid und einem acyclischen Polyamid umfasst; oder
(b) das Polyamid ein acyclisches Polyamid ist.
6. Silicon-Hydrogel gemäß einem der vorstehenden Ansprüche, wobei das erste oder zweite
monofunktionelle hydroxysubstituierte Poly(disubstituiertes Siloxan) ein monofunktionelles
hydroxysubstituiertes Poly(dimethylsiloxan) gemäß einer der Formeln VIIa-IXb umfasst:
wobei R1 Methyl oder H ist; n zwischen 4 und 30, 4-8 oder 10-20 beträgt; wobei Z ausgewählt
ist aus O, N, S und NCH2CH2O, wobei, wenn Z O oder S ist, R2 nicht vorhanden ist;
R2 unabhängig ausgewählt ist aus der Gruppe bestehend aus einer linearen, verzweigten
oder cyclischen Alkylgruppe, die ein bis acht Kohlenstoffatome enthält, von denen
jedes ferner mit wenigstens einer Hydroxygruppe substituiert sein kann und das gegebenenfalls
mit Amid, Ether und Kombinationen davon substituiert sein kann;
n1 und n2 unabhängig zwischen 4 und 100; 4 bis 50; oder 4 bis 25 betragen;
n3 1-50, 1-20 oder 1-10 beträgt;
R5 ausgewählt ist aus geraden oder verzweigten C1- bis C8-Alkylgruppen, die gegebenenfalls mit einem oder mehreren Hydroxy, Amid, Ether, Polyhydroxygruppen
ausgewählt aus geraden oder verzweigten C1- bis C8-Gruppen mit einer Formel von CfHg(OH)h, wobei f=1-8 und g+h=2f+1, und cyclischen C1- bis C8-Gruppen mit einer Formel von CfHg(OH)h, wobei f=1-8 und g+h=2f-1, und Kombinationen davon substituiert sein können; oder
R5 ausgewählt sein kann aus Methyl, Butyl und hydroxysubstituiertem C2-C5-Alkyl, einschließlich Hydroxylethyl, Hydroxylpropyl, Hydroxybutyl, Hydroxypentyl
und 2,3-Dihydroxypropyl;
a für die erste hydroxyhaltige Siliconkomponente 4-8 beträgt und für die zweite hydroxyhaltige
Siliconkomponente zwischen 4 und 100 beträgt.
7. Silicon-Hydrogel gemäß einem der vorstehenden Ansprüche, wobei das zweite hydroxysubstituierte
Poly(disubstituiertes Siloxan) Mono(2-hydroxy-3-methacryloxypropyl)propylether-terminiertes
Mono-n-butyl-terminiertes Polydimethylsiloxan (OH-mPDMS) mit fünfzehn Siloxan-Wiederholungseinheiten
umfasst.
8. Silicon-Hydrogel gemäß Anspruch 1 oder 2, wobei:
(a) das hydrophile Monomer eine reaktive Gruppe ausgewählt aus der Gruppe bestehend
aus (Meth)acrylaten, (Meth)acrylamiden, Styrolen, N-Vinyllactamen, N-Vinylamiden,
O-Vinylcarbamaten, O-Vinylcarbonaten, Vinylethern, Vinylestern, Vinylen, Allylen und
Kombinationen davon umfasst; und/oder
(b) das hydrophile Monomer in dem reaktiven Monomergemisch in einer Menge zwischen
15 und 35 Gew.-% vorhanden ist.
9. Silicon-Hydrogel gemäß einem der vorstehenden Ansprüche, ferner umfassend wenigstens
eine geladene Komponente.
10. Silicon-Hydrogel gemäß Anspruch 1 oder 2, wobei die zweiten hydroxysubstituierten
Poly(disubstituiertes Siloxan)e wenigstens eine Verbindung der Formel XII umfassen:
Wobei R1 unabhängig ein Wasserstoffatom oder eine Methylgruppe ist; Z ausgewählt ist aus O,
N, S und NCH2CH2O, wobei für Z = O und S R2 nicht erforderlich ist;
R2 ausgewählt ist aus der Gruppe bestehend aus H und einer linearen, verzweigten oder
cyclischen Alkylgruppe, die ein bis acht Kohlenstoffatome enthält, von denen jedes
ferner mit wenigstens einer Hydroxygruppe, Amido, Ether, Amino, Carboxy, Carbonylgruppen
und Kombinationensubstituiert sein kann; einer linearen oder verzweigten Alkylenoxygruppe,
insbesondere Ethylenoxygruppen [CH2CH2O]p, wobei p zwischen 1 und 200 oder 1 und 100 oder 1 und 50 oder 1 und 25 oder 1 und
20 beträgt, gegebenenfalls substituiert mit einem oder mehreren Hydroxy, Amino, Amido,
Ether, Carbonyl, Carboxy und Kombinationen davon; einer linearen oder verzweigten
C1-C6-Fluoralkylgruppe, gegebenenfalls substituiert mit einem oder mehreren Hydroxy, Amino,
Amido, Ether, Carbonyl, Carboxy und Kombinationen davon; einer substituierten oder
unsubstituierten Arylgruppe, insbesondere Phenylgruppen, wobei die Substituenten ausgewählt
sind aus Halogen, Hydroxy, Alkoxy, Alkylcarbonyl, Carboxy und linearen oder verzweigten
oder cyclischen Alkylgruppen, die ferner mit Halogen, Hydroxy, Alkoxy, Alkylcarbonyl
und Carboxygruppen und Kombinationen davon substituiert sein können;
n1 und n2 unabhängig ausgewählt sind aus 4 bis 100; 4 bis 50; oder 4 bis 25; und
n3 1-50, 1-20 oder 1-10 ist.
11. Silicon-Hydrogel gemäß Anspruch 1 oder 2, wobei das hydrophile Monomer ausgewählt
ist aus hydrophilen Amidmonomeren; gegebenenfalls
(a) wobei das reaktive Monomergemisch weniger als 30 Gew.-% oder weniger als 25 Gew.-%
oder weniger als 20 Gew.-% an hydrophilen Amidmonomeren bezogen auf alle Komponenten
in dem Reaktionsgemisch mit der Ausnahme von Verdünnungsmittel umfasst; und/oder
(b) wobei die hydrophilen Amidmonomere in dem reaktiven Gemisch in Mengen zwischen
5 und 28 Gew.-% oder 5 und 25 Gew.-% oder zwischen 8 und 20 Gew.-% bezogen auf alle
Komponenten in dem Reaktionsgemisch mit der Ausnahme von Verdünnungsmittel enthalten
sind.
12. Silicon-Hydrogel gemäß Anspruch 1 oder 2, wobei:
(a) das hydrophile Monomer ausgewählt ist aus der Gruppe bestehend aus N,N-Dimethylacrylamid,
Acrylamid, Ethylenglycolvinylether (EGVE), Di(ethylenglycol)vinylether (DEGVE), N-Vinylpyrrolidon
(NVP), 1-Methyl-3-methylen-2-pyrrolidon, 1-Methyl-5-methylen-2-pyrrolidon, 5-Methyl-3-methylen-2-pyrrolidon;
1-Ethyl-5-methylen-2-pyrrolidon, N-Methyl-3-methylen-2-pyrrolidon, 5-Ethyl-3-methylen-2-pyrrolidon,
1-n-Propyl-3-methylen-2-pyrrolidon, 1-n-Propyl-5-methylen-2-pyrrolidon, 1-Isopropyl-3-methylen-2-pyrrolidon,
1-Isopropyl-5-methylen-2-pyrrolidon, N-Vinyl-N-methylacetamid (VMA), N-Vinyl-N-ethylacetamid,
N-Vinyl-N-ethylformamid, N-Vinylformamid, N-Vinylacetamid, N-Vinylisopropylamid, Allylalkohol,
N-Vinylcaprolactam, N-2-Hydroxyethylvinylcarbamat, N-Carboxy-β-alanin-N-vinylester;
N-Carboxyvinyl-β-alanin (VINAL), N-Carboxyvinyl-α-alanin und Gemischen davon; oder
(b) das hydrophile Monomer ausgewählt ist aus N,N-Dimethylacrylamid, N-Vinylpyrrolidon,
N-Vinyl-N-methylacetamid, N-Vinylacetamid und 1-Methyl-5-methylen-2-pyrrolidon; oder
(c) das hydrophile Monomer N-Vinylpyrrolidon, N,N-Dimethylacrylamid oder Gemische
davon umfasst.
13. Silicon-Hydrogel gemäß einem der vorstehenden Ansprüche, wobei das Silicon-Hydrogel
eine Sauerstoffdurchlässigkeit (Dk) von wenigstens 80 Barrer oder 80 bis 200 Barrer,
90 bis 180 Barrer, 100 bis 160 Barrer aufweist, wenn Sauerstoffdurchlässigkeit unter
Verwendung des in der Beschreibung gegebenen "Sauerstoffdurchlässigkeit"-Prüfverfahrens
gemessen wird.
14. Silicon-Hydrogel gemäß Anspruch 9, wobei das geladene Monomer wenigstens eine ionische
Einheit ausgewählt aus der Gruppe bestehend aus Anionen, Kationen, Zwitterionen, Betainen
und Gemischen davon umfasst.
15. Silicon-Hydrogel gemäß Anspruch 14, wobei das geladene Monomer wenigstens eine Carbonsäuregruppe
umfasst; gegebenenfalls
(a) wobei das geladene Monomer wenigstens ein Carbonsäuremonomer ausgewählt aus der
Gruppe bestehend aus (Meth)acrylsäure, Fumarsäure, Maleinsäure, Itaconsäure, Crotonsäure,
Zimtsäure, Vinylbenzoesäure, Monoestern von Fumarsäure, Maleinsäure und Itaconsäure
und Gemischen davon umfasst; oder
(b) wobei das geladene Monomer ein Gemisch von anionischem und kationischem Monomer
umfasst; oder
(c) wobei das geladene Monomer ausgewählt ist aus der Gruppe bestehend aus (Meth)acrylsäure,
N-[(Ethenyloxy)carbonyl]-P-alanin (VINAL), 3-Acrylamidopropansäure (ACA1), 5-Acrylamidopropansäure
(ACA2), 3-Acrylamido-3-methylbutansäure (AMBA), 2-(Methacryloyloxy)ethyltrimethylammoniumchlorid
(Q-Salz), 2-Acrylamido-2-methylpropansulfonsäure (AMPS), inneres 1-Propanaminium-N-(2-Carboxyethyl)-N,N-dimethyl-3-[(1-oxo-2-propen-1-yl)amino]-Salz
(CBT, Carboxybetain), inneres 1-Propanaminium-N,N-dimethyl-N-[3-[(1-oxo-2-propen-1-yl)amino]propyl]-3-sulfo-Salz
(SBT, Sulfobetain), inneres 3,5-Dioxa-8-aza-4-phosphaundec-10-en-1-aminium-4-hydroxy-N,N,N-trimethyl-9-oxo-Salz,
4-Oxid(9CI)phosphobetain (PBT), 2-Methacryloyloxyethylphosphorylcholin, 3-(Dimethyl(4-vinylbenzyl)ammonio)propan-1-sulfonat
(DMVBAPS), 3-((3-Acrylamidopropyl)dimethylammonio)propan-1-sulfonat (AMPDAPS), 3-((3-Methacrylamidopropyl)dimethylammonio)propan-1-sulfonat
(MAMPDAPS), 3-((3-(Acryloyloxy)propyl)dimethylammonio)propan-1-sulfonat (APDAPS),
Methacryloyloxy)propyl)dimethylammonio)propan-1-sulfonat (MAPDAPS) und Gemischen davon;
oder
(d) wobei das geladene Monomer ausgewählt ist aus der Gruppe bestehend aus (Meth)acrylsäure,
N-[(Ethenyloxy)carbonyl]-P-alanin (VINAL), 3-Acrylamidopropansäure (ACA1), 5-Acrylamidopropansäure
(ACA2) und Gemischen davon.
16. Silicon-Hydrogel gemäß einem der Ansprüche 9 und 15, wobei das wenigstens eine geladene
Monomer bis zu 5 Gew.-% oder zwischen 0,5 und 5 Gew.-% oder zwischen 0,5 und 3 Gew.-%
oder zwischen 0,5 und 2 Gew.-% oder zwischen 1 und 5 Gew.-% oder zwischen 1 und 3
Gew.-% bezogen auf das Gesamtgewicht des reaktiven Monomergemischs umfasst.
17. Silicon-Hydrogel gemäß einem der vorstehenden Ansprüche, umfassend ein geladenes Monomer
ausgewählt aus Acrylsäure, Methacrylsäure und Gemischen davon.
18. Silicon-Hydrogel gemäß Anspruch 1 oder 2, wobei:
(a) das Polyamid ein acyclisches Polyamid ausgewählt aus der Gruppe bestehend aus
PVMA, PNVA und Poly[N-vinyl-N-alkylacetamid]en umfasst, wobei die N-Alkylgruppe ausgewählt
ist aus der Gruppe bestehend aus linearen und verzweigten Alkylgruppen, die zwischen
einem und fünf Kohlenstoffatomen enthalten, und Copolymeren und Gemischen davon; und/oder
(b) wobei das Polyamid Poly(N-vinyl-N-methylacetamid), Poly(N-vinylacetamid), Polydimethylacrylamid
oder ein Gemisch von zwei oder mehr davon umfasst; und/oder
(c) wobei das Polyamid ein Copolymer umfasst; gegebenenfalls
wobei das Copolymer Wiederholungseinheiten ausgewählt aus der Gruppe bestehend aus
N-Vinylamiden, Acrylamiden, Hydroxyalkyl(meth)acrylaten, Alkyl(meth)acrylaten, N-Vinylpyrrolidon,
N,N-Dimethylacrylamid, 2-Hydroxyethylmethacrylat, Vinylacetat, Acrylnitril, Hydroxypropylmethacrylat,
2-Hydroxyethylacrylat, Methylmethacrylat, Butylmethacrylat, Methacryloxypropoyltristrimethylsiloxysilan,
siloxansubstituierten Acrylaten oder Methacrylaten und Gemischen davon umfasst.
19. Silicon-Hydrogel gemäß Anspruch 1 oder 2, wobei das Polyamid Wiederholungseinheiten
der Formel I oder Formel II umfasst,
wobei X eine direkte Bindung, - (CO) - oder - (CO) -NHRe-ist, wobei Re eine C1- bis C3-Alkylgruppe ist;
Ra ausgewählt ist aus H, geraden oder verzweigten, substituierten oder unsubstituierten
C1- bis C4-Alkylgruppen;
Rb ausgewählt ist aus H, geraden oder verzweigten, substituierten oder unsubstituierten
C1- bis C4-Alkylgruppen, Aminogruppen mit bis zu zwei Kohlenstoffatomen, Amidgruppen mit bis
zu vier Kohlenstoffatomen und Alkoxygruppen mit bis zu zwei Kohlenstoffatomen;
Rc ausgewählt ist aus H, geraden oder verzweigten, substituierten oder unsubstituierten
C1- bis C4-Alkylgruppen und Methyl, Ethoxy, Hydroxyethyl und Hydroxymethyl;
Rd ausgewählt ist aus H, geraden oder verzweigten, substituierten oder unsubstituierten
C1- bis C4-Alkylgruppen und Methyl, Ethoxy, Hydroxyethyl und Hydroxymethyl;
wobei die Anzahl von Kohlenstoffatomen in Ra und Rb zusammengenommen 8 oder weniger beträgt und wobei die Anzahl von Kohlenstoffatomen
in Rc und Rd zusammengenommen 8 oder weniger beträgt; gegebenenfalls
(a) wobei das Polyamid ein Copolymer ist, das wenigstens 80 mol-% an den Wiederholungseinheiten
der Formel I oder Formel II umfasst; und/oder
(b) wobei Rb ausgewählt ist aus geraden oder verzweigten unsubstituierten C1- bis C4-Alkylgruppen.
20. Silicon-Hydrogel gemäß Anspruch 1 oder 2, wobei das Polyamid zwischen 3 und 15 Gew.-%
des reaktiven Monomergemischs bezogen auf alle reaktiven Komponenten umfasst; oder
wobei das Polyamid zwischen 3 und 12 Gew.-% des reaktiven Monomergemischs bezogen
auf alle reaktiven Komponenten umfasst.
21. Silicon-Hydrogel gemäß einem der vorstehenden Ansprüche, wobei das Polyamid ein cyclisches
Polyamid umfasst; gegebenenfalls
Wobei das cyclische Polyamid Polyvinylypyrrolidon (PVP) in einer Menge bis zu 15 Gew.-%
oder in einer Menge in dem Bereich von 2 bis 15 Gew.-% oder in einer Menge in dem
Bereich von 5 bis 15 Gew.-% umfasst.
22. Silicon-Hydrogel gemäß Anspruch 1 oder 2, wobei das reaktive Monomergemisch ferner
wenigstens einen zusätzlichen Bestandteil ausgewählt aus der Gruppe bestehend aus
einem Verdünnungsmittel, einer UV-absorbierenden Verbindung, einem medizinischen Mittel,
einer antimikrobiellen Verbindung, einer pharmazeutischen Verbindung, einer nutrazeutischen
Verbindung, einer photochromen Verbindung, einer reaktiven Farbe, einem Pigment, einem
copolymerisierbaren Farbstoff, einem nichtpolymerisierbaren Farbstoff, einem Trennmittel,
einem Copolymer und Kombinationen davon umfasst.
23. Silicon-Hydrogel gemäß einem der vorstehenden Ansprüche, ferner umfassend wenigstens
ein Hydroxylalkyl(meth)acrylatmonomer; gegebenenfalls:
(a) wobei das Hydroxyalkyl(meth)acrylatmonomer ausgewählt ist aus der Gruppe bestehend
aus 2-Hydroxyethyl(meth)acrylat, 3-Hydroxypropyl(meth)acrylat, 2-Hydroxypropyl(meth)acrylat,
2,3-Dihydroxypropyl(meth)acrylat, 2-Hydroxybutyl(meth)acrylat, 3-Hydroxybutyl(meth)acrylat,
1-Hydroxypropyl-2-(meth)acrylat, 2-Hydroxy-2-methylpropyl(meth)acrylat, 3-Hydroxy-2,2-dimethylpropyl(meth)acrylat,
4-Hydroxybutyl(meth)acrylat, Glycerol(meth)acrylat, Polyethylenglycolmonomethacrylat
und Gemischen davon; oder
(b) wobei das Hydroxyalkyl(meth)acrylatmonomer ausgewählt ist aus der Gruppe bestehend
aus 2-Hydroxyethylmethacrylat, Glycerolmethacrylat, 2-Hydroxypropylmethacrylat, Hydroxybutylmethacrylat,
3-Hydroxy-2,2-dimethylpropylmethacrylat und Gemischen davon; oder
(c) wobei das Hydroxyalkyl(meth)acrylatmonomer ausgewählt ist aus der Gruppe bestehend
aus 2-Hydroxyethylmethacrylat, 3-Hydroxy-2,2-dimethylpropylmethacrylat, Hydroxybutylmethacrylat
und Glycerolmethacrylat.
24. Silicon-Hydrogel gemäß einem der vorstehenden Ansprüche, wobei das reaktive Monomergemisch
ferner wenigstens eine zusätzliche siliconhaltige Verbindung ohne eine Hydroxygruppe
umfasst.
25. Silicon-Hydrogel gemäß Anspruch 1, wobei das zweite hydroxysubstituierte Poly(disubstituiertes
Siloxan) ausgewählt aus der Gruppe bestehend aus einem monofunktionellen hydroxysubstituierten
linearen Poly(disubstituiertes Siloxan) mit 10 bis 20 Siloxan-Wiederholungseinheiten
und einem multifunktionellen hydroxysubstituierten linearen Poly(disubstituiertes
Siloxan) mit 10 bis 200 oder 10 bis 100 Siloxan-Wiederholungseinheiten; und
wobei das Verhältnis des ersten hydroxysubstituierten linearen Poly(disubstituiertes
Siloxan)s zu dem zweiten hydroxysubstituierten linearen Poly(disubstituiertes Siloxan)
in einem Bereich von 0,4 bis 1,2 oder 0,4 bis 1,0 liegt.
26. Silicon-Hydrogel gemäß einem der vorstehenden Ansprüche, wobei das Polyamid ein gewichtsgemitteltes
Molekulargewicht von wenigstens 100.000 Dalton; oder höher als 150.000 Dalton; oder
zwischen 150.000 und 2.000.000 Dalton oder zwischen 300.000 und 1.800.000 Dalton aufweist,
wenn das Molekulargewicht durch Größenausschlusschromatographie mit Mehrwinkel-Lichtstreuung
bestimmt wird.
27. Silicon-Hydrogel gemäß einem der vorstehenden Ansprüche, wobei das Polyamid so zu
dem Reaktionsgemisch zugegeben wird, dass das Hydrogel um das Polyamid polymerisiert,
um ein semi-interpenetrierendes Netzwerk zu bilden.
28. Kontaktlinse umfassend das Silicon-Hydrogel gemäß einem der vorstehenden Ansprüche.
29. Kontaktlinse gemäß Anspruch 28, wobei die Dk größer als 80 Barrer ist, wobei die Lysozymaufnahme
größer als 50 µg/Linse ist, wobei die Lipidaufnahme kleiner als 10 µg/Linse ist; wobei
die PQ1-Aufnahme kleiner als 15 % ist; und wobei der Kontaktwinkel kleiner als 50°
ist, wenn gemessen unter Verwendung der in der Beschreibung gegebenen "Sauerstoffdurchlässigkeit-",
"Lipidaufnahme-", "PQ1-Aufnahme-", "dynamischer Kontaktwinkel-" und einem der "Lysozymaufnahme"-Prüfverfahren.
1. Hydrogel de silicone formé à partir d'un mélange de monomères réactifs comprenant
:
a. entre 1 et 15 % en poids d'au moins un polyamide, le terme « polyamide » faisant
référence à des polymères et des copolymères comprenant des motifs répétitifs contenant
des groupes amide ;
b. au moins un premier poly(siloxane disubstitué) monofonctionnel, substitué par hydroxyle,
linéaire ayant 4 à 8 motifs répétitifs de siloxane ;
c. au moins un deuxième poly(siloxane disubstitué) substitué par hydroxyle, linéaire
choisi dans le groupe constitué par des poly(siloxane disubstitué) substitués par
hydroxyle monofonctionnels ayant 10 à 200 ou 10 à 100 motifs répétitifs de siloxane
et des poly(siloxane disubstitué) substitués par hydroxyle multifonctionnels ayant
10 à 200 ou 10 à 100 motifs répétitifs de siloxane et des mélanges correspondants
;
d. 5 à 35 % en poids d'au moins un monomère hydrophile ;
le premier poly(siloxane disubstitué) substitué par hydroxyle, linéaire et le deuxième
poly(siloxane disubstitué) substitué par hydroxyle monofonctionnel, linéaire étant
présents en des cconcentrations pour fournir un rapport de % en poids de tous les
premiers poly(siloxane disubstitué) substitués par hydroxyle, linéaires sur tous les
deuxièmes poly(siloxane disubstitué) substitués par hydroxyle, linéaires de 0,4-1,3,
ou 0,4-1,0 ;
le terme « fonctionnel » signifiant un groupe qui peut subir une polymérisation par
des radicaux libres ;
les concentrations de composants étant données en % en poids de tous les composants
dans le mélange réactionnel, à l'exclusion d'un diluant.
2. Hydrogel de silicone selon la revendication 1, le deuxième poly(siloxane disubstitué)
substitué par hydroxyle, linéaire étant choisi parmi des poly(siloxane disubstitué)
linéaires substitués par hydroxyle monofonctionnels ayant 10 à 200 ou 10 à 100 motifs
répétitifs de siloxane.
3. Hydrogel de silicone selon la revendication 1 ou 2,
(a) le premier poly(siloxane disubstitué) substitué par hydroxyle, monofonctionnel
comprenant des composés de formule VII-1

Z étant choisi parmi O, N, S ou NCH2CH2O, lorsque Z est O ou S alors R2 n'étant pas présent ;
R1 étant indépendamment H ou méthyle ;
R2 étant H ou étant un groupe alkyle linéaire, ramifié ou cyclique contenant un à huit
atomes de carbone, l'un quelconque desquels pouvant en outre être substitué par au
moins un groupe hydroxy, amide, éther et des combinaisons correspondantes ;
R3 et R4 étant indépendamment un groupe alkyle linéaire, ramifié ou cyclique contenant un
à huit atomes de carbone, l'un quelconque desquels pouvant en outre être substitué
par au moins un groupe hydroxy, amide, éther et des combinaisons correspondantes ;
R3 et R4 pouvant être indépendamment choisis parmi méthyle, éthyle ou phényle ou pouvant être
méthyle ;
n étant 4-8 ; et
R5 étant choisi parmi des groupes C1 à C8 alkyle linéaires ou ramifiés, qui peuvent être éventuellement substitués par un ou
plusieurs hydroxyle, amide, éther et des combinaisons correspondantes ; et/ou
(b) le deuxième poly(siloxane disubstitué) substitués par hydroxyle comprenant un
Composé de formule VII-2 :

Z étant choisi parmi O, N, S ou NCH2CH2O, lorsque Z est O ou S, R2 n'étant pas présent ;
R1 étant indépendamment H ou méthyle ;
R2 étant H ou étant un groupe alkyle linéaire, ramifié ou cyclique contenant un à huit
atomes de carbone, l'un quelconque desquels pouvant en outre être substitué par au
moins un groupe hydroxy, amide, éther et des combinaisons correspondantes ;
R3 et R4 étant indépendamment un groupe alkyle linéaire, ramifié ou cyclique contenant un
à huit atomes de carbone, l'un quelconque desquels pouvant en outre être substitué
par au moins un groupe hydroxy, et qui peut être éventuellement substitué par amide,
éther et des combinaisons correspondantes ; R3 et R4 pouvant être indépendamment choisis parmi méthyle, éthyle ou phényle ou pouvant être
méthyle ;
n étant le nombre de motifs de siloxane et étant de 10 à 200, ou 10-100, ou 10-50,
ou 10-20, ou 12-18 ; et
R5 étant choisi parmi des groupes C1 à C8 alkyle linéaires ou ramifiés, qui peuvent être éventuellement substitués par un ou
plusieurs hydroxyle, amide, éther et des combinaisons correspondantes ; et/ou
(c) le deuxième poly(siloxane disubstitué) substitué par hydroxyle comprenant en outre
un poly(siloxane disubstitué) substitué par hydroxyle difonctionnel de formule XI

R1 étant indépendamment un atome d'hydrogène ou un groupe méthyle ;
R2 et R3 étant indépendamment un groupe alkyle linéaire, ramifié ou cyclique contenant un
à huit atomes de carbone, l'un quelconque desquels pouvant en outre être substitué
par au moins un groupe hydroxy, amido, éther, amino, carboxyle, des groupes carbonyle
et des combinaisons correspondantes ; ou étant choisis parmi méthyle, éthyle et -
(CH2CH2O)XOCH3, où x est de 1 à 20 ; et
n étant de 1 à 200.
4. Hydrogel de silicone selon l'une quelconque des revendications précédentes, le premier
poly(siloxane disubstitué) substitué par hydroxyle monofonctionnel et le deuxième
poly(siloxane disubstitué) substitué par hydroxyle étant présents dans le mélange
de monomères réactifs en une concentration totale comprise entre 40 et 70 % en poids,
ou 45 à 70 % en poids sur la base de tous les composants dans le mélange réactionnel,
à l'exclusion d'un diluant.
5. Hydrogel de silicone selon l'une quelconque des revendications précédentes,
(a) le polyamide comprenant un polyamide cyclique, un polyamide acyclique ou un mélange
d'un polyamide cyclique et d'un polyamide acyclique ; ou
(b) le polyamide étant un polyamide acyclique.
6. Hydrogel de silicone selon l'une quelconque des revendications précédentes, le premier
ou le deuxième poly(siloxane disubstitué) substitué par hydroxyle monofonctionnel
comprenant un polydiméthylsiloxane monofonctionnel substitué par hydroxyle de l'une
quelconque des formules VIIa-IXb :
R1 étant méthyle ou H ; n étant compris entre 4 et 30, 4-8 ou 10-20 ; Z étant choisi
parmi O, N, S ou NCH2CH2O, lorsque Z est O ou S, R2 n'est pas présent ;
R2 étant indépendamment choisi dans le groupe constitué par un groupe alkyle linéaire,
ramifié ou cyclique contenant un à huit atomes de carbone, l'un quelconque desquels
pouvant en outre être substitué par au moins un groupe hydroxy, et qui peut être éventuellement
substitué par amide, éther et des combinaisons correspondantes ; n1 et n2 étant indépendamment compris entre 4 et 100 ; 4 et 50 ; ou 4 et 25 ;
n3 étant 1-50, 1-20, ou 1-10 ;
R5 étant choisi parmi des groupes C1 à C8 alkyle linéaires ou ramifiés, qui peuvent être éventuellement substitués par un ou
plusieurs hydroxyle, amide, éther, des groupes polyhydroxyle choisis parmi des groupes
C1 à C8 linéaires ou ramifiés ayant une formule de CfHg(OH)h, f = 1 - 8 et g + h = 2f + 1 et des groupes C1 à C8 cycliques ayant une formule de CfHg(OH)h, f = 1 - 8 et g + h = 2f - 1 et des combinaisons correspondantes ; ou R5 pouvant être choisi parmi méthyle, butyle ou C2-C5 alkyle substitué par hydroxyle, y compris hydroxyléthyle, hydroxylpropyle, hydroxylbutyle,
hydroxylpentyle et 2,3-dihydroxypropyle ;
a étant 4-8 pour le premier composant de type silicone contenant hydroxyle et entre
4-100 pour le deuxième composant de type silicone contenant hydroxyle.
7. Hydrogel de silicone selon l'une quelconque des revendications précédentes, les deuxièmes
poly(siloxane disubstitué) substitués par hydroxyle comprenant polydiméthylsiloxane
à terminaison éther de mono-(2-hydroxy-3-méthacryloxypropyl)-propyle à terminaison
mono-n-butyle (OH-mPDMS) ayant quinze motifs répétitifs de siloxane.
8. Hydrogel de silicone selon la revendication 1 ou 2,
(a) le monomère hydrophile comprenant un groupe réactif choisi dans le groupe constitué
par (méth)acrylates, (méth)acrylamides, styrènes, N-vinyllactames, N-vinylamides,
O-vinylcarbamates, O-vinylcarbonates, éthers de vinyle, esters de vinyle, vinyles,
allyles et des combinaisons correspondantes ; et/ou
(b) le monomère hydrophile étant présent dans le mélange de monomères réactifs en
une quantité comprise entre 15 et 35 % en poids.
9. Hydrogel de silicone selon l'une quelconque des revendications précédentes comprenant
en outre au moins un composant chargé.
10. Hydrogel de silicone selon la revendication 1 ou 2, les deuxièmes poly(siloxane disubstitué)
substitués par hydroxyle comprenant au moins un composé de formule XII
R1 étant indépendamment un atome d'hydrogène ou un groupe méthyle ; Z étant choisi parmi
O, N, S ou NCH2CH2O, pour Z = O et S, R2 n'étant pas requis ;
R2 étant choisi dans le groupe constitué par H ou un groupe alkyle linéaire, ramifié
ou cyclique contenant un à huit atomes de carbone, l'un quelconque desquels pouvant
en outre être substitué par au moins un groupe hydroxy, amido, éther, amino, carboxyle,
des groupes carbonyle et des combinaisons ; un groupe alkylèneoxy linéaire ou ramifié,
spécifiquement des groupes éthylèneoxy, [CH2CH2O]p, p étant compris entre 1 et 200, ou 1 et 100, ou 1 et 50, ou 1 et 25, ou 1 et 20,
éventuellement substitués par un ou plusieurs hydroxyle, amino, amido, éther, carbonyle,
carboxyle et des combinaisons correspondantes ; un groupe fluoroalkyle linéaire ou
ramifié en C1-C6 éventuellement substitué par un ou plusieurs hydroxyle, amino, amido, éther, carbonyle,
carboxyle et des combinaisons correspondantes ; un groupe aryle substitué ou non substitué,
spécifiquement des groupes phényle, les substituants étant choisis parmi halogène,
hydroxyle, alcoxy, alkylcarbonyle, carboxy, et des groupes alkyle linéaires ou ramifiés
ou cycliques qui peuvent en outre être substitués par des groupes halogène, hydroxyle,
alcoxy, alkylcarbonyle et carboxyle et des combinaisons correspondantes ;
n1 et n2 étant indépendamment choisis parmi 4 à 100 ; 4 à 50 ; ou 4 à 25 ; et
n3 étant 1-50, 1-20 et 1-10.
11. Hydrogel de silicone selon la revendication 1 ou 2, le monomère hydrophile étant choisi
parmi des monomères hydrophiles de type amide ; éventuellement
(a) le mélange de monomères réactifs comprenant moins de 30 % en poids, ou moins de
25 % en poids ou moins de 20 % en poids de monomères hydrophiles de type amide sur
la base de tous les composants dans le mélange réactionnel, à l'exclusion d'un diluant
; et/ou
(b) les monomères hydrophiles de type amide étant compris dans le mélange réactif
en des quantités comprises entre 5 et 28 % en poids, ou 5 et 25 % en poids, ou entre
8 et 20 % en poids sur la base de tous les composants dans le mélange réactionnel,
à l'exclusion d'un diluant.
12. Hydrogel de silicone selon la revendication 1 ou 2,
(a) le monomère hydrophile étant choisi dans le groupe constitué par N,N-diméthylacrylamide,
acrylamide, éther vinylique de l'éthylène glycol (EGVE), éther vinylique du di(éthylène
glycol) (DEGVE), N-vinyle pyrrolidone (NVP), 1-méthyl-3-méthylène-2-pyrrolidone, 1-méthyl-5-méthylène-2-pyrrolidone,
5-méthyl-3-méthylène-2-pyrrolidone ; 1-éthyl-5-méthylène-2-pyrrolidone, N-méthyl-3-méthylène-2-pyrrolidone,
5-éthyl-3-méthylène-2-pyrrolidone, 1-n-propyl-3-méthylène-2-pyrrolidone, 1-n-propyl-5-méthylène-2-pyrrolidone,
1-isopropyl-3-méthylène-2-pyrrolidone, 1-isopropyl-5-méthylène-2-pyrrolidone, N-vinyl-N-méthylacétamide
(VMA), N-vinyl-N-éthylacétamide, N-vinyl-N-éthylformamide, N-vinylformamide, N-vinylacétamide,
N-vinylisopropylamide, alcool allylique, N-vinylcaprolactame, N-2-hydroxyéthylcarbamate
de vinyle, ester de N-vinyle de N-carboxy-β-alanine ; N-carboxyvinyl-β-alanine (VINAL),
N-carboxyvinyl-α-alanine et des mélanges correspondants ; ou
(b) le monomère hydrophile étant choisi parmi N,N-diméthylacrylamide, N-vinylpyrrolidone,
N-vinyl-N-méthylacétamide, N-vinylacétamide et 1-méthyl-5-méthylène-2-pyrrolidone
; ou
(c) le monomère hydrophile comprenant N-vinylpyrrolidone, N,N-diméthylacrylamide ou
des mélanges correspondants.
13. Hydrogel de silicone selon l'une quelconque des revendications précédentes, l'hydrogel
de silicone ayant une perméabilité à l'oxygène (Dk) d'au moins 80 barrers, ou 80 à
200 barrers, 90 à 180 barrers, 100 à 160 barrers, lorsque la perméabilité à l'oxygène
est mesurée en utilisant le procédé de test « perméabilité à l'oxygène » donné dans
la description.
14. Hydrogel de silicone selon la revendication 9, le monomère chargé comprenant au moins
un groupement ionique choisi dans le groupe constitué par des anions, des cations,
des zwitterions, des bétaïnes et des mélanges correspondants.
15. Hydrogel de silicone selon la revendication 14, le monomère chargé comprenant au moins
un groupe acide carboxylique ; éventuellement
(a) le monomère chargé comprenant au moins un monomère d'acide carboxylique choisi
dans le groupe constitué par l'acide (méth)acrylique, l'acide fumarique, l'acide maléique,
l'acide itaconique, l'acide crotonique, l'acide cinnamique, l'acide vinylbenzoïque,
les monoesters de l'acide fumarique, de l'acide maléique et de l'acide itaconique
et des mélanges correspondants ; ou
(b) le monomère chargé comprenant un mélange de monomère anionique et cationique ;
ou
(c) le monomère chargé étant choisi dans le groupe constitué par acide(méth)acrylique,
N-[(éthényloxy)carbonyl]-P-alanine (VINAL), acide 3-acrylamidopropanoïque (ACA1),
acide 5-acrylamidopropanoïque (ACA2), acide 3-acrylamido-3-méthylbutanoïque (AMBA),
chlorure de 2-(méthacryloyloxy)éthyltriméthylammonium (sel Q), acide 2-acrylamido-2-méthylpropane
sulfonique (AMPS), 1-propanaminium, N-(2-carboxyéthyl)-N,N-diméthyl-3-[(1-oxo-2-propène-1-yl)amino]-,
sel interne (CBT, carboxybétaïne), 1-propanaminium, N,N-diméthyl-N-[3-(1-oxo-2-prop-1-yl)amino]propyl]-3-sulfo-,
sel interne (SBT, sulfobetaïne,), 3,5-Dioxa-8-aza-4-phosphaundéc-10-en-1-aminium,
4-hydroxy-N,N,N-triméthyl-9-oxo-, sel interne, 4-oxyde (9CI) phosphobétaïne (PBT),
2-méthacryloyloxyéthylphosphorylcholine, 3-(diméthyl(4-vinylbenzyl)ammonio)propane-1-sulfonate
(DMVBAPS), 3-(3-acrylamidopropyl)diméthyllammonio)propane-1-sulfonate (AMPDAPS), 3-((3-méthacrylamidopropyl)diméthylammonium)propane-1-sulfonate
(MAMPDAPS), 3-((3-(acryloyloxy)propyl)diméthylammonium)propane-1-sulfonate (APDAPS),
méthacryloyloxy)propyl)diméthylammonium)propane-1-sulfonate (MAPDAPS) et des mélanges
correspondants ; ou
(d) le monomère chargé étant choisi dans le groupe constitué par l'acide (méth)acrylique,
la N-[(éthenyloxy)carbonyl]-P-alanine (VINAL), l'acide 3-acrylamidopropanoïque (ACA1),
l'acide 5-acrylamidopropanoïque (ACA2) et des mélanges correspondants.
16. Hydrogel de silicone selon l'une quelconque des revendications 9 ou 15, l'au moins
un monomère chargé représentant jusqu'à 5 % en poids, ou entre 0,5 et 5 % en poids,
ou entre 0,5 et 3 % en poids, ou entre 0,5 et 2 % en poids, ou entre 1 et 5 % en poids
ou entre 1 et 3 % en poids, sur la base du poids total du mélange de monomères réactifs.
17. Hydrogel de silicone selon l'une quelconque des revendications précédentes, comprenant
un monomère chargé choisi parmi l'acide acrylique, l'acide méthacrylique et des mélanges
correspondants.
18. Hydrogel de silicone selon la revendication 1 ou 2,
(a) le polyamide comprenant un polyamide acyclique choisi dans le groupe constitué
par PVMA, PNVA et des poly[N-vinyl-N-alkyl-acétamide], le groupe N-alkyle étant choisi
dans le groupe constitué par des groupes alkyle linéaires et ramifiés contenant entre
un et cinq atomes de carbone et des copolymères et des mélanges correspondants ; et/ou
(b) le polyamide comprenant un poly(N-vinyl-N-méthylacetamide), un poly(N-vinylacétamide),
un polydiméthylacrylamide ou un mélange de deux ou plus de ceux-ci ; et/ou
(c) le polyamide comprenant un copolymère ; éventuellement
le copolymère comprenant des motifs répétitifs choisis dans le groupe constitué par
N-vinylamides, acrylamides, (méth)acrylates d'hydroxyalkyle, (méth)acrylates d'alkyle,
N-vinylpyrrolidone, N,N-diméthylacrylamide, 2-hydroxyéthylméthacrylate, acétate de
vinyle, acrylonitrile, méthacrylate d'hydroxypropyle, acrylate de 2-hydroxyéthyle,
méthacrylate de méthyle, méthacrylate de butyle, méthacryloxypropoyl-tristriméthylsiloxysilane,
acrylates ou méthacrylates substitués par des siloxanes et des mélanges correspondants.
19. Hydrogel de silicone selon la revendication 1 ou 2, le polyamide comprenant des motifs
répétitifs de formule I ou de formule II
X étant une liaison directe, - (CO) - ou - (CO) -NHRe-, Re étant un groupe C1 à C3 alkyle ;
Ra étant choisi parmi H, des groupes C1 à C4 alkyle linéaires ou ramifiés, substitués ou non substitués ;
Rb étant choisi parmi H, des groupes C1 à C4 alkyle linéaires ou ramifiés, substitués ou non substitués, des groupes amino ayant
jusqu'à deux atomes de carbone, des groupes amide ayant jusqu'à quatre atomes de carbone
et des groupes alcoxy ayant jusqu'à deux atomes de carbone ;
Rc étant choisi parmi H, des groupes C1 à C4 alkyle linéaires ou ramifiés, substitués ou non substitués, ou méthyle, éthoxy, hydroxyéthyle
et hydroxyméthyle ;
Rd étant choisi parmi H, des groupes C1 à C4 alkyle linéaires ou ramifiés, substitués ou non substitués, ou méthyle, éthoxy, hydroxyéthyle
et hydroxyméthyle ;
le nombre d'atomes de carbone dans Ra et Rb pris ensemble étant 8 ou moins, et le nombre d'atomes de carbone dans Rc et Rd pris ensemble étant 8 ou moins ; éventuellement
(a) le polyamide étant un copolymère comprenant au moins 80 % en moles des motifs
répétitifs de formule I ou de formule II ; et/ou
(b) Rb étant choisi parmi des groupes C1 à C4 alkyle non substitués linéaires ou ramifiés.
20. Hydrogel de silicone selon la revendication 1 ou 2, le polyamide comprenant entre
3 et 15 % en poids du mélange de monomères réactifs, sur la base de tous les composants
réactifs ; ou
le polyamide comprenant entre 3 et 12 % en poids du mélange réactif sur la base de
tous les composants réactifs.
21. Hydrogel de silicone selon l'une quelconque des revendications précédentes, le polyamide
comprenant un polyamide cyclique ; éventuellement
le polyamide cyclique comprenant une polyvinylpyrrolidone (PVP) en une quantité allant
jusqu'à 15 % en poids, ou une quantité dans la plage de 2 à 15 % en poids, ou une
quantité dans la plage de 5 à 15 % en poids.
22. Hydrogel de silicone selon la revendication 1 ou 2,le mélange de monomères réactifs
comprenant en outre au moins un constituant supplémentaire choisi dans le groupe constitué
par un diluant, un composé absorbant des UV, un agent médicinal, un composé antimicrobien,
un composé pharmaceutique, un composé nutraceutique, un composé photochromique, une
teinture réactive, un pigment, un colorant copolymérisable, un colorant non polymérisable,
un agent de libération, un copolymère et des combinaisons correspondantes.
23. Hydrogel de silicone selon l'une quelconque des revendications précédentes comprenant
en outre au moins un monomère de (méth)acrylate d'hydroxyalkyle ; éventuellement ;
(a) ledit monomère de (méth)acrylate d'hydroxyalkyle étant choisi dans le groupe constitué
par (méth)acrylate de 2-hydroxyéthyle, (méth)acrylate de 3-hydroxypropyle, (méth)acrylate
de 2-hydroxypropyle, (méth)acrylate de 2,3-dihydroxypropyle, (méth)acrylate de 2-hydroxybutyle,
(méth)acrylate de 3-hydroxybutyle, 2-(méth)acrylate de 1-hydroxypropyle, (méth)acrylate
de 2-hydroxy-2-méthyl-propyle, (méth)acrylate de 3-hydroxy-2,2-diméthyl-propyle, (méth)acrylate
de 4-hydroxybutyle, (méth)acrylate de glycérol, monométhacrylate de polyéthylène glycol
et des mélanges correspondants ; ou
(b) ledit monomère de (méth)acrylate d'hydroxyalkyle étant choisi dans le groupe constitué
par méthacrylate de 2-hydroxyéthyle, méthacrylate de glycérol, méthacrylate de 2-hydroxypropyle,
méthacrylate d'hydroxybutyle, méthacrylate de 3-hydroxy-2,2-diméthyl-propyle et des
mélanges correspondants ; ou
(c) ledit monomère de (méth)acrylate d'hydroxyalkyle étant choisi dans le groupe constitué
par méthacrylate de 2-hydroxyéthyle, méthacrylate de 3-hydroxy-2,2-diméthyl-propyle,
méthacrylate d'hydroxybutyle ou méthacrylate de glycérol.
24. Hydrogel de silicone selon l'une quelconque des revendications précédentes, le mélange
de monomères réactifs comprenant en outre au moins un composé contenant une silicone
supplémentaire sans un groupe hydroxyle.
25. Hydrogel de silicone selon la revendication 1, le deuxième poly(siloxane disubstitué)
substitué par hydroxyle étant choisi dans le groupe constitué par un poly(siloxane
disubstitué) linéaire, substitué par hydroxyle monofonctionnel ayant 10 à 20 motifs
répétitifs de siloxane et un poly(siloxane disubstitué) linéaire, substitué par hydroxyle
multifonctionnel ayant 10 à 200, ou 10 à 100 motifs répétitifs de siloxane ; et
le rapport du premier poly(siloxane disubstitué) linéaire substitué par hydroxyle
sur le deuxième poly(siloxane disubstitué) linéaire, substitué par hydroxyle étant
dans une plage de 0,4 à 1,2, ou de 0,4 à 1,0.
26. Hydrogel de silicone selon l'une quelconque des revendications précédentes, le polyamide
ayant un poids moléculaire moyen en poids d'au moins 100 000 Daltons ; ou supérieur
à 150 000 Daltons ; ou compris entre 150 000 et 2 000 000 Daltons, ou compris entre
300 000 et 1 800 000 Daltons lorsque le poids moléculaire est déterminé par chromatographie
d'exclusion stérique avec diffusion de lumière multi-angle.
27. Hydrogel de silicone selon l'une quelconque des revendications précédentes, le polyamide
étant ajouté au mélange réactionnel de sorte que l'hydrogel polymérise autour du polyamide,
formant un réseau semi-interpénétrant.
28. Lentille de contact comprenant l'hydrogel de silicone selon l'une quelconque des revendications
précédentes.
29. Lentille de contact selon la revendication 28, le Dk étant supérieur à 80 barrers,
l'absorption de lysozyme étant supérieure à 50 µg/lentille, l'absorption de lipides
étant inférieure à 10 µg/lentille ; l'absorption de PQ1 étant inférieure à 15 % ;
et l'angle de contact étant inférieur à 50° lorsqu'ils sont mesurés en utilisant les
procédés de test « perméabilité à l'oxygène », « absorption de lipides », « absorption
de PQ1 », « angle de contact dynamique », et l'un ou l'autre des procédés de test
« absorption de lysozyme » donnés dans la description.